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Abstract	
Role	of	Metal	Ions	in	Metal	on	Metal	Total	Hip	Replacement	
Metal-on-metal	(MoM)	total	hip	replacement	(THR)	offered	theoretical	advantages	of	
decreased	wear	and	increased	functional	outcomes.	MoM	bearings	have	been	
associated	with	sterile	inflammatory	masses	and	significant	soft	tissue	destruction	
with	poorer	outcomes	following	revision	surgery.	The	natural	history	of	adverse	
reactions	to	metal	debris	(ARMD)	is	unknown,	but	may	represent	contributions	from	
bearing	surface	wear,	taper	junction	wear,	and	corrosion.	Immunological	and	genetic	
factors	may	influence	susceptibility	to	development	of	ARMD.			
	
Between	1997	and	2004,	652	Ultima	TPS	THRs	(DePuy)	were	implanted	in	545	
patients	who	went	on	to	experience	a	high	rate	of	early	implant	failure	(13.8%).		
Management	of	these	patients	has	evolved	beyond	regular	clinical	follow	up	with	plain	
radiographs	to	include	surveillance	monitoring	of	trends	in	levels	of	blood	metal	ions	
and	staging	of	disease	using	metal	artefact	reduction	(MAR)	MRI.		
This	study	investigated:	
? The	natural	history	of	ARMD	in	28mm	MoM	THR	using	MAR	MRI.	
? The	possibility	of	diurnal	variation	of	cobalt	(Co)	and	chromium	(Cr).	
? Differences	in	gene	expression	profiles	of	patients	undergoing	revision	of	a	
metal-on-polyethylene	(MoP)	THR	for	aseptic	loosening	and	those	with	ARMD	
arising	from	MoM	THR.	
	
	
	
	 vii	
In	patients	whose	MARS	MRI	staging	on	initial	scan	is	normal	or	where	mild	evidence	
of	disease	is	demonstrated,	further	deterioration	is	unlikely.	Where	it	does	occur,	the	
rate	of	deterioration	is	slow	and	there	may	be	a	latent	period	of	many	years.	
	
There	is	no	diurnal	variation	in	levels	of	cobalt	(Co)	in	plasma	or	urine.	There	is	
diurnal	variation	in	levels	of	plasma	chromium,	but	this	is	not	clinically	significant.		
	
Patterns	of	gene	expression	in	patients	with	aseptic	loosening	of	a	metal-on-
polyethylene	(MoP)	THR,	and	patients	with	ARMD	from	a	MoM	THR	investigated	by	a	
microarray	experiment	were	found	to	be	similar	on	a	genome-wide	level	suggesting	
that	they	may	share	common	factors	in	their	aetiologies.			
	
These	studies	have	helped	to	describe	the	natural	history	of	ARMD	on	a	cellular	and	
radiological	level,	and	have	provided	a	contribution	to	the	evidence	base	that	will	
inform	as	to	the	optimum	strategy	for	monitoring	these	patients	before	they	develop	
catastrophic	complications.	
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1 :	Introduction	
1.1 Background	
	
Total	Hip	Replacement	(THR)	is	a	common	surgical	intervention	to	improve	quality	of	
life	for	patients	with	painful	hip	arthritis.	It	is	one	of	most	successful	and	commonly	
performed	elective	surgical	interventions	of	the	modern	era	and	is	considered	by	the	
World	Health	Organisation	to	be	one	of	the	most	cost-effective	interventions	in	
medicine1.	In	2012	there	were	over	90,000	hip	replacement	procedures	recorded	by	
the	National	Joint	Registry	of	England	and	Wales.	Of	these	76,448	were	primary	
procedures	and	10,040	were	revision	procedures	2.	Increasing	demand	for	
arthroplasty	procedures	is	driven	by	an	ageing	population	who	wish	to	remain	active	
and	an	escalation	in	the	number	of	obese	patients3.	
	
The	success	of	a	THR	design	can	be	measured	via	a	number	of	factors	that	may	be	used	
in	isolation	or	in	concert.	These	measures	can	be	patient	reported,	radiographic,	or	be	
based	on	implant	longevity.		
	
Patients	can	give	valuable	insight	as	to	the	success	of	their	operation	using	validated	
instruments	known	as	patient	reported	outcome	measures	(PROMS).	These	involve	
answering	a	number	of	subjective	questions	whose	responses	are	assigned	a	
numerical	score;	these	scores	are	then	added	together	to	give	a	final	overall	score.	
Some	PROMS	are	specific	to	hip	arthroplasty	e.g.	the	Oxford	Hip	Score	(OHS)	4	whilst	
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others	incorporate	aspects	of	general	health,	perceived	well-being	and	quality	of	life	
e.g.	EQ-5D5,6.		
	
Radiological	methods	can	be	used	to	evaluate	a	THR	via	evaluation	of	the	quality	of	the	
fixation	in	terms	of	the	quality	of	cementation7,	the	component	position8	and	evidence	
of	loosening9.	These	methods	are	not	universally	adopted	and	may	not	apply	to	all	
implant	types.		
	
Longevity	of	an	implant	can	be	measured	as	the	time	from	implantation	to	time	to	
failure	mandating	revision	surgery.	There	is	evidence	that	conventional	cemented	
metal-on-polyethylene	bearing	THRs	have	a	survival	rate	greater	than	90%	at	12	years	
10	whilst	certain	designs	have	demonstrated	up	78%	survival	at	30	years11.	
	
The	long-term	survival	of	an	implant	is	subject	to	a	number	of	intricately	related	
factors	(Figure	1.1-1)	and	implant	failure	remains	a	leading	cause	of	pain	and	loss	of	
function.		The	causes	of	implant	failure	can	be	broadly	classified	into	three	categories:	
1) Factors	relating	to	implant	design,	materials,	and	fabrication	
2) Factors	which	are	related	to	the	surgeon;	poor	patient	or	implant	selection,	
poor	surgical	technique	resulting	in	adverse	component	positioning	and	soft	
tissue	balancing	which	adversely	affect	implant	survival.	
3) Patient	related	factors	including	body	weight,	level	of	physical	activity,	
comorbidity	predisposing	to	delayed	bone	healing,	and	compliance.		
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It	remains	one	of	the	major	challenges	in	orthopaedic	engineering	to	develop	an	
implant	system	with	superior	wear	resistant	properties	with	a	high	degree	of	
biocompatibility.		
	
	
Figure	1.1-1	Parameters	affecting	the	long-term	survival	of	a	Total	Hip	Arthroplasty	(THA)	
	
The	ideal	bearing	solution	for	a	THR	should	possess	a	number	of	important	properties.	
The	articulating	surfaces	should	be	resistant	to	wear	and	be	made	of	biologically	inert	
materials	so	as	not	to	evoke	a	host	response	to	the	implant	itself	or	wear	debris	
generated.	In	terms	of	material	composition	all	parts	should	be	chemically	stable	and	
	 4	
not	prone	to	corrosion,	tough	enough	to	resist	fracture,	and	be	hard	and	non-ductile	to	
reduce	susceptibility	to	scratching	and	third	body	wear12.	
	
Metal-on-metal	bearing	surfaces	were	thought	to	confer	such	advantages	and	in	
particular	to	be	an	ideal	choice	of	bearing	surface	in	younger	or	more	active	
individuals.	However,	it	could	be	argued	that	existing	designs	are	excellent	and	that	
further	attempt	at	improvement	are	ultimately	not	cost	effective.		
1.2 Periprosthetic	Osteolysis	&	Aseptic	Loosening	
	
The	process	of	periprosthetic	osteolysis	with	accompanying	aseptic	loosening	is	a	
major	factor	affecting	longevity	of	any	device	and	is	the	result	of	wear	debris	
generated	at	the	bearing	surface	between	the	replacement	femoral	head	and	
acetabular	cup.	Aseptic	loosening	is	the	most	commonly	recorded	indication	for	
revision	surgery,	accounting	for	40%	of	all	revisions2.			
	
All	bearing	surface	combinations	will	wear	in	use	and	will	generate	particulate	debris	
which	can	be	responsible	for	adverse	tissue	reactions;	this	phenomenon	is	not	
exclusive	to	MoM	bearings.	Particles	of	ultra-high-molecular-weight	polyethylene	
(UHMWPE),	polymethylmethacrylate	(PMMA)	cement,	titanium	alloy,	aluminium	
oxide	(Al2O3)	and	zirconium	dioxide	(ZrO2)	have	all	been	demonstrated	to	be	
biologically	active	when	produced	as	wear	debris13	
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Both	the	volume	and	morphology	of	wear	debris	are	factors	in	determination	of	the	
host	response	and	subsequent	survival	of	the	implant.	Wear	particles	generate	a	
complex		inflammatory	and	foreign	body	reaction	resulting	in	increased	macrophage	
and	foreign	body	giant	cell	activity	with	the	net	result	of	periprosthetic	tissue	
destruction	and	implant	loosening.	Submicrometer	particles	stimulate	periprosthetic	
macrophages	to	express	proinflammatory	and	pro-osteoclastic	cytokines,	cell	surface	
receptors	and	signalling	molecules	that	promote	formation,	accumulation,	activity	and	
survival	of	osteoclasts	and	inhibit	the	osteogenic	activity	of	osteoblasts	with	the	result	
that	bone	resorption	predominates	over	osteogenesis	at	the	bone-implant	interface.		
	
Macrophage	activation	is	central	to	the	initiation	of	an	osteolytic	response.	The	
reaction	of	macrophages	depends	on	particle	size.	With	particles	of	size	<10μm,	
macrophages	and	foreign	body	giant	cells	are	able	to	adhere	to	and	phagocytose	the	
particles14.	This	leads	to	the	production	of	pro-inflammatory	signalling	molecules	and	
production	of	an	array	of	inflammatory	mediators	including	prostaglandin	E2	(PGE2),	
Tumour	Necrosis	Factor-alpha	(TNFα),	interleukin-1beta	(IL-1β),	interleukin-6	and	
matrix	metalloproteinases	(MMPs).	For	larger	particles	in	the	size	range	20-100	μm	
that	cannot	be	effectively	phagocytosed	by	a	single	macrophage,	foreign	body	
granulomas	are	formed.	These	were	first	described	by	Harris	et	al	in	197615		who	
observed	aggressive	granulomatous	lesions	in	cemented	MoP	THR	with	localised	
tumour-like	bone	resorption	in	the	definite	absence	of	infection.	
	
Osteoclasts	are	the	only	cell	capable	of	active	bone	resorption	and	are	recruited	
through	up-regulated	expression	of	monocyte	chemotactic	protein	(MCP-1)	and	
macrophage	inflammatory	protein	(MIP-1alpha)	in	periprosthetic	tissues	in	response	
	 6	
to	wear	debris16.	Osteoclastic	function	is	mediated	via	signal	pathways	from	wear-
debris-activated	macrophages	predominantly	via	up-regulation	of	the	cytokines	IL1,	
TNFalpha,	and	IL6.	These	cytokines	induce	expression	of	receptor	activator	of	NF-κB	
(RANK)	ligand	(RANKL)	which	itself	is	a	key	regulator	of	osteoclast	generation.	The	
RANK	receptor	is	found	predominantly	on	the	surface	membrane	of	osteoclasts.	
Ligand	binding	at	the	RANK	receptor	is	the	initiator	for	osteoclast	differentiation.	This	
process	is	antagonised	by	the	soluble	decoy	receptor	osteoprotegrin	(OPG)	which	is	
secreted	by	osteoblasts	and	regulates	osteoclastic	activity	by	providing	an	alternate	
binding	site	for	RANKL.	Hence	the	RANK	pathway	is	the	key	modulator	of	bone	
turnover	and	can	be	considered	the	“on-switch”	for	bone	loss	
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Figure	1.2-1	Simplified	summary	of	cellular	interactions	occurring	in	periprosthetic	
osteolysis13	
	
	
	
The	volume	of	particulate	debris	generated	is	an	important	factor	in	biological	
clearance.	Particles	that	are	of	a	size	small	enough	to	be	phagocytosed	by	macrophages	
are	transported	away	from	the	joint	via	lymphatic	drainage,	hence	the	volume	of	
debris	that	can	be	transported	is	finite.	This	either	results	in	the	attainment	of	a	state	
of	equilibrium	whereby	the	volume	of	debris	generated	is	transported	and	eliminated	
at	the	rate	at	which	it	is	formed	or	a	state	whereby	particles	are	allowed	to	accumulate	
in	the	synovium	where	they	may	produce	a	biological	reaction17.		
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As	hip	replacement	arthroplasty	evolved	it	became	apparent	that	to	improve	longevity,	
both	wear	and	particle	generation	would	have	to	be	minimised.		
	
1.3 Development	of	Metal-on-Metal	Total	Hip	Arthroplasty	
	
The	first	generation	of	metal-on-metal	total	hip	replacements	was	designed	by	Philip	
Wiles,	who	in	1938	implanted	his	stainless	steel	acetabular	and	femoral	prosthesis	at	
the	Middlesex	Hospital	in	London18.	The	acetabular	cup	gained	fixation	by	2	screws	
and	the	femoral	component	was	secured	by	a	bolt	through	the	neck	of	the	femur.	The	
operation	was	performed	in	six	patients	for	the	indication	of	Still’s	disease.	All	patients	
were	previously	bed-ridden	and	the	operation	restored	their	mobility.	Thirteen	years	
later	only	one	patient	was	alive	and	despite	the	disintegration	of	her	acetabular	
component	and	limited	overall	mobility,	her	operated	hip	caused	her	no	pain19.		
	
Figure	1.3-1	“Ball	&	Cup”	arthroplasty	radiograph	taken	with	implant	in	situ	at	13	years.	
Originally	implanted	by	Wiles	in	1938.	The	retaining	lug	and	screws	for	the	metal	acetabular	
component	have	disintegrated,	there	is	femoral	resorption	of	bone	and	the	bolt	has	broken	
away	from	the	head.	Despite	all	this	the	patient	was	pain	free.	19	
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It	was	Wiles’	one-time	registrar,	Kenneth	McKee,	a	Consultant	at	the	Norfolk	&	
Norwich	Hospital	who	envisaged	in	the	1940s	that:		
“If	one	could	replace	the	bearing	of	a	motor	car	then	it	must	be	possible	in	human	
joints”20	
The	prevailing	wisdom	of	that	time	was	to	use	osteotomy	in	early	arthritis	and		
arthrodesis	for	advanced	and	painful	arthritis.	Inspired	by	a	visit	to	the	United	States	
in	1953,	McKee	began	work	on	developing	a	total	hip	replacement	system	using	Cobalt	
Chromium	Molybdenum	(CoCrMo)	“vitallium”	alloys.	His	earlier	designs	had	used	
stainless	steel,	but	these	had	become	loose	in	less	than	one	year	whereas	using	CoCr	he	
found	that	prostheses	remained	held	tight.	McKee	believed	CoCr	alloy	to	be	superior	
due	to	lower	frictional	wear	and	a	belief	that	there	would	be	a	“complete	lack	of	any	
reaction	by	the	body	tissues	to	this	metal”21.	Cobalt	alloys	are	particularly	suitable	as	a	
bearing	surface	due	to	their	“self-healing”	properties	in	that	they	are	able	to	polish	out	
visible	surface	scratches	with	continued	wear	cycles	rather	than	allowing	a	
progressive	deterioration	of	surface	topography	leading	to	accelerated	wear22;	it	was	
the	use	of	CoCr	alloys	which	characterised	the	first	generation	of	metal-on-metal	THRs.	
	
	McKee	also	believed	the	metal-on-metal	combination	to	be	superior	to	the	evolving	
Charnley	metal-on-polyethylene	bearing	combination	since	he	thought	metal	on	
plastic	may	give	rise	to	trouble	because	of	fine	particles	rubbed	off	the	plastic	would	be	
liable	to	cause	tissue	irritation	and	bone	absorption.		Despite	this,	McKee	does	
acknowledge	that	in	his	earlier	series	wear	took	place	due	to	components	not	having	
been	“lapped-in”	sufficiently	since	at	that	time	the	Thompson	head	was	not	deemed	to	
be	perfectly	spherical	and	had	to	be	manufactured	with	a	perfectly	matching	
acetabular	component.			
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Tribiology	is	the	science	and	engineering	of	interacting	surfaces	in	relative	motion.	It	is	
a	branch	of	mechanical	engineering	and	material	sciences	incorporating	the	study	and	
application	of	principles	of	friction,	lubrication,	and	wear.		At	the	time	of	manufacture	
important	tribological	factors	which	we	now	consider	to	be	important	such	as	
sphericity,	clearance,	and	surface	roughness	were	yet	to	be	fully	understood	and	so	the	
success	or	failure	of	a	McKee-Farrar	bearing	coupling	is	now	thought	to	have	been	due	
to	the	random	chance	occurrence	of	a	compatible	couple23.	
	
As	well	as	being	a	pioneer	of	the	MoM	articulation,	McKee	unwittingly	became	one	of	
the	first	heralds	of	what	was	to	prove	the	Achilles’	heel	of	his	creations	and	its	
progeny;	the	process	that	has	now	been	described	as	either	aseptic	lymphocytic	
vasculitis	associated	lesion	(ALVAL),	metal-on-metal	pseudotumour	or	adverse	
reaction	to	metal	debris	(ARMD).		In	revising	his	earlier	series	of	MoM	implants	McKee	
noted	the	presence	of	“sludge”	although	since	he	believed	the	CoCr	alloy	to	be	inert	it	
was	his	overall	conclusion	that	there	were	no	undesirable	effects	from	the	sludge	
acting	on	soft	tissues	or	bone.		
	
McKee	in	conjunction	with	Watson-Farrar	went	onto	further	refine	MoM	prosthesis	
design	by	recessing	the	neck	of	the	femoral	component	to	minimise	impingement,	
introducing	smaller	component	diameters	in	order	to	improve	the	bony	cover	of	the	
acetabular	cup	and	reducing	femoral	head	sizes	to	convert	a	more	equatorial	bearing	
on	earlier	models	with	associated	increased	wear,	to	a	polar	bearing	where	the	head	
was	smaller	than	the	socket	(Figure	1.3-2).	Upon	subsequent	revision	of	later	
generation	(post	1968)	McKee-Farrar	prostheses,	no	significant	biological	reaction	
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was	apparent	from	the	metallic	staining	that	was	encountered	intraoperatively24.	
McKee	ceased	using	the	MoM	THR	in	1972,	but	his	prosthesis	went	on	to	be	the	first	
MoM	THR	to	be	used	in	North	America.		
	
Figure	1.3-2	Final	designs	of	the	McKee-Farrar	Total	Hip	Replacement	system.	2	head	sizes	(1	
𝟓𝟓
𝟖𝟖
	
and	1
𝟑𝟑
𝟖𝟖
		inch	with	the	option	of	either	a	short	or	a	long	neck.	24	
	
	
The	prosthesis	fell	out	of	favour	due	to	reports	of	early	failures	25	and	fell	victim	to	the	
success	of	Charnley’s	low	friction	arthroplasty,	however,	the	longer	term	survival	of	
the	McKee-Farrar	is	comparable	to	those	of	the	Charnley	with	one	series	
demonstrating	a	28	year	survival	rate	of	74%26.	
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The	other	major	first	generation	CoCr	MoM	prosthesis		was	created	by	Peter	Ring	at	
Redhill,	Surrey	in	1964.	It	was	a	cementless	design	featuring	a	hemispherical	cup	with	
a	long	threaded	stem	that	inserted	into	the	iliopubic	bar.	This	was	paired	with	a	
standard	40mm	fenestrated	Moore	prosthesis.	The	original	design	underwent	a	series	
of	revisions	in	response	to	an	initially	disappointing	56%	satisfactory	outcome	at	11-
14	years	27.	The	eventual	final	iteration	comprised	of	a	paired	polar	bearing	with	a	
femoral	component	with	a	neck-shaft	angle	of	135	degrees	and	a	choice	of	3	lengths.	
Although	survivorship	did	increase	with	design	modifications,	the	further	use	of	the	
system	was	abandoned	once	the	metal-on-metal	coupling	was	discontinued	in	favour	
of	using	a	polyethylene	press-fit	cup	which	resulted	in	granulomatous	lesions	as	the	
result	of	polyethylene	wear	debris28,29.	As	far	as	the	original	metal-on-metal	designs	
are	concerned	little	wear	of	the	CoCr	bearing	surface	was	observed	at	revision	with	
minimal	osteolysis	of	surrounding	bone30	and	with	a	lower	revision	rate	than	the	
McKee-Farrar	of	8.7%	at	a	follow	up	of	5-20	years31.		
	
1.4 Abandonment	of	First	Generation	Metal-on-Metal	Prostheses	
The	use	of	the	MoM	articulation	was	abandoned	in	favour	of	MoP	due	to	a	number	of	
factors.	
1.4.1 Manufacturing	Problems	
Cast	cobalt	chrome	is	much	harder	to	manufacture	than	polyethylene	which	is	easily	
mass	produced.	Contemporary	machine	tools	were	unable	to	retain	the	high	degree	of	
accuracy	required	in	the	manufacturing	process	since	they	required	frequent	
sharpening	and	replacement.		Creation	of	a	CoCr	alloy	prosthesis	was	a	labour	
intensive	process	which	required	skilled	machinists,	hence	mass	manufacture	was	
difficult	and	more	expensive	compared	to	Charnley’s	alternative	bearing	surface32.		
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1.4.2 Frictional	Torque	Issues	
	
Further	concerns	regarding	the	longevity	of	MoM	articulations	arose	from	the	problem	
of	frictional	torque.	Charnley	performed	a	series	of	experiments	using	a	“pendulum	
comparator”	in	which	he	demonstrated	the	superiority	of	his	22mm	MoP	bearing	
couple	above	all	others33.			Using	the	McKee-Farrar	MoM	prosthesis	he	illustrated	that	
when	a	pendular	force	was	applied	the	MoP	articulation	moved	freely	whereas	after	a	
short	period	with	only	a	minimal	load	the	MoM	prosthesis	intermittently	jammed.	
Charnley	believed	the	McKee-Farrar	to	be	a	suboptimal	annular	bearing	and	as	such	
prone	to	having	high	frictional	torque	under	load	and	so	intermittent	seizure	would	
occur	due	to	engagement	of	a	“clutch”	mechanism.		
	
Simulator	experiments	performed	by	Freeman,	Andersson	and	Swanson	34,35confirmed	
higher	frictional	torques	from	MoM	articulations	versus	MoP.	They	recommended	MoP	
on	the	basis	that	heat	generated	from	the	process	of	cementation	weakened	the	
fixation	of	the	cup	in	the	acetabulum	and	hence	the	lower	frictional	torque	seen	with	
MoP	bearings	would	promote	survival.		
	
1.4.3 Wear	Particle	Generation	
	
It	is	now	known	that	all	bearing	surfaces	generate	wear	particles	which	elicit	an	
immune	response	with	subsequent	periprosthetic	osteolysis.	In	the	1970s	advocates	of	
the	second	generation	MoM	agreed	with	McKee	that	CoCr	wear	particles	were	inert.	At	
	 14	
the	time	it	was	not	known	which	bearing	couple	would	eventually	triumph	and	the	
concern	seemed	to	be	more	about	the	possible	deleterious	effects	of	polyethylene	wear	
particles.	The	designers	of	the	Stanmore	MoM	THR	prosthesis	claimed36	
“…if	the	wear	products	of	polyethylene	do	not	produce	an	undesirable	tissue	response;	
neither	adjacent	nor	in	tissues	remote	form	the	implant	then	metal	on	metal	bearings	
will	be	discarded”	
The	hip	simulator	study	by	Swanson	et	al37	comparing	the	McKee-Farrar	MoM	THR	
and	the	Charnley	MoP	articulation	demonstrated	that	over	4	million	cycles	Charnley’s	
design	did	not	release	any	wear	polyethylene	wear	debris	particles	in	contrast	to	the	
McKee	which	produced	a	visible	quantity	of	debris.		
	
1.4.4 Biological	Concerns	
	
The	potential	for	metal	particles	generated	by	MoM	articulations	to	induce	adverse	
reactions	local	and	distant	to	the	site	of	implantation	was	a	major	factor	in	the	original	
abandonment	of	MoM	prostheses	and	the	success	of	MoP.	The	work	of	Swanson,	
Freeman,	and	Heath	37,38	demonstrated	the	carcinogenic	properties	of		CoCrMo	wear	
particles	by	injecting	particles	obtained	by	running	a	MoM	THR	on	a	wear	simulator	
into	the	thigh	of	a	number	of	rats.	The	rats	developed	histological	evidence	of	
malignancy	including	localised	rhabdomyosarcoma	and	lymphosarcoma.	Metal	
particles	had	also	spread	to	the	para-aortic	nodes	and	were	noted	to	be	intracellular.	
Their	conclusion	that	there	may	be	a	risk	of	carcinogenesis	from	CoCrMo	particles	in	
humans,	but	that	the	induction	period	was	likely	to	be	longer	than	the	life	expectancy	
of	most	patients	who	might	benefit	from	a	THR	was	not	reassuring.	Colman,	
Herrington,	and	Scales	(1973)39	were	the	first	to	demonstrate	raised	levels	of	Co	and	
	 15	
Cr	in	the	hair,	blood,	and	urine	and	the	first	to	propose	that	after	a	period	of	
establishing	equilibrium	the	concentration	of	cobalt	and	chromium	in	urine	might	be	
equal	to	the	rate	of	wear	of	the	implant.		
	
It	was	Evans	et	al	in	197440	who	discovered	that	not	only	did	CoCr	implants	release	
both	cobalt	and	chromium	to	the	tissues	adjacent	to	the	prosthesis	but	also	that	these	
metals	were	carried	in	the	bloodstream	and	were	presented	to	the	tissues	of	the	body	
as	a	whole.	Their	study	demonstrated	positive	skin	sensitivity	to	metal	in	9	out	of	14	
patients	who	had	a	loose	MoM	implant,	thus	implying	that	implantation	of	a	MoM	
prosthesis	led	to	a	cascade	of	events	resulting	in	a	delayed	hypersensitivity	reaction	to	
metal	ions	that	led	to	vascular	occlusion,	bone	necrosis	and	implant	loosening.	The	
overall	conclusion	being	that	MoP	was	the	preferred	bearing	combination.		
	
	
1.5 Development	of	Next	Generation	MoM	THR	
	
Interest	in	the	use	of	MoM	bearings	was	re-kindled	in	the	1980s	and	1990s	due	
concerns	about	polyethylene	cup	wear	in	conventional	MoP	THR	designs.	A	review	of	
the	literature	by	Dumbleton	et	al	41in	2002	has	suggested	the	concept	of	an	osteolysis	
threshold	whereby	osteolysis	is	rarely	observed	below	a	wear	rate	of	0.1mm/year	and	
that	a	practical	osteolysis	threshold	of	below	0.05mm/year	would	greatly	reduce	if	not	
eliminate	the	problem.		
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The	perception	that	MoM	bearings	would	be	more	resistant	to	wear	was	supported	by	
good	long-term	results	obtained	by	some	series	of	first-generation	MoM	implants;	it	
was	reported	that	in	a	series	of	Ring	THRs	where	these	implants	were	revised	there	
was	very	little	wear	of	the	Co-Cr	interface	and	minimal	observed	osteolysis	of	
surrounding	bone	31.		This	was	aided	by	publication	of	favourable	long-term	
survivorship	rates	of	up	to	77%	at	20	years	for	first	generation	MoM	McKee-Farrar	
THRs	which	is	comparable	to	those	of	Charnley	devices	which	had	a	73%	aseptic	
probability	of	survival	in	the	same	period	26.	
	
Weber	designed	the	Metasul	prosthesis	in	1988.	This	was	a	forged,	high	carbon	
prosthesis	which	was	made	possible	by	improvements	in	metallurgy	and	
manufacturing	leading	to	consistently	reproducible	and	harder	bearing	surfaces.	This	
MoM	prosthesis	had	improved	clearance	(the	space	between	the	femoral	head	and	
acetabular	surface	permitting	fluid	film	lubrication	and	clearance	of	debris	from	within	
the	joint),	but	despite	early	good	results	with	this	system	it	was	discovered	that	use	of	
a	low	carbon	acetabular	component	and	a	higher	carbon	stem	possibly	contributed	to	
early	osteolysis42	and	that	cam	impingement	from	the	skirted	version	of	the	28mm	
head	may	have	led	to	biological	reactions	to	wear	debris43.		
	
Simulator	studies	and	retrieval	analyses	by	Sieber	et	al	44revealed	that	second	
generation	MoM	had	a	volumetric	wear	rate	60	times	lower	than	that	of	conventional	
MoP,	with	a	typical	linear	wear	rate	of	5μm/	year;	approximately	20	times	lower	than	
a	MoP	bearing.	Less	osteolysis	was	observed	with	MoM	implants	which	suggested	that	
the	biological	response	may	be	governed	more	by	wear	particle	size	as	opposed	to	the	
total	volumetric	amount	of	debris.	It	was	proposed	that	metal	solubility	of	wear	
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particles	may	predispose	to	an	improved	tissue	clearing	capacity	hence	reduced	
induction	of	the	osteolysis	cascade	by	MoM	implants.	The	authors	noted	that	an	
increase	in	serum	and	urine	Co	was	observed	in	patients	with	MoM	implants,	but	that	
in	their	series	no	clinical	abnormality	could	be	attributed	to	this	even	in	patients	with	
an	implantation	time	of	ten	years.	It	was	believed	that	second	generation	MoM	
implants	may	increase	survival	of	THRs	which	would	make	them	more	suitable	for	
younger	patients	with	a	higher	level	of	activity.		
	
Further	developments	in	MoM	THR	were	aided	by	a	greater	understanding	of	
tribology	and	material	science	and	was	accelerated	by	the	successful	development	of	
hip	resurfacing	arthroplasty,	popularised	by	the	Birmingham	Hip	resurfacing	
developed	by	McMinn.	Larger	diameter	bearings	allow	for	a	better	replication	of	
normal	hip	joint	biomechanics	whilst	preserving	bone	stock	and	reducing	risk	of	
dislocation	by	increasing	the	jump-distance	to	subluxation	(the	distance	the	prosthetic	
femoral	head	needs	to	travel	in	order	for	subluxation	to	occur).	This	led	to	the	
emergence	of	three	distinct	categories	of	MoM	bearing	coming	into	popular	usage:	1)	
MoM	resurfacing	arthroplasty,	2)	Large	diameter	THR	(>36mm	femoral	head)	and	3)	
Small	diameter	MoM	THR	(<36mm	femoral	head).		
	
1.6 Failure	of	Current	Generation	MoM	THR	
	
An	estimated	1	million	MoM	hip	bearings	have	been	implanted	worldwide	since	1996	
with	approximately	35%	of	all	hip	implants	in	the	USA	involving	a	MoM	bearing.	In	the	
	 18	
UK	31,171	stemmed	MoM	prostheses	were	implanted	between	2003	and	2011	
representing	8%	of	THRs	performed	in	that	time45.		
	
According	to	the	NJR,	in	2012	over	10,000	hip	revisions	were	performed	which	
equates	to	12%	of	all	hip	arthroplasties.	Whilst	aseptic	loosening	is	the	most	common	
cause	for	revision	surgery	(40%),	revision	for	ARMD	associated	with	a	MoM	
arthroplasty	is	now	the	second	most	common	(13%),	with	infection	(12%)	as	a	cause	
in	third	place.	The	revision	rate	following	primary	MoM	hip	arthroplasty	between	
2003	and	2010	was	13.61%	which	is	three	times	higher	than	any	other	bearing	
combination	at	7	year	follow	up46.	This	contrasts	with	the	UK	National	Institute	for	
Health	and	Clinical	Excellence	(NICE)	recommendation	of	an	acceptable	10%	revision	
rate	for	hip	arthroplasty	at	10	years.	Between	2006	and	2012	use	of	MoM	articulations	
declined	dramatically	from	10.8%	to	just	1.3%	in	response	to	concerns	about	necrosis	
of	periprosthetic	soft	tissue	and	bone.		
	
In	2010	the	UK	Medicines	and	Healthcare	Regulatory	Authority	(MHRA)	issued	a	
medical	device	alert	for	all	MoM	articulations47	with	the	advice	that	all	patients	with	
such	a	bearing	be	followed	up	by	an	orthopaedic	surgeon	with	measurement	of	Co	and	
Cr	levels	in	blood	and	cross	sectional	imaging	with	either	ultrasound	or	metal	artefact	
reduction	sequence	(MARS)	MRI.	Further	guidance	was	issued	in	201248	which	
recommended:	
1) Annual	clinical	review	for	at	least	five	years	in	the	case	of	MoM	hip	resurfacing	
arthroplasty	(HRA)	and	for	the	life	of	the	implant	in	the	case	of	both	large	
(>36mm	head)	and	small	(<36mm)	MoM	THRs.	
	 19	
2) Measurement	of	Co	&	Cr	metal	ion	levels	with	a	level	of	>7ppb	being	suggestive	
of	soft	tissue	reaction.		
3) Cross	sectional	imaging	with	MARS	MRI	or	ultrasound	for	all	symptomatic	
patients	or	in	asymptomatic	patients	with	rising	metal	ion	levels.	
4) Consideration	for	revision	surgery	if	imaging	abnormal	or	metal	ion	levels	
demonstrate	a	rising	trend.	
	
The	revision	burden	for	MoM	bearings	has	significant	financial	implications	with	the	
full	economic	cost	of	a	revision	estimated	at	up	to	£30,00049	this	is	compounded	by	the	
fact	that	these	implants	were	marketed	towards	younger	and	more	active	patients	
who	now	face	revision	surgery	complicated	by	soft	tissue	and	bone	loss	at	an	early	age.	
	
The	United	States	Food	&	Drug	Administration	(FDA),	the	European	Federation	of	
Orthopaedics	&	Traumatology	(EFORT),	The	Australian	Therapeutic	Goods	
Adminstration	and	Health	Canada	have	all	issued	their	own	guidance	and	risk	
stratification	algorithms	for	long	term	follow	up	of	patients	with	a	MoM	hip	
arthroplasty,	but	whilst	there	is	some	consensus	between	them,	their	
recommendations	are	not	uniform,	are	not	wholly	evidence	based	and	may	not	be	
cost-effective50.	
1.6.1 Biology	of	Adverse	Reactions	to	Metal	Debris	
	
As	MoM	resurfacing	and	THR	became	more	commonplace,	an	apparently	new	and	
severe	complication	of	adverse	tissue	reaction	to	metal	debris	became	recognised.	The	
nomenclature	surrounding	the	biological	processes	that	occur	around	a	failing	MoM	
articulation	has	not	been	uniform.		However,	it	is	becoming	clear	that	the	unique	
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reaction	to	MoM	implants	is	due	to	the	simultaneous	presence	of	metal	wear	
nanoparticulates,	corrosion	products,	and	metal	ion	species.	The	biologically	active	
load	is	increased	further	as	wear	nanoparticles	can	themselves	undergo	corrosion	thus	
increasing	the	total	level	of	dissolved	ions.		
	
Co	and	Cr	are	transition	metals	and	are	the	major	constituents	of	orthopaedic	alloys	
commonly	used	in	MoM	arthroplasty	surgery.	Both	are	present	in	the	natural	water	
supply	and	food	and	are	essential	trace	elements	required	by	the	body	for	normal	
cellular	metabolic	function.		
	
Cobalt	is	a	constituent	of	vitamin	B12	(cyanocobalomin).	Chronic	industrial	exposure	
to	cobalt	containing	fumes	or	dust	can	give	rise	to	“hard	metal	lung	disease”,	a	fibrosis	
characterised	by	desquamative	and	giant	cell	interstitial	pneumonitis51.	Cobalt	
poisoning	has	been	associated	with	cardiomyopathy,	neurotoxicity,	thyroid	disorders,	
and	dermatitis52.	It	is	mainly	present	in	vivo	as	Co(II)	oxidation	state.		
	
Chromium	is	required	for	normal	energy	metabolism	where	it	may	enhance	the	
activity	of	insulin	via	glucose	tolerance	factor	(GTF)53.	High	doses	of	Cr	are	potentially	
harmful	since	Cr	distributes	to	virtually	all	tissues	with	highest	concentrations	being	
found	in	the	liver,	kidney,	and	bone.	The	toxicity	profile	is	dependent	upon	the	
oxidation	state.		Cr	(VI)	uptake	into	cells	is	an	active	process	mediated	via	non-specific	
ion	channels.	In	the	intracellular	environment	Cr(VI)	is	unstable	and	reduces	in	a	
stepwise	manner	to	Cr(III)	with	the	release	of	free	radicles.	This	reduction	of	Cr(VI)	to	
Cr(III)	gives	rise	to	reactive	intermediates	which	contributes	to	cytoxicity,	
genotoxicity,	and	carcinogenicity	of	Cr(VI)	containing	compounds;	there	is	an	
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increased	incidence	of	bronchial	and	nasal	carcinoma	in	those	exposed	to	industrial	
levels		54.	Cr(VI)	is	a	class	1	human	carcinogen	by	the	World	Health	Organisation	
(WHO)	and	is	considered	to	be	1000	times	more	toxic	than	trivalent	Cr.		Cr(III)	has	
been	shown	to	have	antigenic	properties	with	the	ability	to	induce	inflammatory	and	
allergic	reactions	55.		
	
Whilst	links	between	metal	ions	and	carcinogenesis	have	been	established	for	
industrial	levels	of	exposure,	no	demonstrable	link	between	raised	metal	ion	levels	
associated	with	failing	MoM	arthroplasty	has	been	demonstrated	in	humans.	A	linkage	
study	between	the	NJR	and	hospital	episode	statistic	(HES)	databases	has	failed	to	
demonstrate	any	increased	risk	of	malignancy	in	MoM	arthroplasty	patients	at	up	to	
seven	years56.	
	
	The	term	“metallosis”	has	come	to	be	the	macroscopic	descriptive	term	for	the	
staining	of	periprosthetic	soft	tissues	by	metal	particulate	debris.	In	recent	times	the	
umbrella	term	of	“adverse	reaction	to	metal	debris”	or	ARMD	has	been	coined	by	
Langton	et	al	57	to	describe	joint	failure	secondary	to	surface	wear	of	the	bearing	
surface	or	corrosion	debris	in	the	absence	of	any	other	obvious	explanation.	It	
encompasses	metallosis,	pseudotumour,	and	ALVAL.	The	United	States	Food	and	Drug	
Administration	(FDA)	has	popularised	the	term	“adverse	local	tissue	reaction”	(ALTR)	
to	describe	the	same	phenomenon	
(http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm335775.htm)	
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In	2008	Pandit	et	al	reported	on	17	patients	(20	hips)	with	a	MoM	resurfacing	
arthroplasty	who	had	suffered	a	soft	tissue	reaction	characterised	by	extensive	tissue	
necrosis	and	bone	loss	termed	and	gave	these	lesions	the	term	“pseudotumour”58.			
The	term	“pseudotumour”	has	been	used	to	describe		a	granulomatous	mass	or	
destructive	cystic	lesion	that	is	neither	infective	or	neoplastic.	There	is	formation	of	a	
synovial-like	biomembrane	which	can	lead	to	bone	absorption	via	production	of	PGE2,	
collagenase,	interleukin-1,	and	tumor	necrosis	factor59	.	Where	pseudotumor	is	
associated	with	a	MoM	hip	arthroplasty	there	is	a	spectrum	of	damage	ranging	from	a	
small	indolent	cyst	to	local	invasion	with	substantial	periarticular	soft	tissue	
destruction	and	at	worst	extensive	bone	destruction	and	pathological	fracture60.	
Patients	may	present	with	pain,	discomfort,	or	a	palpable	swelling.		
	
MoM	periprosthetic	pseudotumour	has	been	described	histologically	by	Willert61	as	an	
aseptic	lymphocytic	vasculitis	associated	lesion	(ALVAL)	characterised	by	areas	of	
tissue	necrosis	and	dense	perivascular	lymphocytic	infiltrate	and	lymphocytic	cuffing	
in	the	absence	of	infection62	(Figure	1.6-1).	After	hip	arthroplasty	a	periprosthetic	
neocapsule	is	formed.	The	neocapsule	is	contained	at	the	deep	surface	associated	with	
a	pseudosynovial	membrane.	Studies	on	explanted	surgical	tissue	from	MoM	revision	
arthroplasty	demonstrated	dense	lymphocytic	infiltration	in	perivascular	tissue	with	
surface	ulceration	noted	to	be	more	extensive	when	compared	to	well	fixed	MoP	
implants	which	raises	the	question	as	to	whether	the	mechanism	of	MoM	implant	
failure	is	immune	mediated.		Metal	particles	are	phagocytosed	by	histiocytes	leading	to	
release	of	inflammatory	and	osteolytic	mediators	which	induce	aseptic	loosening	and	
periprosthetic	osteolysis	63.	Inflammation	and	localised	oedema	can	lead	to	pain,	
however,	this	may	be	a	late	presenting	sign	and	silent	soft	tissue	pathology	is	common	
in	patients	with	a	MoM	THR	64		
	 23	
	
Figure	1.6-1	A	representative	micrograph	of	tissue	from	a	failed	28mm	MoM	Ultima	THR.	The	
section	is	stained	with	haematoxylin	and	eosin	(x100	magnification).	There	are	3	distinct	
layers:	an	outer	layer	(1)	showing	signs	of	ulceration	and	areas	of	fibrinoid	necrosis,	a	middle	
layer	(2)	demonstrating	features	of	necrosis,	with	few	tissue	features	and	typical	“ghost”	nuclei,	
and	a	third	inner	layer	(3)	demonstrating	typical	areas	of	dense	perivascular	lymphocytic	
infiltration	(L),	fibroblasts	(F),	vessels,	and	macrophages	(white	arrows)	
	
	
In	2007,	Goodman	65	proposed	that	there	is	a	non-specific	macrophage-mediated	
immune	response	to	arthroplasty-generated	particulate	debris	and	that	prolonged	
exposure	to	metal	debris	may	be	associated	with	a	generalised	immune	reaction	
initially	involving	monocytes	and	granulocytes	which	has	a	variable	course	and	is	
generally	self-resolving,	but	that	in	some	patients	there	is	activation	of	the	specific	T	
lymphocyte	immune	system	to	metal	particles	complexed	with	specific	serum	protein.	
This	metal-protein	complex	serves	as	a	hapten66,67.	This	would	correlate	with	the	
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perivascular	lymphocytic	cuffing,	granulomatous	response,	and	inflammatory	infiltrate	
observed		in	periprosthetic	tissues	from	revised	MoM	which	would	be	suggestive	of	a	
T-cell	mediated	Type	IV	delayed	hypersensitivity	reaction68	69.	
	
Figure	1.6-2	Simplified	schematic	overview	of	potential	interaction	between	innate	
macrophage	mediated	immune	and	adaptive	T-cell	mediated	response	to	metal	debris	from	a	
MoM	THR.	Adapted	from	Polyzois	et	al	201270	
	
It	is	still	a	source	of	controversy	as	to	whether	the	local	effects	seen	in	ARMD	are	the	
result	of	an	innate	hypersensitivity	to	metals	or	if	it	is	an	adaptive	immune	response.		
In	2009	Caicedo	et	al	proposed	that	cobalt	containing	particles	and	the	ions	produced	
as	the	result	of	their	corrosion	activate	a	response	arising	from	an	“Inflammasome	
Danger-Signalling	Pathway”	which	is	dose-dependent.	The	inflammasome	is	a	
multiprotein	intracellular	complex	that	detects	both	pathogenic	micro-organisms	and	
sterile	stressors	and	through	a	series	of	intermediate	steps	activates	pro-inflammatory	
cytokines	such	as	IL-1b,	IL-18,	TNFα,	and	NFκβ	leading	to	an	array	of	inflammatory	
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responses	including	osteoblast	inhibition	and	maturation	of	osteoclastic	precursors	
leading	ultimately	to	osteolysis.	Inflammasomes	can	also	induce	a	form	of	cell	death	
termed	pyroptosis	and	dysregulation	of	inflammasomes	may	be	associated	with	a	
number	of	autoimmune	conditions.	Further	in	vitro	studies	on	human	macrophages	by	
Caicedo	et	al	2013	71	further	underlines	the	importance	of	particle	size	and	
morphology.	It	was	found	that	increasing	both	CoCrMo-alloy	particle	size	and	surface	
irregularity	induces	increased	macrophage	inflammasome	activation	via	potential	
lysosomal	destabilization	mechanisms.	Small	1μm	round	particles	were	phagocytosed	
by	macrophages	without	inducing	a	measurable	response	in	terms	of	IL-1β	whereas	
larger	6-7μm	particles	induced	a	greater	than	ten-fold	increase	in	IL-1β.	Large,	
irregularly-shaped	6μm	particles	induced	lysosomal	destabilisation	with	release	of	
Cathepsin	B	which	acts	as	a	danger	signal	to	activate	a	NALP-ASC	(NACHT,	LRR	and	
PYD	domains-containing	protein	3)	–	(Apoptosis-associated	speck-like	protein	
containing	a	C-terminal	caspase-recruitment	domain)	inflammasome	complex	of	
proteins	leading	to	caspase-1	activation	and	cleavage	of	pro-IL-1β	to	activated	IL-1β	
which	is	released	from	the	cell	to	exert	further	inflammatory	effects.		
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Figure	1.6-3	Effect	of	particle	size	and	surface	morphology	upon	Nalp3-ASC	inflammasome	
complex	activation.	Reproduced	from	Caicedo	et	al	201371	
	
Flow	cytometric	experiments	using	peripheral	blood	mononuclear	cells	(PBMCs)	
cultured	with	laser-ablated	particles	from	an	Ultima	TPS	stem	have	shown	that	the	
volume	of	nanoparticulate	sized	(6nm)	debris	has	an	effect	on	cellular	proliferation.	
Higher	volumes	of	nanoparticles	resulted	in	fewer	observed	cell	cycles	after	six	days	
incubation	(Figure	1.6-4).	
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Figure	1.6-4		PBMCs	incubated	for	sixe	days	with	different	concentration	of	metal	particles	
from	a	laser	ablated	Ultima	TPS	stem.	CFSE	(carboxyfluorescein	diacetate	succinimidyl	ester)	
staining	on	day	1	and	day	6	reveals	live	cells.	Tall	peak	represents	day	1,	shorter	peak	
represents	day	6.	Data	presented	at	EFORT	2013,	Istanbul72.	Reproduced	with	permission	of	Dr	
P	Court.		
	
At	sites	of	inflammation	there	is	generally	a	decreased	availability	of	oxygen	leading	to	
a	state	of	hypoxia	which	in	turn	is	proinflammatory	and	promotes	further	tissue	
damage73.	A	hypoxic	microenvironment	can	act	as	an	“inflammatogen”	to	activate	
macrophages	which	infiltrate	hypoxic	tissues.	Hypoxia	inducible	factors	1	and	2	(HIFs)	
are	transcription	factors	involved	in	the	adaptation	of	cells	in	a	hypoxic	and	or	
inflammatory	state.	HIF-1	is	a	heterodimeric	protein	comprising	an	alpha	and	beta	
subunits	of	which	the	alpha	subunit	is	oxygen	sensitive.	In	a	hypoxic	environment	the	
HIF1-alpha	subunit	stabilizes,	translocates	to	the	nucleus	and	dimerizes	with	HIF1-
beta	and	begins	the	transcription	of	hypoxia-inducible	genes	including	vascular	
endothelial	growth	factor	(VEGF)	which	has	been	linked	to	aseptic	loosening	and	bone	
resorption74.	Samelko	et	al	in	2013	demonstrated	that	cobalt	alloy	and	its	degradation	
	 28	
products	in	preference	to	other	metal	alloys	can	effect	local	innate	immune	responses.	
Increasing	concentrations	of	Co	ions	caused	significant	up-regulation	of	HIF1-alpha	
with	a	maximal	response	at	0.3mM.	Cobalt	alloy	particles	also	induced	significantly	
elevated	levels	of	HIF1-α,	TNFα,	VEGF,	and	ROS	(reactive	oxygen	species)	expression	
in	human	macrophages	where	Ti	alloy	particles	did	not.	Elevated	HIF1-α	expression	
was	also	found	in	the	periprosthetic	tissues	of	patients	being	revised	for	ARMD	
compared	to	those	being	revised	for	aseptic	loosening	of	a	MoP	implant.			
	
Figure	1.6-5	Schematic	of	HIF-1α	induction	in	response	to	Co	alloy	particulate	debris	and	ions.	
Reproduced	from	Samelko	et	al	201374	
	
	
Further	studies	on	human	macrophages	by	Nyga	et	al		have	confirmed	that	cobalt	
nanoparticles	and	Co	ions	are	“hypoxia	mimetic”	which	facilitates	dimerization	of	
HIF1-alpha	to	the	beta	subunit	with	subsequent	upstream	HIF-1	transcriptional	
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activity	even	in	the	presence	of	oxygen	via	a	ROS-independent	ascorbate	depleting	
mechanism75.		
	
Toll-like	receptors	(TLRs)	are	a	family	of	transmembrane	receptors	expressed	mainly	
in	immune	cells	including	monocytes,	macrophages,	dendritic,	and	B	cells	and	have	
critical	roles	in	regulation	of	immune	responses	and	the	inflammatory	cascade.	Of	the	
known	TLR	subtypes	1	to	10	are	functional	in	humans.	These	receptors	play	a	role	in	
host	immunity	via	recognition	of	various	microbial	components	or	pathogen-
associated	molecular	patterns	(PAMPs).	Activation	of	TLRs	by	ligands	initiates	
downstream	signalling	pathways	such	as	NF-KB,	mitogen-activated	protein	kinase	
(MAPK)	and	type-1	interferon	pathways	that	are	important	in	inflammatory	responses	
and	may	ultimately	lead	to	rapid	cellular	differentiation	and	apoptosis76.	
	
In	examining	if	hypoxic	stress	modulates	the	TLR	activity	of	macrophages,	Kim	et	al	73	
demonstrated	that	TLR4	expression	in	macrophages	is	upregulated	via	HIF-1	in	
response	to	both	hypoxic	stress	and	to	the	hypoxia	mimetic	CoCl2.	TLR4	is	associated	
with	a	risk	of	hypoxia	related	disease,	for	example	its	expression	is	upregulated	in	the	
tissues	of	patients	with	myocardial	ischaemic-reperfusion	injury.	In	TLR4-deficient	
mice,	tissue	inflammatory	responses	and	pathological	changes	are	significantly	
decreased	in	response	to	ischaemic	injury.		
	
TLR4	requires	adaptor	proteins	for	activation	including	myeloid	differentiation	
primary	response	gene	(MyD88)	and	toll/interleukin-1	receptor	domain-containing	
adaptor-inducing	interferon-beta	(TRIF).	Although	activated	by	the	TLR4	receptor,	
stimulation	of	the	MyD88	and	TRIF	pathways	leads	to	the	secretion	of	a	diverse	array	
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of	cytokines.	In	the	MyD88	pathway	there	is	ultimate	secretion	of	interleukin-6	(IL-6)	
and	interleukin-8	(IL-8)	which	are	both	involved	in	the	innate	immune	response	e.g.	
neutrophil	recruitment	to	sites	of	inflammation77.	Additionally	IL-8	has	been	shown	to	
cause	peripheral	blood	mononuclear	cells	(PBMCs)	to	differentiate	into	osteoclasts.	
The	TRIF	pathway	results	in	the	secretion	of	type	1	interferon	as	well	as	pro-
inflammatory		C-X-C	motif	chemokine	(CXCL10)	which	is	involved	in	the	adaptive	
immune	response	where	its	function	is	to	recruit	activated	T-lymphocytes	which	
prolong	the	immune	response.	Lawrence	et	al	in	201478	have	demonstrated	using	a	
human	monocytic	cell	line	(Monomac	6)	that	Co2+	ions	at	clinically	relevant	
concentrations	specifically	activate	human	TLR4	resulting	in	increased	IL-8	and	
CXCL10	secretion	and	gene	expression	via	activation	of	both	the	MyD88	and	TRIF	
arms	of	the	TLR4	signalling	pathway.	Overall	this	suggests	Co2+	can	initiate	both	innate	
and	adaptive	immune	responses	and	that	Co	ions	may	cause	a	prolonged	inflammatory	
response	in	periprosthetic	tissues.	However,	even	accounting	for	implant	related	
factors	which	may	contribute	to	a	higher	periprosthetic	Co	load,	not	all	patients	
develop	ARMD	and	in	those	that	do,	ARMD	does	not	appear	at	a	uniform	rate	post	
implantation	which	suggests	that	genetic	variability	and	other	patient	factors	may	
have	a	role	to	play.		
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Figure	1.6-6	Cobalt	alloy	particle	mediated	TLR4	activation	via	the	MyD88	and	TRIF	pathways.	
TLR4	with	co-receptors	for	myeloid	differentiationfactor-2	(MD-2)	and	cluster	of	
differentiation-14	(CD-14)	which	are	required	for	activation	which	initiates	an	intracellular	
signalling	cascade,	via	2	main	mechanisms.	The	MyD88	pathway	leads	to	activation	of	the	
enzyme	complex	inhibitor	of	kappa	B	Kinase	(IKK)	and	the	transcription	factor	Nuclear	Factor	
Kappa-B	(NFκB)	with	upregulation	of	proinflammatory	cytokines	IL-6	and	IL-8.	Activation	of	
the	TRIF	pathway	increases	the	expression	of	Type	I	interferon,	CXCL10	and	subsequent	MHC	II	
expression	and	T	cell	activation	in	the	alternative	pathway.	Modified	from	Lawrence	et	al	
201478	
	
Despite	this	recent	expansion	in	knowledge	of	possible	cellular	mechanisms	by	which	
metal	particles	and	ions	may	effect	an	inflammatory	response,		the	precise	mechanism	
of	how	ARMD	develops	in	vivo	and	the	roles	and	interplay	of	Inflammasome	danger	
signalling	pathway,	HIF-1	pathway,	and	TLR4	mediated	IL-8	and	CXCL10	secretion	has	
yet	to	be	conclusively	established.	
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1.6.2 Implant	Factors	
	
MoM	hip	implants	are	manufactured	from	Cobalt-Chromium-Molybdenum	(Co-Cr-Mo)	
alloys	which	conform	to	the	standards	set	by	The	American	Society	for	Testing	and	
Materials	(ASTM).	Alloys	are	composed	of	58.9-69.5%	Co,	27-30%	Cr,	5-7%	Mo	and	
smaller	amounts	of	other	elements	(Manganese,	Silicone,	Nickel,	Iron,	and	Carbon)		in	
order	to	comply	with	ASTM	F-75	for	cast	alloys	or	F-1537	for	wrought	alloys.	Surgical	
grade	cobalt	based	alloys	are	generally	well	suited	to	use	as	a	bearing	couple	due	to	
their	hardness	and	corrosion	resistance.	They	have	a	capacity	to	“self-heal”	that	is	to	
polish	out	visible	surface	scratches	with	continuous	wear	cycles	as	opposed	to	
undergoing	progressive	deterioration	of	the	surface	leading	to	accelerated	wear79.	
	
Based	on	their	carbon	contents	CoCrMo	alloys	can	be	divided	into	either	high-carbon	
alloy	(0.05-0.35wt%)	and	low-carbon	alloys	(<0.05%wt%).	High-carbon	alloys	are	
superior	in	terms	of	wear-resistance	owing	to	strengthening	effects	of	carbides	and	the	
fact	that	low-carbon	bearings	initially	experience	a	higher	wear	rate	in	the	“bedding-
in”	phase	whilst	steady	state	wear	between	high	and	low	carbon	alloys	is	
indistinguishable80.	Second	and	third	generation	MoM	implants	have	a	higher	wear	
resistance	secondary	to	their	higher	carbide	content.		
	
MoM	bearings	generate	greater	numbers	of	particles	of	a	smaller	diameter	than	MoP	
bearings.	In	the	retrieval	study	by	Doorn	et	al	81,	MoM	bearings	were	estimated	to	
generate	approximately	5x1011	particles	per	annum	in	comparison	to	MoP	implants	
which	produce	approximately	in	the	order	of	6.7x1012	to	2.5x1014	particles	per	annum	
with	the	majority	of	wear	particles	being	less	than	50nm	in	diameter;	ten	times	
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smaller	than	polyethylene	wear	particles.	Due	to	their	smaller	size,	metal	wear	debris	
and	their	degradation	products	are	bioactive	and	may	enter	the	cell	and	affect	cellular	
function.	
	
Metal	wear	particles	are	insoluble	and	are	principally	composed	of	Co-Cr-Mo	
nanoparticles.	Particles	of	100nm	or	greater	in	size	remain	trapped	in	the	joint	since	
the		synovial	membrane	acts	as	a	porous	barrier.	These	particles	are	subject	to	
corrosion	in	the	biological	environment	of	the	hip	joint,	its	surrounding	fluid,	and	
tissues.	Corrosion	leads	to	the	presence	of	the	ionic	species	Co(II),	Cr(III)	and	Cr(VI)	in	
the	extracellular	and	intracellular	solutions.	Since	these	larger	particles	remain	
trapped	in	the	joint	space	their	concentration	builds	up	over	the	course	of	time	and	the	
concentration	of	metal	ions	in	joint	fluid	is	therefore	typically	higher	than	that	found	in	
the	bloodstream	or	in	urine82.		
	
Examination	of	bearings	from	simulator	studies	and	from	explanted	articulations	have	
led	to	the	observation	of	corrosion	at	both	the	articulating	surface	and	the	taper	at	the	
neck	of	modular	THRs.	Both	Co	and	Cr	are	highly	reactive	and	are	rapidly	oxidized	at	
an	implant	surface	to	form	Cr2O3.	The	oxide	layer	provides	a	barrier	between	a	
solution	and	the	implant	surface.	This	process	is	known	as	passivation	and	reduces	
corrosion.	Orthopaedic	implants	are	artificially	over-passivated	as	part	of	the	
manufacturing	process	to	create	a	build	up	of	protective	oxide	film	to	prevent	in-vivo	
corrosion83.	During	the	lifetime	of	the	implant	this	passivation	film	can	be	
mechanically	removed	leaving	the	reactive	substrate	exposed	to	the	environment	and	
free	to	oxidise	or	corrode.	This	is	known	as	tribocorrosion.		
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It	is	generally	acknowledged	that	MoM	hip	articulations	are	subject	to	sliding	
tribocorrosion	at	the	articulation	as	well	as	fretting-corrosion	at	the	modular	taper	
and	stem-cement	interfaces.	Fretting-corrosion	is	defined	as	a	wear	phenomenon	
occurring	between	two	surfaces	having	oscillatory	relative	motion	of	small	amplitude	
in	which	there	is	a	chemical	dissolution	of	a	metallic	substrate84.		Additionally	
depending	upon	the	nature	and	composition	of	the	articulation	a	galvanic	cell	may	be	
established	with	resultant	galvanic	corrosion	as	seen	in	the	28mm	Ultima	TPS	MoM	
THR85.		Galvanic	interactions	occur	when	a	potential	difference	is	established	between	
two	electrically	connected	metals	immersed	in	a	corrosive	or	conductive	solution	as	
well	as	between	areas	of	passive	and	depassivated	alloy.	
	
The	tribological	interaction	of	an	exposed	solid	surface	with	an	interfacing	material	
and	the	environment	leads	to		material	loss	or	“wear”.	From	an	engineering	viewpoint	
the	failure	of	MoM	bearing	surfaces	is	thought	to	be	a	combination	of	wear	and	
corrosion.		
	
The	correct	function	of	a	MoM	implant	is	dependent	upon	the	presence	of	lubrication	
and	where	the	fluid	film	lubrication	of	a	MoM	articulation	is	disturbed,	such	as	may	
occur	due	to	the	phenomenon	of	edge	loading,	there	is	increased	susceptibility	to	
wear.	Edge	loading	can	be	described	as	either	primary,	whereby	the	acetabular	
component	is	positioned	at	a	steep	orientation	(typically	>55	degrees)	or	secondary	
edge	loading	where	there	is	impingement	at	the	neck-cup	junction	leading	to	
contrecoup	edge	loading	upon	weight	bearing86.	Both	of	these	lead	to	material	loss	and	
characteristic	“stripe	wear”	observable	on	explants.		Certain	designs,	typified	by	the	
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ASR	system	by	Depuy	are	particularly	prone	to	edge	loading,	especially	with	respect	to	
smaller	head	sizes	and	in	females	due	to	their	acetabular	morphology.		
	
In	MoM	THRs	the	presence	of	a	tapered	femoral	neck	connecting	the	femoral	head	to	
the	stem	adds	a	further	source	of	wear	since	frictional	torque	at	the	bearing	surface	is	
thought	to	be	translated	from	the	head	to	the	neck	with	resultant	damage	to	the	
taper87.	This	is	compounded	further	by	the	use	of	modular	implants88,	laterally	
engaging	taper	systems	and	larger	head	diameters	which	increase	the	lever	arm	acting	
on	the	head	neck	junction.		
	
1.6.3 The	Ultima	Tapered	Polished	Stem	(TPS)	MoM	THR	
	
This	thesis	was	developed	to	contribute	to	the	understanding	of	the	failure	associated	
with	a	specific	MoM	THR	as	well	as	the	failure	mechanisms	which	may	be	common	to	
all	MoM	THRs.	
	
The	Ultima	TPSTM	(Tapered	Polished	Stem)	developed	by	Depuy	International,	Leeds	is	
a	second	generation	hybrid	MoM	THR	introduced	in	1997.	It	consists	of	a	collarless,	
triple	tapered,	highly	polished	wrought	low	carbon	(LC)	CoCrMo	cemented	femoral	
stem	with	a	12/14	modular	taper.	The	articulation	itself	comprises	of	a	28mm	10/12	
LC	CoCrMo	Ultima	femoral	head	and	a	28mm	high	carbon	(HC)	CoCrMo	Ultima	
acetabular	liner.	The	outer	acetabular	shell	was	porous	coated	Ti-6Al-4V	ranging	from	
48mm	to	68mm	in	size	with	3	holes	available	for	supplementary	fixation	(Figure	
1.6-7).	The	femoral	component	was	cemented	with	either	a	plain	PMMA	bone	cement	
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or	antibiotic	cement	containing	either	Gentamicin	(Palacos,	Heraeus	Inc)	or	
Erythromycin	and	Colistin	(Simplex,	Stryker)	
	
	
	
	
	
	
	
	
	
	
Figure	1.6-7	The	Ultima	TPSTM	TPS	THR	(Depuy,	Leeds)	used	in	the	Norwich	cohort	
	
Despite	earlier	studies	by	Wilert	which	claimed	that	the	mechanism	of	crevice	
corrosion	was	not	applicable	to	cobalt	and	iron	based	implant	alloys	89	it	became	
evident	that	this	was	not	the	case	with	the	Ultima	TPS.	In	2007	the	MHRA	released	a	
Medical	Device	Alert	for	the	Ultima	TPS	in	response	to	43	early	revisions	in	which	
extensive	soft	tissue	necrosis	was	encountered	with	extensive	corrosion	of	the	femoral	
stem	component90.	In	2010,	Donell	et	al91	reported	on	a	series	of	545	patients	with	652	
Ultima	TPS	THRs	implanted	between	1997	and	2004.	There	was	an	unacceptably	high	
early	failure	rate	of	13.8%	at	five	years	in	which	90	hips	had	undergone	early	revision;	
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17(18.9%)	for	periprosthetic	fracture,	early	dislocation	in	3	hips	(3.3%),	late	
dislocation	in	16	(17.8%)	cases,	and	infection	in	9	hips(10%).	44	hips	(48.9%)	
required	revision	for	pain	arising	from	extensive,	periarticular	soft	tissue	necrosis	
(Figure	1.6-8)	of	these	35	patients	had	normal	radiographs.	Talroth	et	al	92	
demonstrated	that	the	first	clinical	sign	of	a	pseudotumour	was	often	pain	prompting	
radiological	examination	and	detection	of	lesions	around	the	stem	of	the	prosthesis	
which	can	sometimes	be	recognised	by	the	presence	of	calcar	resorption	or	osteolysis	
93	94.	
	
Figure	1.6-8	Severe	macroscopic	periarticular	necrosis	characteristic	of	soft	tissue	reaction	
found	at	revision	of	an	Ultima	TPS	THR.	
	
	
By	early	2014,	178	patients	(M:F	88:90)	had	been	revised	(27.4%)	at	a	mean	time	to	
revision	of	6.65	years	(unpublished	data)	
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Figure	1.6-9	Kaplan-Meier	survival	curve	for	the	Ultima	TPS	THR	
	
The	surveillance	of	the	Norwich	cohort	has	been	an	evolving	process	which	now	
incorporates	annual	clinical	follow-up,	plain	radiographs,	measurement	of	blood	metal	
ion	levels	and	local	staging	of	soft	tissue	reactions	using	the	MARS	MRI95	96protocols	
and	staging	systems97	developed	at	Norwich.	In	common	with	other	cohorts	of	ASR	
MoM	THRs	98	99	it	is	known	that	blood	metal	ion	levels	in	Ultima	TPS	patients	on	their	
own	are	insufficient	as	a	screening	tool	for	ARMD	and	do	not	correlate	with	MAR	MRI	
scan	findings	(Figure	1.6-10).		
	
	 39	
	
Figure	1.6-10	Box	and	whisker	plots	demonstrating	Co	and	Cr	levels	in	152	Ultima	TPS	MoM	
THR	with	normal	(Anderson	Grade	A)	and	Abnormal	(Anderson	Grade	C1-C3)	MARS	MRI.	The	
box	represents	the	median	and	interquartile	range	and	the	whiskers	represent	the	range	of	
data	excluding	numbered	outliers	(Ebreo	et	al,	BHS	2012).	
	
CoCrMo	polished	stems	have	been	demonstrated	to	have	a	good	survivorship	with	
revision	rates	of	4.1%	at	10	years	post	implantation	in	the	case	of	the	collarless	
polished	tapered	CPT	stem100	(Zimmer,	Warsaw,	Indiana).	However,	it	has	come	to	
light	that	localised	tribocorrosion	at	the	stem-cement	interface	has	the	ability	to	
increase	metal	ion	release	and	may	lead	to	ARMD	associated	with	marked	macroscopic	
corrosion	of	well-fixed	femoral	stems	as	is	commonly	seen	on	the	Ultima	femoral	stem	
component	on	explantation	(Figure	1.6-11).	Such	corrosive	phenomenon	has	also	been	
observed	with	the	CPT	stem	when	used	with	a	large	diameter	hybrid	MoM	head	
articulation	101.		
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Figure	1.6-11	Ultima	TPS	femoral	stem	explant	exhibiting	characteristic	macroscopic	
corrosion.		
	
	
Shetty	et	al102	compared	the	performance	of	the	Ultima	TPS	CoCrMo	femoral	stem	
and	the	established	benchmark	stainless	steel	Exeter	design	with	both	using	a	MoP	
Charnley	cup	and	found	at	two	years	there	was	no	difference	in	clinical	scores	and	
there	was	no	evidence	of	osteolysis	on	radiographs.	This	suggests	that	the	ARMD	
seen	with	the	Ultima	TPS	is	a	product	of	the	cemented	femoral	stem	used	in	
conjunction	with	the	Ti	backed	MoM	articulation;	this	was	later	confirmed	by	the	
manufacturer	in	a	Field	Safety	Notice	in	May	2012	after	extensive	laboratory	
testing	(personal	communication	Depuy	Int).		
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The	Ultima	TPS	THR	system	differs	from	large	diameter	systems	in	that	the	stem-
cement	interface	appears	to	be	the	source	of	release	of	potentially	toxic	metal	ions	
since	the	bearing	surfaces	of	explants	were	found	to	be	macroscopically	clean	of	any	
evidence	of	wear	or	abrasion103	
	
The	mode	of	failure	of	the	Ultima	TPS	THR	MoM	system	is	thought	to	be	via	
galvanically-enhanced	fretting	crevice	corrosion	of	the	cemented	femoral	stem104.	
	
Using	an	in-vitro	model	where	Ultima	stems	were	cemented	in	PMMA	cement,	Bryant	
et	al105	have	demonstrated	that	at	the	metal-cement	interface	fretting	corrosion	does	
occur	and	that	this	corrosion	is	accelerated	by	the	presence	of	sulphates	associated	
with	antibiotics	and	radio-opaque	agents	contained	within	cement.	The	wear	
mechanisms	present	at	the	stem-cement	interface	are	a	complex	combination	of	
mechanical	wear	accompanied	by	electrochemical	dissolution	of	the	metallic	substrate	
with	a	characteristic	electrochemical	response	to	cyclic	loading.	The	CoCrMo	surface	is	
in	a	constant	state	of	depassivation	and	repassivation	due	to	cyclic	micromotion	at	the	
stem-cement	interface.	With	each	loading	cycle	the	Cr	rich	passive	film	is	fractured	
exposing	the	base	alloy	to	the	aqueous	solution.	Oxidation	is	thought	to	occur	at	the	
point	of	contact	between	the	stem	and	the	cement	with	accompanying	liberation	of	
free	electrons.	This	results	in	the	formation	of	a	thick	Cr2O3	rich	film	and	debris	on	the	
CoCrMo	femoral	stem	and	the	counterpart	PMMA	bone	cement.		Cr	is	the	favoured	
species	to	undergo	reaction	due	to	the	lower	activation	energy	required	for	its	
oxidation	to	Cr2O3,	which	then	leaves	Co2+	which	is	extremely	soluble	to	migrate85.		
Plastic	and	elastic	deformation	of	the	surfaces	may	also	result	in	formation	of	3rd	body	
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particulates	which	may	also	contribute	to	the	overall	quantity	of	metallic	ions	and	
PMMA	debris	released	into	the	biological	environment	to	contribute	to	the	osteolytic	
and	inflammatory	response106.	Bryant	et	al	have	further	examined	the	role	of	galvanic	
corrosion	in	bio-tribocorrosion	systems	via	electrochemical	experiments	where	they	
have	confirmed	that	galvanic	coupling	can	occur	between	depassivated	and	still	
passive	areas	of	the	stem	alloy.	Further	increase	in	the	corrosion	rate	and	release	of	
metal	ions	into	bulk	solution	also	occurs	in	the	Ultima	system	since	the	Ti	alloy	in	the	
acetabular	shell	is	electrically	connected	to	the	stem-cement	interface	thus	forming	a	
galvanic	couple.	These	findings	are	in	support	of	the	findings	and	hypothesis	presented	
by	Hart	et	al	(2012)107	who	demonstrated	that	in	periprosthetic	tissue	retrieved	from	
the	Norwich	cohort	Co	was	found	to	be	10-fold	more	abundant	than	Cr	and	may	be	the	
clinically	relevant	active	agent	for	periprosthetic	tissue	reactions	due	to	the	ability	of	
Co	to	stimulate	inflammatory	pathways	in	macrophages.		
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2 :	Study	Questions	&	Proposals	
	
The	aim	of	this	MD	project	is	to	evaluate	adverse	reactions	to	metal	debris	(ARMD)	
and	its	cellular	mechanisms	in	a	local	cohort	of	patients	with	a	MoM	THR.	
2.1 Overall	Study	Questions	
	
1. What	is	the	natural	history	of	ARMD	using	MARS	MRI?	
2. What	is	the	relevance	of	blood	and	urine	metal	ion	levels	as	a	predictor	of	
disease	activity	and	does	diurnal	variation	exist	in	cobalt	and	chromium	ion	
levels	in	patients	with	a	MoM	THR	
3. Is	there	a	difference	in	the	activation	of	biological	cascades	between	patients	
revised	for	periprosthetic	osteolysis	arising	from	polyethylene	wear	debris	
versus	patients	with	a	MoM	THR	undergoing	revision	arthroplasty	for	adverse	
reaction	to	metal	debris?	
	
	
2.2 Radiology	Study	
Hypothesis:	
“In	those	patients	whose	staging	on	initial	MARS	MRI	is	normal	or	where	only	mild	
evidence	of	disease	is	demonstrated,	further	deterioration	over	time	is	unlikely.	Where	it	
does	occur	the	rate	of	deterioration	is	slow	and	there	may	be	a	latent	period	of	many	
years.”	
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To	test	the	hypothesis	a	retrospective	review	of	MARS	MRI	scans	of	a	cohort	of	
patients	with	a	MoM	THR	was	undertaken	with	the	inclusion	criteria	being	that	
patients	had	to	have	at	least	two	MRI	scans	and	that	they	had	not	undergone	revision	
surgery.		
	
The	MARS	MRIs	were	evaluated	by	an	experienced	musculoskeletal	radiologist	and	
staged	according	to	a	recognised	radiological	method.	
	
2.3 Diurnal	Variation	Study	
Hypothesis:	
“Circulating	levels	of	metal	ion	levels	fluctuate	with	activity	in	a	fashion	analogous	to	
blood	glucose	level	and	that	this	variation	is	diurnal	in	nature”	
In	order	to	test	the	hypothesis	a	feasibility	study	was	undertaken.	At	the	Norfolk	&	
Norwich	University	Hospital	(NNUH)	all	patients	who	have	received	an	Ultima	TPS		
THR	(Depuy)	are	recorded	in	a	database.	Prospective	data	has	been	collected	and	
institutional	and	ethical	approval	for	this	has	previously	been	secured.		
	
Ethical	approval	was	secured	to	sample	the	blood	and	urine	of	12	of	these	patients	to	
determine	the	following:	
1. If	there	exists	variation	in	metal	ion	levels	detectable	in	blood	and	urine	over	
the	course	of	a	day	and	over	longer	periods.	
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2. Whether	data	supporting	the	existence	of	diurnal	variation	of	blood	and	urine	
metal	ion	levels	exists	in	this	population	and	if	so	how	variable	are	the	data?	
3. What	further	study	needs	to	be	undertaken	should	a	variation	exist.	
4. Determination	of	an	appropriate	scale	for	future	study	dependent	on	the	
magnitude	of	variation	observed.		
	
2.4 Laboratory	Study	
Hypothesis:		
“There	is	a	difference	in	the	activation	of	biological	cascades	between	patients	revised	for	
periprosthetic	osteolysis	arising	from	polyethylene	wear	debris	versus	patients	with	a	
MoM	THR	undergoing	revision	arthroplasty	for	adverse	reaction	to	metal	debris”	
	
RNA	expression	analysis	was	used	to	quantify	gene	expression	at	the	time	of	revision	
surgery.	In	order	to	address	the	hypothesis	several	preliminary	questions	needed	to	be	
addressed:	
1. Can	gene	expression	in	joints	affected	by	ARMD	be	reliably	measured?	
2. Do	joints	affected	by	ARMD	have	a	different	gene	expression	profile	compared	
with	native	joints	and	joints	with	osteolytic	change	arising	from	metal-on-
polyethylene	bearings.	
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3 Serial	Magnetic	Resonance	
Imaging	of	Metal-on-Metal	Total	Hip	
Replacements	
3.1 Background	
	
Magnetic	resonance	imaging	(MRI)	is	now	widely	used	to	assess	pathological	changes	
associated	with	metal-on-metal	(MoM)	total	hip	replacements	(THRs)	95,96,108,109	.	Metal	
artefact	reduction	(MAR)	MRI	allows	assessment	of	the	extent	of	soft-tissue	pathology	
pre-operatively	and	the	planning	of	revision	surgery	in	cases	where,	for	instance,	
neurovascular	structures	are	at	risk.	MAR	MRI	may	also	demonstrate	pathology	
outside	the	hip	that	may	account	for	symptoms.	An	advantage	over	ultrasound	is	the	
potential	to	diagnose	smaller,	deeper	foci	of	adverse	reactions	to	metal	debris	
(ARMD),110	but	it	may	miss	lesions	in	the	zone	of	the	metal	artefact,	which	ultrasound	
may	detect	more	readily.	
MoM	bearings	offer	the	theoretical	advantages	of	decreased	wear	and	increased	
functional	outcome	for	younger	and	more	active	patients,	but	have	been	associated	
with	the	development	of	sterile	inflammatory	masses	58,111-113.	These	may	include	soft-
tissue	destruction	with	poorer	outcomes	following	revision	surgery114.	These	lesions	
have	also	been	described	as	aseptic	lymphocytic	vasculitis-associated	lesions	
(ALVAL)115,	adverse	local	tissue	reactions	(ALTR)116	or	pseudotumours58.	The	
mechanism	by	which	they	arise	is	uncertain,	but	may	be	associated	with	wear	at	the	
bearing	surface,	61,117	taper	junction	wear	93,118	and	corrosion	119,120.	
MAR	MRI	has	the	potential	to	facilitate	a	classification	system	for	ARMD	that	
characterises	and	provides	comparison	of	soft-tissue	and	bony	pathology	over	time.	
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Various	systems	of	scoring	the	severity	of	ARMD	have	been	described97,121,122,but	only	
that	of	Anderson	et	al	97has	been	shown	to	have	interobserver	reliability.	This	system	
assesses	not	only	the	size	and	cystic	or	solid	nature	of	a	lesion,	but	also	any	
involvement	of	muscle,	tendon	and	bone.		
Although	pain	is	a	presenting	symptom	in	a	poorly	functioning	THR,	silent	soft-tissue	
pathology	is	common64and	may	occur	with	an	asymptomatic	well-functioning	MoM	
THR110,123.	The	Medicines	and	Healthcare	Products	Regulatory	Authority	(MHRA)	has	
issued	renewed	guidance	recommending	cross-sectional	imaging	for	all	symptomatic	
MoM	THRs48.	Annual	clinical	follow-up	is	recommended	as	well	as	measurement	of	
metal	ion	levels	in	the	blood.	There	is	no	recommendation	as	to	the	optimal	timing	of	
an	initial	investigation	with	cross-sectional	imaging,	nor	at	what	intervals	patients	
should	be	scanned	as	part	of	the	surveillance.	This	cross-sectional	study	aimed	to	
describe	the	natural	history	of	MoM	ARMD	using	MAR	MRI	in	patients	whose	initial	
scans	were	normal	or	showed	low-grade	ARMD.	
	
3.2 Patients	&	Methods	
Cases	were	identified	from	an	original	cohort	of	545	patients	(650	THRs)	who	
underwent	28	mm	hybrid	MoM	THR	(Ultima	TPS;	Depuy,	Leeds,	United	Kingdom)	
between	May	1997	and	August	2004	performed	by	three	surgeons	including	the	senior	
author	(JFN),	as	previously	reported91.	Inclusion	criteria	were	the	availability	of	at	
least	two	MRI	scans	and	no	revision	surgery	before	any	scans	included	in	this	review.	
A	total	of	37	THRs	in	38	patients	were	excluded	from	the	study	as	they	had	been	
revised	without	a	prior	MAR	MRI.	Also,	81	THRs	in	72	patients	were	revised	after	a	
single	MAR	MRI	scan	and	were	therefore	excluded.	Of	the	original	cohort,	80	patients	
were	found	to	fulfil	the	inclusion	criteria,	35	of	whom	were	men	(44%).	Of	these	
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patients,	57	(71%)	had	unilateral	THRs	and	the	rest	were	bilateral,	resulting	in	a	total	
of	103	THRs.	
MRI	was	undertaken	using	MAR	sequences	with	a	1.5T	MR	scanner	(Siemens	
Symphony;	Siemens,	Ehrlingen,	Germany).	The	MAR	sequence	used	the	following	
specification:	coronal	T1-weighted	(T1W)	turbo	spin-echo,	echo	time	(TE)	23	ms,	
repetition	time	(TR)	669	ms	and	short	τ	inversion	recovery	(STIR);	TE	37	ms,	TR	
3840	ms,	axial	T1W	(TE	23	ms,	TR	534	ms)	and	T2-weighted	(T2W)	turbo	spin-echo	
(TE	69	ms,	TR	5600	ms)	of	the	whole	pelvis	and	a	sagittal	T2W	turbo	spin-echo	of	the	
hip	(TE	69	ms,	TR	2900	ms).	The	section	thickness	used	was	5	mm,	with	a	340	×	
340	mm	field	of	view,	matrix	size	up	to	448	×	336	and	pixel	bandwidth	620	MHz	
All	scans	were	reported	and	graded	by	the	same	radiologist	(AT).	Scans	were	classified	
as	A	(Normal),	B	(Infection),	C1	(Mild	MoM	ARMD),	C2	(Moderate)	or	C3	(Severe)	
according	to	the	classification	of	Anderson	et	al97.	
	
3.3 Statistical	analysis	
Statistical	analysis	was	carried	out	using	the	Statistical	Package	for	Social	Sciences	
(SPSS)	PASW	Statistics	version	18.0	(SPSS	Inc.,	Chicago,	Illinois).	Parametric	tests	were	
used	for	normal	data	and	non-parametric	tests	for	non-normally	distributed	data,	and	
significance	was	set	at	p	≤	0.05.	
3.4 Results	
	
The	mean	age	of	the	80	patients	was	57.9	years	(25	to	69).	There	were	35	men	(mean	
age	58.1	years	(25	to	68))	and	45	women	(mean	age	58.2	years	(29	to	69)).	A	total	of	
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17	patients(17	THRs)	who	had	already	had	at	least	two	scans	underwent	revision	at	a	
mean	of	seven	years	(2	to	11)	post-operatively.	
Between	2002	and	2011	a	total	of	239	MRIs	were	performed	on	103	THRs	(two	to	four	
per	THR).	All	patients	had	two	MRIs,	29	had	a	third	and	four	a	fourth	(Figure	3.4-1)	
	
	
Figure	3.4-1	Box	and	whisker	plot	showing	the	time	from	primary	surgery	until	the	first,	
second,	third,	and	fourth	metal-artefact-reduction	(MAR)	MRI	scans.	The	boxes	represent	the	
median	and	interquartile	range	and	the	whiskers	denote	the	range	of	data.	
	
	When	the	grades	of	all	239	MRIs	were	considered	together,	there	was	a	significant	
increase	in	grade	as	the	post-operative	time	increased,	with	a	Spearman’s	ρ	of	0.235	(p	
<	0.001).	The	first	scan	was	then	considered	in	isolation,	analysing	the	relationship	
between	all	first	scans	and	the	time	from	the	operation,	and	again	a	positive	
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correlation	existed	between	increasing	post-operative	time	and	increasing	severity	of	
grade	(Spearman’s	ρ	0.257	(p	<	0.009	for	103	first	scans).	
	
Overall,	140	of	239	MAR	MRI	scans	were	normal	(Table	3.4-1),	and	of	these,	63	had	a	
normal	(Grade	A)	first	scan.	Of	those	patients	with	a	normal	initial	scan,	only	four	
advanced	in	grade	between	the	first	and	second	scans.	In	total,	six	patients	(9.5%)	
went	on	to	develop	MR	changes	consistent	with	ARMD.	In	those	whose	stage	became	
more	advanced,	they	did	so	between	seven	and	11	years	post-operatively,	with	most	
developing	mild	(C1)	or	moderate	(C2)	changes	(Figure	3.4-2)	.	Only	15	(15%)	of	103	
THRs	with	sequential	scans	showed	worsening	of	disease	on	subsequent	imaging.		
	 	
One	patient	with	a	normal	initial	scan	progressed	to	a	Grade	B	appearance	suggestive	
of	infection,	which	was	confirmed	on	aspiration	and	a	revision	was	subsequently	
undertaken.	Four	scans	were	initially	reported	as	suggestive	of	infection.	Repeat	scans	
in	one	patient	led	to	downgrading	to	a	normal	appearance	owing	to	spontaneous	
regression	of	a	peri-prosthetic	collection.	For	the	remaining	three	patients,	no	
evidence	of	infection	was	found	on	blood	tests.	Subsequent	scans	indicated	the	
presence	of	ARMD.	Two	patients	developed	radiological	appearances	of	Grade	C3	
ARMD	and	underwent	revision.	One	patient	developed	asymptomatic	C2	ARMD	and	is	
under	surveillance.	
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Table	3.4-1	Total	numbers	of	patients	undergoing	revision	surgery	per	grade	of	metal-artefact	
reduction	(MAR)	MRI	scan	
	
	
	
Figure	3.4-2	Scatter	plot	showing	the	change	in	metal-artefact-reduction	(MAR)	MRI	grading	
with	subsequent	scans	in	patients	whose	initial	scan	is	normal	(Grade	A)	
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On	the	initial	scan	16	hips	had	the	appearances	of	mild	ARMD	(Grade	C1),	but	between	
five	and	seven	years	post-operatively	three	were	downgraded	to	a	normal	Grade	A	
appearance	on	repeat	scans.	A	further	two	patients	progressed	to	higher	grades	
between	11	and	12	years	post-operatively	(Figure	3.4-3).	The	relationships	between	
the	grade	and	revision	are	illustrated	in	Figure	3.4-4.		
	
Figure	3.4-3	Scatter	plot	showing	the	change	in	metal-artefact-reduction	(MAR)	MRI	grading	
with	subsequent	scans	in	patients	whose	initial	scan	showed	Grade	C1	(mild	disease)	
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Figure	3.4-4	Flow	diagram	illustrating	changes	in	metal-artefact-reduction	(MAR)	MRI	grade	
with	serial	scans	and	progress	to	revision	surgery	
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3.5 Discussion	
	
Of	the	cohort	of	103	THRs,	63	(61%)	had	a	normal	initial	scan,	and	of	these,	six	(9.5%)	
went	on	to	require	revision	surgery.	Where	the	initial	scans	were	normal,	progressive	
changes	occurred	unpredictably	between	seven	and	11	years	after	operation	and	at	a	
rate	of	11%.	Of	the	four	cases	initially	reported	as	suggestive	of	infection,	three	
progressed	to	more	severe	stages	on	subsequent	scans,	with	the	remainder	being	
downgraded	to	normal	on	a	follow-up	scan.	Previous	evidence	suggests	that	
differentiating	a	small	degree	of	ARMD	from	infection	may	not	be	reliable	using	MRI	
alone,97	and	therefore	greater	emphasis	should	be	placed	on	other	clinical	and	
serological	markers	of	infection	in	these	patients.		
	
The	natural	history	of	patients	with	a	C1	staging	is	unknown.	Most	patients	who	were	
initially	classified	as	having	mild	(C1)	disease	retained	their	original	classification	on	a	
second	scan	at	a	mean	of	one	year	and	nine	months	later.	Only	one	patient	went	on	to	
develop	severe	(C3)	disease	requiring	revision	surgery.	From	our	observations	it	is	not	
a	certainty	that	the	disease	will	progress,	and	indeed	progression	does	not	appear	to	
be	commonplace	and	where	it	does	occur	the	rate	of	change	is	unclear.	Where	
regression	to	a	normal	post-operative	appearance	has	been	observed	on	MRI,	the	
mechanism	for	this	phenomenon	can	at	present	only	be	speculated	upon,	and	is	a	
potential	avenue	for	further	research.	Most	THRs	in	this	study	had	normal	MRI	scans	
and	did	not	have	any	progression	of	disease.	Where	there	is	a	change	in	grade	it	is	
more	likely	to	indicate	progression,	and	in	turn	this	significantly	increases	with	time	
since	surgery.	
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Our	results	suggest	that	there	may	be	a	latent	period	of	many	years	prior	to	any	
evidence	of	disease	being	detectable	radiologically.	There	appears	to	be	a	bimodal	
distribution,	where	a	larger	proportion	of	patients	present	early	with	severe	disease	
and	are	revised	and	a	smaller	proportion	present	later,	between	seven	and	11	years,	
with	mild	or	moderate	changes.		
	 	
The	MHRA	guidelines	now	recommend	imaging	in	the	form	of	MAR	MRI	or	ultrasound	
for	small-diameter	MOM	THRs	in	symptomatic	patients,	or	‘if	concern	exists	for	the	
cohort’.	We	have	previously	reported	a	13.8%	failure	rate	of	our	entire	series	of	Ultima	
TPS	THRs	at	five	years91.	This	has	now	increased	to	20.3%,	with	a	mean	time	to	
revision	of	5.9	years	(range	1	to	14	years).	The	MHRA	guidance	has	emphasised	a	
follow-up	period	of	five	years	or	more	for	small-diameter	MOM	THRs.	The	guidance	
refers	to	the	presence	of	symptoms	as	suggestive	of	the	need	for	longer	follow-up.	
However,	it	is	our	experience	that	radiological	evidence	of	disease	can	be	
demonstrated	in	asymptomatic	patients	in	both	small	109and	large-diameter	MoM	
THRs64.	
	
The	clinical	picture	in	the	management	of	these	patients	has	been	evolving.	Significant	
disease	can	occur	in	the	absence	of	symptoms	123,124.Our	findings	suggest	that	long-
term	surveillance	of	MoM	THRs	for	the	life	of	the	implant	is	essential.		
	
Patients	in	our	cohort	are	routinely	invited	for	review	annually.	An	MRI	scan	has	been	
offered	to	all	our	patients,	although	some	have	declined.	No	patient	has	been	
discharged.		
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The	assessment	of	these	patients	is	complex	and	extends	beyond	the	categorisation	of	
imaging,	symptoms	and	serum	metal	ion	levels.	In	isolation	it	is	difficult,	and	perhaps	
not	useful,	to	assign	a	negative	predictive	value	to	a	normal	MRI	scan.	
	
We	have	an	increasing	number	of	patients	with	more	than	one	scan.	It	seems	likely	
that	patients	presenting	with	a	normal	scan	initially	may	be	safely	observed	with	
annual	clinical	review,	and	a	subsequent	scan	should	there	be	any	change	in	
symptoms.	This	reflects	current	practice	at	our	institution.		
	
The	study	is	limited	by	its	retrospective	design.	There	is	a	selection	bias	in	that	we	
have	not	included	patients	who	were	revised	prior	to	having	MAR	MRI	scans,	or	those	
in	whom	revision	was	undertaken	after	a	single	scan.	The	cohort	of	patients	with	two	
or	more	scans	may	not	be	representative	of	the	whole,	but	in	practice	many	cohorts	of	
patients	with	MoM	THRs	will	include	some	who	have	required	early	revision	and	some	
with	initially	low-grade	problems	that	are	observed	over	time.	The	timing	of	the	
sequential	scans	has	not	been	at	defined	intervals	according	to	any	given	protocol.	This	
leaves	us	unable	to	comment	on	precisely	when	a	normal	MRI	or	a	Grade	C1	may	
progress	in	radiological	staging.	We	have	not	accounted	for	variability	in	symptoms	or	
serum	metal	ion	levels,	which	are	factors	that	frequently	contribute	to	the	referral	for	
MAR	MRI	scans.	Our	findings	may	not	be	directly	applicable	to	larger-diameter	
implants,	as	a	small-diameter	28	mm	MoM	THR	has	a	smaller	zone	of	artefact	around	
the	prosthesis.	This	means	that	smaller	significant	lesions	are	picked	up	earlier	in	
these	patients,	and	hence	may	be	revised	before	a	second	scan	is	undertaken.	 
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We	would	recommend	follow-up	with	MAR	MRI	scans	as	determined	by	a	detailed	
clinical	assessment	at	intervals	no	more	frequently	than	annually.	On	the	basis	of	the	
evidence	presented,	we	are	unable	to	recommend	a	specific	optimal	interval	between	
scans.	Further	study	is	needed	to	correlate	MRI	grading	with	intra-operative	findings,	
histological	staging	and	patient-reported	outcome	measures.	This	would	offer	a	better	
understanding	of	the	status	of	patients	with	normal	scans	and	mild	disease.	
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4 Diurnal	Variation	of	Metal	Ions		
4.1 Introduction	
Elevated	levels	of	metal	ions	in	blood,	urine,	and	synovial	fluid	following	MoM	THR	or	
resurfacing	arthroplasty	are	commonly	reported	125	126	127	with	systemic	levels	of	
Cobalt	(Co)	and	Chromium	(Cr)	reaching	a	steady	state	approximately	1	year	following	
implantation	128,129.		
	
Metal	ion	levels	have	been	proposed	as	a	monitoring	tool	for	detection	of	adverse	
reaction	to	metal	debris	(ARMD)	130	with	the	goal	of	early	intervention	before	
significant	soft	tissue	damage	has	occurred114.	Raised	metal	ion	levels	are	known	to	
arise	via	a	number	of	mechanisms	which	may	work	in	concert	including	wear	at	the	
bearing	surfaces	secondary	to	malposition	or	poor	implant	design57,115,	corrosion,	
either	at	the	head-neck	or	taper	junction131	87,	corrosion	of	particulate	wear	debris70	
and	in	the	case	of	the	Ultima	TPS,	mechanically-assisted	crevice	corrosion	at	the	
cement-implant	interface103		
	
Whilst	there	has	been	an	association	between	poorly	functioning	implants	and	high	
levels	of	metal	ions	in	the	blood	stream	123	132,	133,	there	is	evidence	that	high	levels	do	
not	correlate	with	findings	at	revision	surgery.	Griffin	et	al134	in	their	study	of	90	
patients	demonstrated	that	there	was	no	correlation	between	average	preoperative	Co	
and	Cr	levels	and	the	level	of	soft	tissue	damage	observed	intraoperatively,	however	a	
very	significant	correlation	was	noted	between	implant	time	in	situ	and	tissue	damage,	
suggesting	that	the	biological	reaction	to	metal	debris	in	some	patients	may	be	more	a	
time-dependent	than	dose-dependent	phenomenon.	Although	high	levels	of	metal	ions	
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have	been	shown	to	be	associated	with	abnormal	MAR	MRI	98,99,	the	sensitivity	and	
specificity	of	such	observations	at	the	UK	Medicines	and	Healthcare	products	
Regulatory	Agency	(MHRA)	cut-off	level	of	7ppb	is	poor.	There	remains	no	consensus	
as	to	an	appropriate	threshold	level	which	would	mandate	revision	surgery.		
	
There	is	evidence	that	physiological	exercise	by	fit	patients	with	a	MoM	bearing	results	
in	a	measurable	rise	in	plasma	Co	and	Cr	levels135.	It	is	not	known	if	metal	ion	levels	in	
blood	and	urine	fluctuate	during	the	course	of	normal	daily	activity	in	a	fashion	
analogous	to	blood	glucose.	The	aim	of	this	study	was	to	establish	if	such	diurnal	
variation	in	metal	ion	levels	exists	and	if	there	was	any	correlation	to	symptoms,	MAR	
MRI	scan,	or	functional	scores.	
4.2 Study	Protocol	
4.2.1 Ethical	Approval	
	
The	National	Research	Ethics	Service	(NRES)	facilitates	ethical	review	in	the	UK	via	
local	Regional	Ethics	Committees	(RECs).	Application	was	made	via	the	Integrated	
Research	Application	System	(IRAS)	which	acts	as	an	online	portal	and	repository	for	
dissemination	of	required	documentation	comprising:	Study	Protocols,	Patient	
Invitation	Letters,	GP	Information	Letter,	Investigator	CVs	and	GCP	certification,	
confirmation	of	indemnity	information	and	sponsor	details.	An	appointment	was	made	
to	appear	before	a	local	REC	in	Norwich	having	submitted	via	IRAS	(IRAS	project	ID	
105822)	and	a	“favourable	opinion”	was	granted	on	March	4th	2013	(Norwich	REC	
reference:	13/EE/0037).			
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4.2.2 Patients	&	Methods	
	
Patients	were	also	asked	to	provide	informed	consent	for	storage	of	a	sample	of	blood	
and	urine	in	the	Human	Tissue	Bank.	No	details	were	passed	to	anyone	outside	of	the	
clinical	team	or	involved	in	the	patient’s	usual	care	until	the	patient	has	agreed	to	
enter	the	study.	The	full	study	protocol	can	be	found	in	the	appendices.	
Cases	were	identified	from	an	original	cohort	of	545	patients	(650	THRs)	who	
underwent	28mm	hybrid	MoM	THR	(Ultima	TPS;	DePuy,	Leeds,	United	Kingdom)	
between	May	1997	and	August	2004	performed	by	three	surgeons	(including	the	
senior	author	JFN),	as	previously	reported91.	Ethical	permission	was	granted	by	the	
National	Research	Ethics	Service	Committee	–	East	of	England	[REF	13/EE/0037]	and	
our	institutional	review	board.		All	patients	who	had	an	Ultima	TPS	MoM	THR	in	situ	
were	eligible	to	participate.	Patients	who	had	undergone	revision	of	their	Ultima	
prosthesis,	those	that	were	taking	medications	or	supplements	known	to	increase	
excretion	of	cobalt	or	chromium,	those	on	immunosuppressant	medication,	and	those	
who	were	unable	to	provide	informed	consent	at	the	time	of	recruitment	were	
excluded.	Patients	with	bilateral	MoM	THRs	in	situ	were	also	excluded	as	it	is	well	
recognised	that	these	patients	will	have	significantly	higher	levels	of	detectable	Co	and	
Cr	in	blood	and	urine132	136.	No	patients	with	evidence	of	infection	were	recruited.		
	
Patients	were	seen	in	an	outpatient	clinic	in	the	course	of	their	normal	follow-up	as	
recommended	by	the	MHRA.	Patient	selection	was	performed	on	the	basis	of	reported	
symptoms	(pain,	limp,	or	mass)	and	whether	their	MAR	MRI	was	normal	(Grade	A)	or	
abnormal	(Grade	C1-C3)	according	to	the	classification	of	Anderson	et	al97	.	Since	no	
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prior	publication	on	the	magnitude	of	effect	of	diurnal	variation	upon	metal	ion	
concentration	in	either	blood	or	urine	exists,	ethical	approval	was	granted	to	recruit	a	
maximum	of	12	patients	as	being	adequate	for	this	feasibility	study.	Patients	were	
stratified	into	four	categories:	asymptomatic	with	normal	MAR	MRI	(AN),	
asymptomatic	with	abnormal	MAR	MRI	(AA),	symptomatic	with	normal	MAR	MRI	(SN)	
and	symptomatic	with	abnormal	MAR	MRI	(SA).	
	
	
4.2.3 Trial	Schedule	
	
Patients	were	invited	to	attend	a	Clinical	Trials	Research	Unit	on	four	occasions	and	
were	asked	to	donate	blood	and	urine	specimens	for	analysis	of	Cobalt	and	Chromium	
levels	at	a	specialist	(TEQAS	accredited)	reference	laboratory	for	trace	metal	analysis	
via	Inductively	Coupled	Plasma	Mass	Spectrometry.	Protocols	for	specimen	collection,	
transport,	and	analysis	were	already	well	established.		
Patients	attended	on	4	days	with	at	least	a	week	between	visits.	On	the	first	day	
patients	completed	an	Oxford	Hip	Score	and	had	blood	and	urine	samples	collected	in	
the	morning	between	08:00	to	09:30	(T1),	at	lunch-time	between	11:45	to	13:30	(T2),	
and	later	in	the	afternoon	between	15:30	to	16:40	(T3).	Participants	were	encouraged	
to	engage	in	their	usual	level	of	activity	in	between	visits.	To	establish	if	there	was	
significant	longitudinal	variation	in	Co	or	Cr	levels	patients	had	a	corresponding	repeat	
sample	of	blood	and	urine	taken	on	Week	A	in	the	morning	(TA),	Week	B	at	lunchtime	
(TB)	and	Week	C	in	the	late	afternoon	(TC).		
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Figure	4.2-1	Study	design.	Each	participant	visited	on	4	separate	days.	Upon	first	visit	each	
participant	provided	blood	and	urine	samples	for	Co	&	Cr	analysis	as	well	as	blood	sample	for	
measurement	of	urea	&	electrolytes.	Participants	completed	an	Oxford	Hip	Score	on	this	first	
visit.	At	all	subsequent	visits	only	samples	of	blood	and	urine	for	Co	&	Cr	analysis	were	taken.			
	
4.2.3.1 Study	Endpoint	
The	study	was	concluded	at	the	last	visit	of	the	last	patient	and	once	results	of	all	
investigations	had	been	completed	and	verified.		
4.2.4 Trace	Metal	Analysis	
Plasma	metal	ion	levels	were	measured	using	venous	blood	samples	(5	ml)	obtained	
using	the	vacutainer	system	(Vacuette;	Greiner	Bio-One	GmbH,	Kremsmünster,	
Austria)	and	directly	collected	in	K2EDTA	trace	element	tubes	with	no	purging	of	
samples137.	The	plasma	metal	ion	analysis	was	carried	out	by	the	Department	of	
Biochemistry	at	the	University	Hospital	Wales,	Cardiff,	which	is	a	participating	
laboratory	in	the	Trace	Elements	External	Quality	Assessment	Scheme	(TEQAS)	in	
accordance	with	MHRA	guidance.	The	levels	of	cobalt	and	chromium	were	measured	
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by	an	inductively-coupled	plasma	mass	spectrometer	(Agilent	7700x,	Agilent	
Technologies,	Berkshire,	UK).	Plasma	samples,	standards	and	quality	control	
material	were	diluted	1	in	15	with	diluent	containing	0.01%	triton	(Romil,	
Cambridge,	UK),	0.01%EDTA	(AnalaR,	VWR,	Lutterworth,	UK),	0.2%	ammonia	
(Romil,	Cambridge,	UK)	and	20	ppb	Gallium	as	an	internal	standard	(Inorganic	
Ventures,	Madrid,	Spain).	For	urine	samples,	standards	and	quality	control	material	
were	diluted	1	in	10	with	diluent	containing	0.05%	nitric	acid	(BDH	Aristar,	VWR,	
Lutterworth,	UK)	1%	isopropanol	(Romil	Super	Pure,	Cambridge,	UK)	0.1%	triton	
and	20	ppb	Gallium	as	an	internal	standard.	Isotopes	59	and	52	were	measured	for	
Co	and	Cr	respectively	using	Helium	gas	for	interference	correction	for	both	
plasma	and	urine	samples.		
	
4.2.5 Radiological	Analysis	
	
MRI	was	undertaken	using	MAR	sequences	with	a	1.5	T	MR	machine	(Siemens	
Symphony;	Siemens,	Ehrlingen,	Germany).	The	MAR	sequence	used	the	following	
specification:	coronal	T1	weighted	(W)	turbo	spin-echo	(echo	time	(TE	23ms,	
repetition	time	(TR)	669ms)	and	short	tau	inversion	recovery	(STIR;	TE	37ms,	TR	
3840ms),	axial	T1W	(TE	23ms,	TR	534ms)	and	T2W	turbo	spin-echo	(TE	69ms,	TR	
5600ms)	of	the	whole	pelvis	and	a	sagittal	T2W	turbo	spin-echo	of	the	hip	(TE	69,	TR	
2900ms).	The	section	thickness	used	was	5mm	with	a	340	x	340mm	field	of	view,	
matrix	size	up	to	448	x	336	and	pixel	bandwidth	620MHz.	
	
All	scans	were	reported	and	graded	by	a	musculoskeletal	radiologist.	Scans	were	
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classified	using	as	either	normal	(Grade	A)	or	abnormal	(Grades	C1-C3)	using	the	
classification	of	Anderson	et	al97.	No	patients	with	an	infected	(Grade	B)	arthroplasty	
were	included.		
	
4.2.6 Statistical	Methods	
	
Statistical	analysis	was	performed	using	GraphPad	Prism	version	6	(GraphPad	
Software,	Sand	Diego,	CA)	and	Stata	(StataCorp.	2013.	Stata	Statistical	Software:	
Release	13.	College	Station,	TX:	StataCorp	LP).	The	median	and	interquartile	range	
(IQR)	of	Co	and	Cr	in	plasma	and	urine	for	each	time	point	were	calculated.	Metal	ion	
concentrations	were	also	normalised	to	more	clearly	assess	diurnal	variation;	
normalised	metal	ion	concentrations	were	derived	for	each	patient	by	dividing	metal	
ion	concentration	by	the	mean	concentration	at	the	three	time	points	observed	for	that	
species.	Results	were	analysed	using	nonparametric	Friedman’s	test	with	Dunn’s	post	
hoc	multiple	comparison	test	to	assess	diurnal	variability	across	the	three	time	points.	
Wilcoxon	matched	pairs	signed	rank	test	was	used	to	compare	any	differences	in	metal	
ion	level	between	baseline	values	obtained	on	the	first	day	and	metal	ion	levels	taken	
at	matched	time	points	at	intervals	of	a	week	and	greater.	P	value	<0.05	was	
considered	significant.	 
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4.3 Results	
	
A	total	of	11	patients	with	a	mean	age	of	68	years	(range	51	to	77	years)	were	
recruited.	There	were	five	men	(mean	age	71	years;	range	65	to	77	years)	and	six	
women	(mean	age	66	years;	range	51	to	72	years)	at	an	overall	mean	of	11	years	from	
original	surgery	(range	9	to	14	years).			
	
Only	two	patients	were	recruited	into	the	category	“symptomatic	with	normal	MRI”	
(SN).	During	the	course	of	investigation,	it	was	found	that	their	pain	was	likely	to	be	
referred	from	a	site	extrinsic	to	the	hip.	Given	that	this	particular	category	represents	
a	rare	presentation,	further	recruitment	was	not	possible.	
	
Over	the	course	of	a	single	day	there	was	no	diurnal	variation	in	levels	of	plasma	Co,	
plasma	Cr	and	urinary	Cr,	however,	significant	variations	in	urinary	Co	levels	were	
noted,	with	the	median	level	peaking	at	lunchtime	(p<0.03)	(Figure	4.3-1).		
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Figure	4.3-1	Normalised	biomarker	concentration	over	the	course	of	a	single	day	(T1=	
morning,	T2=	lunchtime,	T3	=	late	afternoon).	Within	a	patient,	the	biomarker	value	
for	a	specific	time	point	was	normalised	by	dividing	by	the	mean	of	the	3	time	points.	
Each	box	represents	the	25th	and	75th	percentiles.	Lines	outside	the	boxes	represent	
the	10th	and	90th	percentiles	(minimum	and	maximum	limits	respectively).	Lines	inside	
boxes	represent	the	median.		
Pairwise	comparison	between	metal	ion	levels	taken	during	the	course	of	a	single	day	
with	repeated	measurements	demonstrated	significant	differences	in	morning	levels	
of	urine	Co	(p=0.003*)	and	urine	Cr	(p=0.007*)	only.	Using	the	standard	deviation	for	
the	change	between	T1	and	T2	for	urine	biomarkers,	the	sample	size	needed	for	80%	
power	was	found	to	be	371	patients	(s.d.	24.28)	for	a	difference	in	means	of	5ppb.		
	
At	intervals	of	a	week	or	greater,	only	plasma	Cr	demonstrated	any	significant	degree	
of	variability	over	the	three	time	points	(p=0.04*)	(Figure	4.3-2).		
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Figure	4.3-2	Normalised	biomarker	concentrations	over	time	at	intervals	of	one	week	
or	greater	(TA	=	Week	A	morning,	TB	=	Week	B	lunchtime,	TC	=	Week	C	evening).	
Within	a	patient,	the	biomarker	value	for	a	specific	time	point	was	normalised	by	
dividing	by	the	mean	of	the	3	time	points.	Each	box	represents	the	25th	and	75th	
percentiles.	Lines	outside	the	boxes	represent	the	10th	and	90th	percentiles	(minimum	
and	maximum	limits	respectively).	Lines	inside	boxes	represent	the	median.		
	
	
When	examining	diurnal	variation	of	metal	ion	levels	using	values	across	all	time	
points	only	plasma	Cr	was	observed	to	show	any	significant	variation	(p<0.03*)	with	
the	highest	median	concentration	(2.3	ppb)	being	in	the	evening		(Figure	4.3-3)	
(Figure	4.3-3).		
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Table	4.3-1	Diurnal	variation	of	metal	ion	levels	combining	values	obtained	from	
patients	in	a	single	day	(T1,	T2,	T3)	and	at	intervals	of	a	week	or	greater	(TA,TB,	TC).	
Results	were	analysed	using	non-parametric	Friedman’s	test	with	Dunn’s	post	hoc	
multiple	comparison	test	(*p<0.05)	
	
	 	 Median,	IQR	(range)	ppb	
(n=22)	 AM	 PM	 EVE	 p	
Plasma	Co	 10,	11.3	(4.8-20)		 10,	11.4	(4.7-22)	 10,	9(4.7-22)	 0.66	
Plasma	Cr	 2,	1.7	(0.69-7.1)	 2.1,	1.7	(0.75-7.1)	 2.3,	1.9	(0.93-7.2)	 0.03*	
Urine	Co	 41,	47		(6.1-175)	 53,	38	(5.6-209)	 35,	31	(9-149)	 0.19	
Urine	Cr	 3.1,	3.4	(0.78-16)	 4.6,	3.9	(1.4-13)	 3.5,	2.1	(0.84-11)	 0.19	
	
	
Figure	4.3-3	Overall	normalised	biomarker	concentrations.	Data	for	each	time	point	
was	combined	from	the	two	data	sets	(variation	within	one	day	and	variation	at	
intervals	of	a	week	and	greater).		Within	a	patient,	the	biomarker	value	for	a	specific	
time	point	was	normalised	by	dividing	by	the	mean	of	the	3	time	points.	Each	box	
represents	25th	&	75th	percentiles.	Lines	outside	boxes	represent	the	10th	&	90th	
percentiles	(minimum	&	maximum	limits	respectively).	Lines	inside	boxes	represent	
the	median.	
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Post-hoc	analysis	revealed	this	to	be	due	to	inter-patient	variability	and	the	presence	
of	outlier	values	as	opposed	to	an	actual	difference	in	medians	(Figure	4.3-4).	
	
Figure	4.3-4	Overall	within-patient	diurnal	variation	of	plasma	Cr	levels	(ppb)	
	
There	were	no	differences	by	gender,	symptoms,	or	MAR	MRI	scan	(Table	4.3-2).	
There	was	no	evidence	of	a	correlation	between	any	of	the	biomarkers	and	the	Oxford	
Hip	Score	(r	=	0.20,	p=0.5601;r=0.04,	p=0.9038;	r=-0.15,	p=0.6561;	r=-0.29,	p=0.3876	
for	Plasma	Co,	Plasma	Cr,	Urine	Co,	and	Urine	Cr	respectively).	
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Table	4.3-2	Overall	median	biomarker	levels	(ppb)	by	sex,	symptoms,	and	MAR	MRI	
scan.	Mann-Whitney	test,	(P<0.05*)	
	
4.4 Discussion	
Over	the	course	of	10	hours	there	was	no	diurnal	variation	in	plasma	metal	ion	levels,	
however,	significant	diurnal	variation	in	urinary	Co	levels	was	observed	with	peak	
concentration	in	the	afternoon	(p<0.03*).	Including	all	measurements	taken	during	a	
single	day	and	repeated	measurements	at	intervals	of	at	least	a	week,	only	a	significant	
variation	in	plasma	Cr	was	detected	(p<0.03*).	Whilst	these	results	suggest	that	
diurnal	variation	may	exist	for	plasma	Cr	and	urinary	Co,	such	fluctuations	may	well	be	
accounted	for	within	the	sphere	of	acceptable	laboratory	variation.	For	the	low	plasma	
Co	and	Cr	concentrations	observed	in	this	study	the	co-efficient	of	variation	(CV%)	
from	our	laboratory’s	internal	quality	control	is	6.6%	for	Cr	and	4.5%	for	Co	and	for	
urine	this	rises	to	10%	for	Cr	and	20%	for	Co.	Our	laboratory	participates	in	the	Trace	
Element	External	Quality	Assessment	Scheme	(TEQAS)	and	as	such	these	variations	
are	comparable	to	other	laboratories	within	the	scheme.		
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Measurement	of	metal	ion	levels	in	either	in	whole	blood,	serum,	or	plasma	remains	a	
useful	tool	as	part	of	the	long-term	monitoring	of	patients	with	a	MoM	THR.	Urine	
levels	of	Co	and	Cr	are	more	prone	to	fluctuation	across	the	course	of	the	day	and	may	
be	affected	by	renal	impairment	and	by	an	individual’s	level	of	hydration,	making	them	
an	unsuitable	method	for	monitoring.		
	
No	significant	fluctuation	with	time	was	observed	with	measurement	of	plasma	Co,	
hence	it	may	be	a	more	reliable	marker	than	plasma	Cr	for	ARMD.	This	raises	the	
question	as	to	whether	it	is	necessary	to	measure	both	ions	in	the	course	of	normal	
practice.	Significant	inter-laboratory	variation	has	been	noted	in	levels	of	plasma	Co	
than	Cr	at	the	MHRA	cut-off	of	7ppb.	It	is	not	known	if	measuring	a	single	species	
might	affect	the	detection	rates	of	ARMD138.		It	can	be	a	source	of	confusion	when	there	
is	a	large	difference	between	the	Co	and	Cr	values	and	where	only	one	value	exceeds	
the	designated	threshold	level.	In	our	study	higher	levels	of	Co	were	observed	at	all	
time	points	in	comparison	to	Cr.	It	is	known	that	changes	in	levels	of	Co	and	Cr	
correlate	with	each	other139.	In	the	Ultima	TPS	cohort	Co	may	be	the	clinically	relevant	
active	agent	responsible	for	periprosthetic	tissue	reactions107,	but	this	may	not	be	true	
for	all	MoM	implants.		
	
There	is	some	debate	as	to	whether	metal	ion	levels	in	whole	blood,	serum,	or	plasma	
should	be	used	for	monitoring.	Since	there	can	be	a	significant	degree	of	inter-
laboratory	variation138	it	is	essential	to	in	the	context	of	long	term	clinical	follow	up	to	
consistently	examine	the	same	fraction	and	use	the	same	laboratory.		It	has	been	
demonstrated	that	Co	concentrations	are	similar	in	red	blood	cells	(RBCs)	and	
plasma140	and	it	is	believed	that	a	state	of	equilibrium	between	Co	in	RBCs	and	
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plasma	exists.		Co	is	mainly	present	in	the	plasma	fraction	in	vivo141.	Cr	levels	in	
plasma	for	this	cohort	are	consistently	lower	than	Co	which	in	part	is	due	to	alloy	
composition	in	which	the	Co:Cr	is	typically	in	the	order	of	60%:30%	as	well	as	
differing	rates	of	tribocorrosion	and	solubility142.		
	
The	differences	in	Co	and	Cr	concentration	in	urine	may	be	explained	by	
differences	in	binding	to	plasma	proteins.	Cr	binds	to	both	transferrin	and	albumin	
in	plasma	and	hence	is	not	filtered	by	the	kidney	and	excreted	into	urine	and	hence	
has	an	extended	half	life	in	the	body140.	
	
At	our	institution	it	is	our	practice	to	consider	the	trend	in	blood	Co	levels	over	time	as	
an	adjunct	to	serial	clinical	examination	and	MAR	MRI	to	avoid	any	such	confusion	in	
the	decision	making	process.	Metal	ion	levels	considered	in	isolation	remain	an	
inadequate	screening	tool	for	ARMD.		
	
This	study	is	limited	by	the	small	sample	size	and	by	our	exclusion	of	patients	with	
bilateral	implants.	The	main	mechanism	of	failure	of	the	Ultima	TPS	is	corrosion.	The	
results	of	this	study	may	not	be	generalisable	to	systems	where	more	particulate	metal	
is	generated	secondary	to	bearing	wear.		
	
We	would	recommend	that	blood	metal	ion	levels	continue	to	be	used	for	long	term	
monitoring	and	that	for	diagnostic	purposes	the	time	of	day	at	which	the	sample	is	
taken	is	not	relevant.		
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5 Gene	Expression	Profiling	
5.1 Introduction	
	
The	aim	is	to	establish	if	a	difference	exists	in	the	activation	of	biological	cascades	in	
human	hip	tissue	of	patients	with	end-stage	osteoarthritis,	those	revised	for	
periprosthetic	osteolysis	arising	from	polyethylene	wear	debris	and	those	with	a	MoM	
THR	undergoing	revision	arthroplasty	for	ARMD.	A	gene	expression	microarray	
experiment	was	used	to	identify	the	range	of	differences	in	gene	expression	between	
these	groups.	This	was	used	to	determine	the	different	pathways	of	cellular	
interactions,	how	they	differed	between	each	group	and	were	further	explored	using	
pathway	analysis	software.	Quantitative	real	time	polymerase	chain	reaction	(qRT	
PCR)	analysis	was	used	to	validate	the	findings	of	the	microarray.		
	
The	biological	pathways	responsible	for	the	changes	seen	in	ARMD	are	not	known.	
There	may	be	a	spectrum	of	necrotic	and	inflammatory	changes	in	response	to	Co-Cr	
wear	particles	in	periprosthetic	tissues.	Coagulative	necrosis	and	a	macrophage	and	T	
lymphocyte	response	occur	in	implant	failure	and	pseudotumors,	in	which	there	is	also	
granuloma	formation.	The	pathogenesis	of	these	changes	is	uncertain,	but	it	may	
involve	both	a	cytotoxic	response	and	a	type	IV	delayed	hypersensitivity	response	to	
Co-Cr	nanoparticles111.		
	
The	discipline	of	genomics	incorporates	the	study	of	all	features	of	the	genome	and	
individual	genes	at	the	level	of	DNA.	Genomics	encompasses	the	study	of	the	pattern	of	
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transcription	(gene	expression)	as	a	function	of	clinical	conditions	in	response	to	
natural	or	toxic	agents	or	at	different	times	during	defined	biological	processes	e.g.	at	
specific	stages	in	the	cell	cycle.	The	aim	of	the	study	of	gene	expression	is	to	discover	
which	genes	are	up-	or	down-regulated	under	specific	conditions143	.	In	doing	so	we	
may	be	able	to	find	specific	disease	biomarkers	that	may	be	important	in	genetic	
epidemiology.		This	study	does	not	aim	to	identify	any	novel	pathway,	but	to	clarify	
which	pathways	may	be	differentially	activated	in	those	patients	undergoing	revision	
surgery	for	ARMD	associated	with	a	MoM	THR	and	those	being	revised	for	aseptic	
loosening	or	periprosthetic	osteolysis	of	a	MoP	THR	using	the	gene	expression	in	
patients	with	advanced	osteoarthritis	undergoing	primary	joint	replacement	as	a	
control.	No	studies	prior	to	these	have	been	conducted	using	microarray	experiments	
in	this	context.	
	
5.2 Microarray	
	
Quantitative	real-time	polymerase	chain	reaction	(qRT-PCR)	and	gene	expression	
microarrays	are	complementary	approaches	used	to	determine	quantitative	or	relative	
levels	of	gene	expression.		
	
Previously	gene	expression	analysis	was	performed	in	a	low-throughput	manner	by	
examining	handfuls	of	genes	at	a	time	by	techniques	such	as	Northern	blot	analysis	or	
semi-quantitative	end	point	RT-PCR.		This	limitation	of	volume	has	been	overcome	by	
the	development	of	high-throughput	technologies	such	as	microarray.	Whilst	allowing	
rapid	quantification	of	the	expression	of	a	large	number	of	genes,	the	measurement	of	
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the	expression	of	each	individual	gene	depends	on	the	probe	used	on	the	array	and	
may	not	be	quantitative	144.	qRT-PCR	can	also	be	done	in	other	ways	than	using	a	
Taqman®	probe	(i.e.	via	incorporating	the	dye	SyBr	green),	although	our	belief	is	that	
Taqman®	is	superior	since	it	uses	a	probe	which	can	cross	exon-exon	boundaries	for	
specificity.		For	these	reasons	quantitative	RT-PCR	has	been	used	to	validate	the	
results	of	these	microarray	experiments.		
	
Microarrays	allow	the	identification	of	genes	that	are	expressed	in	different	cell	types	
and	give	the	opportunity	to	examine	how	gene	expression	levels	may	change	in	
disease	states.	They	may	also	be	used	to	identify	which	cellular	processes	genes	may	
participate	in.		
	
A	microarray	can	generate	data	in	order	to	fulfil	the	following	general	experimental	
objectives145:	
1. Class	comparison.	This	is	where	one	looks	for	differential	gene	expression	
between	two	or	more	conditions	e.g.	healthy	versus	tumour	cells.	
2. Class	prediction.	If	we	wish	to	develop	a	statistical	model	that	might	be	used	to	
predict	which	class	an	individual	might	belong	to.	Examples	of	this	include	
prediction	of	the	response	to	treatment	(response	vs.	non-response)	and	
disease	progression	(relapse	vs.	cured)	
3. Class	discovery.		Here	the	objective	is	to	identify	novel	subtypes	of	individuals	
within	a	given	population.	In	some	conditions	it	may	be	hard	to	differentiate	
between	different	subtypes	based	on	cell	morphology	alone,	hence	definitive	
classification	may	be	possible	using	gene	expression.		
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4. Pathway	analysis.	These	studies	attempt	to	find	genes	whose	co-regulation	
suggests	that	they	may	participate	in	the	same	or	related	biochemical	
processes.		
	
The	basic	aim	of	the	microarray	experiment	is	to	quantify	concentration	of	a	gene(s)	
mRNA	transcript	in	a	given	cell	type	at	a	given	time.		The	number	of	molecules	of	
mRNA	arising	from	the	transcription	of	a	given	gene	is	used	as	an	approximation	to	the	
level	of	expression	of	that	gene143.	
	
Whilst	there	are	cohorts	of	genes	known	to	be	involved	in	the	process	of	aseptic	
loosening,	the	cellular	mechanisms	underlying	the	process	of	ARMD	are	not	
conclusively	known.	The	use	of	a	microarray	enables	an	unbiased	approach	which	will	
enable	examination	of	not	only	gene	families	known	to	be	affected	in	aseptic	loosening	
across	both	the	MoP	and	MoM	phenotypes,	but	may	also	highlight	pathways	that	are	
differentially	activated	in	ARMD	that	would	be	more	suggestive	of	the	adaptive	
immune	responses	which	are	not	present	in	aseptic	loosening.		
	
Microarray	technology	is	based	on	the	complementarity	principle	of	nucleic	acid	base	
pairing.	In	microarray	experiments	thousands	of	DNA	probes	are	fixed	to	a	solid	
surface.	RNA	samples	(targets)	are	labelled	with	fluorescent	dyes	for	hybridization.	
After	hybridization	laser	light	is	used	to	excite	the	fluorescent	dye;	the	hybridization	
intensity	is	represented	by	the	amount	of	fluorescence	emitted	from	which	an	estimate	
of	the	relative	amounts	of	the	different	transcripts	that	are	represented	within	a	
sample	can	be	made.		
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There	are	different	platforms	for	whole-genome	microarray	can	be	carried	out	on	
cDNA	or	mRNA	and	may	utilise	either	single	colour	or	two	colours.	Earlier	systems	
used	two-colour	cDNA	microarray	where	both	probes	and	targets	are	cDNAs.	Sample	
mRNA	undergoes	reverse	transcription	and	at	the	same	time	is	labelled	with	the	
fluorescent	cyanidine	dyes	Cy3	and	Cy5.	Post	hybridization	the	fluorescence	of	each	is	
measured	separately	and	a	composite	image	is	formed	which	needs	further	processing	
prior	to	analysis146.		
	
High-density	oligonucleotide	microarray	use	pairs	of	probes	which	each	consist	of	25-
mer	oligonucleotides	with	each	probe	pair	containing	a	perfect	match	(PM)	probe	and	
a	mismatch	probe	(MM).	The	MM	probe	is	identical	to	the	PM	probe	except	for	the	
central	base	and	functions	as	an	internal	control143.	Unlike	cDNA	microarray	the	mRNA	
sample	is	converted	to	biotynlated	cRNA	with	only	one	target	hybridized	and	only	a	
single	fluorescent	colour	is	used.	This	is	the	basis	of	the	widely	used	Affymetrix	Gene	
Chip.		
	
Illumina	Inc	(San	Diego,	CA)	produces	a	whole-genome	microarray	platform,	the	
Human	HT12	v4	Expression	Beadchip.	Sample	RNA	undergoes	first	and	second	strand	
reverse	transcription	followed	by	a	single	in	vitro	amplification	that	incorporates	
biotin-labelled	nucleotides.	Subsequent	steps	include	array	hybridization,	washing,	
blocking	and	streptavidin-Cy3	staining.	Fluorescence	emission	by	Cy3	is	quantitatively	
detected	for	downstream	analysis	(Figure	5.2-1).	This	platform	was	selected	since	
early	quality	control	experiments	highlighted	very	low	yields	of	high	quality	RNA	from	
fresh	and	frozen	periprosthetic	tissue	from	both	osteolytic	MoP	THR	and	ARMD	MoM	
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THR	revisions.	The	Illumina	platform	has	been	shown	to	maintain	a	low	false	
discovery	rate	(FDR)	even	with	small	amounts	of	RNA	(10ng).	Lynch	et	al147	have	
demonstrated	that	a	bias	in	expression	levels	obtained	when	using	lower	amounts	of	
RNA	can	be	compensated	by	using	more	replicates	to	achieve	the	same	levels	of	
precision,	however,	any	decrease	in	sensitivity	cannot	be	compensated	for	by	
increasing	sample	size.	The	net	effect	of	this	strategy	is	that	an	experiment	with	few	
biological	replicates	and	a	low	starting	concentration	of	RNA	may	fail	to	detect	subtle	
changes,	but	using	the	Illumina	Beadchip	system	one	can	be	reasonably	confident	in	
any	changes	that	are	reported.		
	
	
	
	
	
Figure	5.2-1	Schematic	overview	of	microarray	experiment	using	Illumina	HT12	v4	Beadchip	
platform.	Reproduced	from	Illumina	HT12v4	Human	Beadchip	technical	note	(2012)	148	
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5.3 Real-time	Quantitative	Polymerase	Chain	Reaction.		
Quantitative	real-time	polymerase	chain	reaction	(qRT-PCR)	involves	the	repeated	
amplification	of	cDNA	using	sequence	specific	oligonucleotides,	heat	stable	DNA	
polymerase,	and	thermal	cycling.	In	traditional	“end	point”	PCR,	detection	and	
quantification	of	the	amplified	sequence	are	preformed	at	the	end	of	the	reaction	after	
the	last	PCR	cycle	and	typically	involve	post	PCR	analysis	via	gel	electrophoresis	and	
image	analysis.		
qRT-PCR	uses	a	double	stranded	template	during	low	temperature	cycles	a	primer	
anneals	to	the	gene	of	interest	and	a	probe	binds	to	a	downstream	sequence.	The	
Taqman®	probes	are	covalently	joined	to	two	other	molecules;	a	reporter	and	a	
quencher.		At	the	5’	end	is	a	fluorescent	molecule	termed	a	“reporter”,	so	termed	as	it	
gives	off	or	reports	a	detectable	signal	as	more	product	is	generated.	At	the	3’end	is	a	
molecule	termed	the	quencher	that	quenches	the	fluorescent	signal	from	the	reporter	
as	long	as	the	probe	itself	remains	intact.	When	an	intact	probe	is	exposed	to	light	the	
fluorescent	reporter	molecule	does	not	give	off	a	detectable	signal	as	there	is	energy	
transfer	between	the	reporter	and	the	quencher	via	a	process	termed	fluorescent	
resonance	energy	transfer	(FRET)149.	Each	time	a	new	PCR	amplicon	is	produced	the	
reporter	and	quencher	are	permanently	split	such	that	the	reporter	produces	a	
detectable	signal	in	the	presence	of	light	and	fluorescence	will	increase	proportionally	
with	product.	The	first	step	in	qRT	PCR	involves	denaturing	the	double	stranded	
template	at	a	high	temperature.	As	that	temperature	is	lowered,	the	probe	and	primers	
bind,	the	Taqman®	polymerase	enzymes	then	enter	and	begin	the	extension	phase	of	
PCR	by	creating	new	complementary	strands	of	DNA.	When	the	Taq	polymerase	
encounters	the	reporter	end	of	the	probe	its	inherent	exonuclease	activity	causes	the	
probe	to	be	destroyed,	a	new	amplicon	is	created,	and	the	reporter	and	quencher	
molecules	are	physically	separated	creating	a	permanent	increase	in	fluorescence	
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which	perfectly	accords	with	the	doubling	of	product150(Figure	5.3-1).	The	real-time	
instrument	can	monitor	and	record	this	increase	in	fluorescence	after	each	cycle	to	
generate	an	amplification	plot	for	interpretation.		
	
	
	
Figure	5.3-1	Principles	of	Taqman®.	5’	nuclease	activity	of	thermostable	polymerases	used	in	
the	PCR	cleaves	hydrolysis	probes	during	the	amplicon	extension	step	that	separates	the	
detectable	reporter	fluorophore	(R)	from	the	quencher	(Q).	Fluorescence	emitted	when	excited	
by	an	external	light	source	(hv)	at	each	PCR	cycle	is	proportional	to	the	amount	of	product	
formed.	Reproduced	from	Koch	(2004)	150	
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5.4 Materials	and	Methods	
5.4.1 Ethics	
Ethical	approval	for	analysis	of	tissue	held	in	the	Norwich	Human	Tissue	Bank	(REC	
Reference	08/H0304/85)	was	sought	from	the	Faculty	of	Medicine	&	Health	Sciences	
Research	Ethics	Committee	at	the	University	of	East	Anglia	(Reference	2011/2012-62)	
after	an	informal	peer	review	process	amongst	consultant	orthopaedic	surgeons.	
Ethical	approval	was	granted	on	September	19th	2012.		
	
The	ethics	submission	inclusive	of	patient	information	materials	and	consent	forms	
are	included	in	the	Appendices.		
	
5.4.2 Tissue	Sampling	&	Storage	
	
Tissue	samples	were	taken	intraoperatively	from	patients	undergoing	primary	hip	
arthroplasty	for	the	indication	of	osteoarthritis,	patients	with	a	MoP	primary	
arthroplasty	in	situ	undergoing	revision	arthroplasty	for	aseptic	loosening,	or	patients	
with	a	MoM	primary	arthroplasty	undergoing	revision	arthroplasty	for	ARMD.		
	
Samples	of	hip	capsule	or	acetabular	membrane	were	excised	during	the	procedure.	
All	samples	were	stored	at	room	temperature	submerged	in	an	RNA	stabilising	agent	
(RNALater,	Qiagen,	Crawley,	UK)	and	transferred	to	a	-80OC	freezer	within	an	hour.		
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5.4.3 Consent	Process	
	
Informed	consent	is	essential	for	research	undertaken	on	human	tissue.	Patients	were	
fully	informed	about	the	study	including	potential	risks	and	benefits.	Ethical	approval	
for	use	of	human	tissue	collected	as	part	of	existing	Human	Tissue	Bank	infrastructure	
was	granted	by	the	University	of	East	Anglia	Faculty	of	Medicine	and	Health	Sciences	
Research	Ethics	Committee	on	19th	September	2012	(REF:	2011/2012-62).	Patients	
were	approached	prior	to	surgery	by	the	Primary	Investigator	who	explained	the	
study,	invited	the	patient	to	take	part,	and	answered	any	questions	that	arose	during	
the	consultation.	Patients	were	given	written	information	and	provided	their	consent	
using	the	Human	Tissue	Bank	consent	forms.	All	patients	approached	to	take	part	in	
the	study	agreed	to	participate.	A	copy	of	the	completed	consent	forms	is	retained	at	
the	NNUH	and	in	the	Academic	Orthopaedic	Department.		
	
5.4.4 Determination	of	Sample	Size	
	
Traditional	approaches	to	determining	statistical	power	are	not	routinely	used	for	
microarray	experiments	since	due	to	their	nature	microarrays	can	be	used	to	test	
multiple	hypotheses,	use	FDR	estimates	for	inference,	and	can	use	classification	
techniques	with	thousands	of	transcripts.	
	
For	experimental	designs	where	groups	of	cases	are	evaluated	for	differential	
expression	a	minimum	of	5	biological	cases	per	group	are	seen	as	acceptable146.	The	
Illumina	HT12v4	BeadChip	has	capacity	for	12	samples	per	array.	With	8	samples	per	
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category	across	2	separate	chips	this	experiment	overall	is	cost-effective	and	
adequately	powered	to	detect	differential	gene	expression	as	supported	by	the	method	
outlined	in	by	Pan	et	al151	where	a	Type	1	error	rate	α	=0.05/	10,000	genes	for	a	2-fold	
magnitude	of	expression	change	has	80%	power.	
	
5.4.5 Patient	Identification	and	Data	Collection	
	
Potential	patients	were	identified	via	the	waiting	lists	of	consultant	hip	arthroplasty	
surgeons	at	the	NNUH.	Patients	were	approached	pre	operatively.		
Patients	were	considered	eligible	for	inclusion	via	the	following	criteria:	
Primary	Hip	Arthroplasty:		
Undergoing	primary	total	hip	arthroplasty	for	osteoarthritis	
MoP	Revision	Arthroplasty:	
Undergoing	revision	arthroplasty	for	aseptic	loosening	of	a	MoP	cemented	THR	
MoM	Revision	Arthroplasty:	
Undergoing	revision	arthroplasty	of	a	primary	MoM	THR	for	ARMD.		
Exclusion	criteria	were:	
1. Infection	
2. Alternate	bearing	surfaces	i.e.	ceramics	
3. Fracture		
4. Autoimmune	disease	
5. Immunosuppressant	medication	or	immunocompromised	state	
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6. Inability	to	provide	informed	consent	
Patient	demographic	data	were	stored	in	an	anonymised	form.		
	
5.4.6 RNA	Extraction	&	Purification	
	
RNA	extraction	has	been	optimised	by	adaption	of	the	tissue	homogenisation	and	cell	
lysing	method	described	for	RNA	extraction	from	hip	tissue	previously	described	by	
our	laboratory152.		The	full	protocol	is	detailed	in	the	Appendix.	In	order	to	extract	
RNA,	the	source	tissue	must	first	be	homogenised,	the	cells	lysed,	and	the	RNA	
dissolved	into	solution.	The	RNA	fraction	is	isolated	from	the	residue	via	phase	
separation	using	chloroform	and	then	passed	through	spin	columns	to	further	purify.		
The	previously	described	method	involved	use	of	an	UltraTurrax	homogeniser.	The	
blade	assembly	of	this	instrument	could	not	be	completely	disassembled	to	adequately	
sterilise	in	between	samples	to	avoid	cross	contamination.	In	addition	initial	yields	
from	tissues	affected	by	ARMD	were	low	using	this	equipment.		We	substituted	the	use	
of	an	UltraTurrax	homogeniser	with	a	TissueLyser	LT	(Qiagen,	Manchester)	which	
uses	a	cooled	centrifugal	system	and	an	agitating	ball	to	homogenise	the	sample.	This	
optimisation	delivered	an	approximate	40%	increase	in	RNA	yield	(Appendix	A).		
	
Tissues	samples	taken	from	patients	were	stored	in	RNALater®	(Ambion)	at	4	oC.	The	
samples	were	divided	using	sterile	scissors	and	tweezers	and	placed	in	to	RNAse	free	
Safe	Lock	Eppendorf®	tubes	and	kept	on	ice.	Where	archival	tissue	from	the	Human	
Tissue	Bank	or	frozen	tissue	was	used	a	cryotome	was	used	to	section	tissue	as	
required.		For	0.5	g	of	tissue	500	µl	TRIzol®	(Invitrogen)	was	added	to	a	tube	along	
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with	a	stainless	steal	ball	bearing	cooled	to	-80	oC.	The	tubes	were	then	placed	into	a	
TissueLyserLT	(Qiagen)	and	then	the	machine	set	to	50	Hz	for	2	minutes.	The	tubes	
were	then	cooled	on	ice	for	2	minutes	and	returned	to	the	machine	for	a	further	2	
minutes.	This	cycle	was	repeated	a	total	of	5	times.	The	TRIzol®	was	removed	from	
the	Eppendorf	and	placed	into	a	new	1.5	ml	Eppendorf	and	200	µl	chloroform	was	
added,	vortexed	for	30	s	and	spun	at	13,000	rpm	(~19,000	rcf)	at	4	o	C	for	15	minutes.	
	
5.4.7 RNA	Quality	Control	
	
RNA	quality	plays	a	major	role	in	the	generation	of	accurate	quantitative	results	from	
gene	expression	analysis	experiments.	Isolation	of	high	quality	and	intact	RNA	from	
human	tissue	can	be	problematic	due	in	part	to	the	need	for	expedient	handling,	
transport	and	storage	of	samples	in	an	RNAse	free	environment.	RNA	is	more	labile	
than	DNA	and	is	susceptible	to	degradation	by	endogenous	cellular	RNases	as	well	as	
by	chemicals	or	heat	such	as	is	generated	via	surgical	diathermy.		Where	the	original	
tissue	sample	has	been	grossly	affected	by	a	pathological	process	and	is	of	poor	overall	
quality	in	the	first	instance,	as	seen	in	ARMD,	optimal	RNA	yields	for	downstream	
processing	can	be	difficult	to	obtain.	The	determination	of	RNA	quality	is	therefore	a	
crucial	step	in	the	workflow	of	quantitative	gene	expression.		
	
5.4.7.1 Nanodrop	RNA	Quantification	
	
Quantification	of	RNA	yield	was	performed	via	the	use	of	a	spectrophotometer	
(Nanodrop:	Nanodrop	Technologies,	Wilmington,	DE).	Nanodrop	allows	quantification	
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of	proteins	and	nucleic	acids	by	use	of	absorption	spectrometry.	Quantification	of	RNA	
is	necessary	prior	to	reverse	transcription.		
The	Nanodrop	is	an	essential	quality	control	step	to	ensure	an	acceptable	amount	of	
RNA	of	an	adequate	quality	has	been	extracted.	Good	quality	RNA	gives	rise	to	a	
characteristic	absorption	curve	Figure	5.4-1:	
	
		
Figure	5.4-1	Sample	Nanodrop	spectrophotometer	curve	for	RNA	extracted	from	human	
hip	tissue	demonstrating	classical	“double	tick”	morphology.	Absorbance	is	plotted	on	
the	y-axis	against	wavelength	(mm)	on	the	x-axis	
	
DNA	and	phenol	are	common	sources	of	sample	contamination	that	can	be	screened	
for	at	this	stage.	Sample	contamination	can	be	determined	with	reference	to	the	
260:280	absorption	ratio.	Proteins	are	absorbed	at	280;	a	260:280	ratio	between	1.9	
and	2.1	is	indicative	of	low	levels	of	protein	contamination.		
	
The	260:230	ratio	is	used	as	a	secondary	measure	of	nucleic	acid	purity	with	expected	
values	commonly	in	the	range	2.0-2.2,	if	the	ratio	is	lower	then	the	presence	of	
contaminants	which	are	absorbed	at	230nm	such	as	carbohydrate,	phenol	or	TRIzol	
phenolic	reagent.		
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5.4.7.2 RNA	Degradation	Assessment	
	
RNA	was	extracted	using	RNEasy	Mini-kit	(Qiagen).	Isolation	of	RNA	was	carried	out	
as	per	the	manufacturer’s	instructions.	The	RNA	was	checked	for	degradation	using	
the	ExperionTM	RNA	StdSens	system	(Bio-Rad	Laboratories	Inc).	The	ExperionTM		
automated	electrophoresis	system	(Bio-Rad	Laboratories	Inc)	provides	an	effective	
method	for	both	confirming	the	results	from	the	Nanodrop	RNA	quantification,	and	of		
determining	the	RNA	quality	prior	to	any	further	gene	expression	experiment.	The	
integrity	of	a	sample	can	be	measured	using	as	little	as	200pg	total	RNA,	much	less	
than	the	5-10ug	of	RNA	needed	to	determine	RNA	quality	via	the	traditional	method	of	
agarose	gel	electrophoresis.	This	was	of	particular	benefit	in	the	context	of	performing	
microarray	experiments	that	typically	require	relatively	large	amounts	(5-10ug)	of	
RNA.		
	
The	RNA	StdSens	chips	were	loaded	with	1	µl	of	RNA	samples,	which	had	been	
denatured	at	90oC	for	2	min.	The	chips	were	loaded	on	the	ExperionTM		and	run	
according	to	manufacturer	instructions.	Degraded	RNA	shows	a	smear,	RNA	that	has	
not	been	degraded	shows	2	distinct	bands	on	the	gel,	one	representing	18S	RNA	and	
the	other	28S	RNA.		
	
RNA	samples	with	RNA	Integrity	Number	(RIN)	or	RNA	Quality	Index	(RQI)	≥	7	were	
selected	for	whole-genome	expression	array	experiments.	The	RIN	(Agilent	
Technologies)	and	RQI	(Bio-Rad	Inc)	represent	different	methods	of	using	software	
algorithms	to	standardize	and	quantitate	RNA153.	Both	methods	return	a	number	
between	1	(highly	degraded	RNA)	to	10	(intact	RNA).			
	 88	
		
	 	 	 	 	 	 	
Figure	5.4-2	Example	of	an	Experion™	quality	control	experiment.	Column	L	represents	the	
calibration	RNA	reference	ladder.	Visual	inspection	reveals	two	well-defined	bands	
qualitatively	indicating	good	quality	RNA	has	been	obtained	in	samples	1,	2,	5,	and	6.	This	is	
quantitatively	supported	by	the	RQI	(RNA	Quality	Index).	The	experiment	has	failed	in	columns	
3	and	4	either	due	to	contamination	or	human	error	filling	the	wells.		
	
5.4.8 Microarray	Experiment	&	Analysis	
	
Microarray	experiments	are	complex	and	require	expensive	specialised	equipment,	
leading-edge	computer	hardware	and	software	as	well	as	specialist	expertise	and	a	
high	level	of	technical	skill.	For	these	reasons	it	is	common	practice	to	prepare	samples	
to	an	agreed	standard	according	to	the	MIAME	(Minimum	information	about	a	
microarray	experiment)	standard	154		and	to	outsource	microarray	hybridization	to	a	
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third	party.	These	industry	partners	perform	further	quality	control,	perform	the	
experiment	and	generate	gene-expression	values	ready	for	statistical	analysis.		
	
The	microarrays	were	carried	out	using	an	Illumina	whole-genome	expression	array	
Human	HT-12	v4	(Illumina	Inc.,	Illumina	United	Kingdom,	Saffron	Walden,	UK)	to	
profile	gene	expression	of	RNA	samples	according	to	the	manufacturer’s	protocol	
(www.illumina.com/technology/direct_hybridization_assay.ilmn.).		
	
The	first	12-sample	microarray	was	performed	by	Source	Bioscience	PLC,	the	second	
12-sample	microarray	by	High	Throughput	Genomics,	Wellcome	Trust	Centre	for	
Genomics,	Oxford	University.	Across	the	two	microarrays	experiments	there	were	8	
biological	replicates	from	3	groups	(8	x	Primary	osteoarthritis,	8	x	metal-on-
polyethylene	revision	for	aseptic	loosening	and	8	x	metal	–	on-metal	revision	for	
ARMD).	Of	the	biological	replicates	for	MoM	revision	for	ARMD,	six	were	from	patients	
with	an	Ultima	TPS	28mm	THR,	and	two	from	patients	with	a	large	diameter	(>36mm)	
ASR	THR.				Raw	expression	data	were	analysed	using	R	155	and	processed	with	Lumi	
package	Raw	data	were	normalised	with	a	quantile	algorithm.		
	
RNA	was	isolated	using	the	RNeasy	Mini	Kit-Qiagen.	Total	RNA	from	24	patients	was	
labeled	and	hybridized	onto	Illumina	HumanHT-12	v4	Expression	BeadChips	covering	
31,000	annotated	genes	with	over	47,000	probes		incorporating	microRNAs	and	splice	
variants(Illumina,	San	Diego,	CA).		
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Microarray	raw	data	were	analysed	using	Lumi156	with	quantile	normalization	in	R155		
(Bioconductor).	Post	normalisation,	the	data	was	annotated	using	the	HumanHT-
12_v4_0_R1_15002873_b.bgx	package	(www.switchtoi.com/annotationfiles.ilmn)	
Multiple	Experiment	Viewer	(MEV)157	was	used	for	further	analysis.		Genes	
differentially	expressed	were	selected	using	ANOVA,	with	a	p	value,	based	on	
permutations,	<0.05.	Genes	were	filtered	for	a	fold	≥2	in	at	least	one	
condition.		Hierarchical	clustering	was	done	using	Euclidian	distance.	Pathways	
analysis	was	done	in	Ingenuity	Pathway	Analysis	(IPA).	Data	sets	were	deposited	as	
Gene	Expression	Omnibus	(GEO)	datasets	(accession	number	pending)	
	
5.4.9 Reverse	Transcription	Polymerase	Chain	Reaction	(RT	PCR)		
	
Synthesis	of	complementary	DNA	(cDNA)	via	reverse	transcription	was	performed	
using	900ng	of	RNA	(100ng/µL)	added	to	a	sterile	and	RNAse	free	Eppendorf	tube	
with	200ng	random	hexamers	(Invitrogen)	and	incubated	at	70°C	for	10	minutes.	This	
anneals	the	random	hexamers	to	the	RNA	chains	which	then	act	as	a	primer.		
The	samples	were	incubated	on	ice	and	to	each	the	following	were	added:	
? 4µL	5x	Superscript	buffer	
o Provides	optimum	conditions	for	RT	enzyme	and	stabilises	pH	at	8.3	
? 2µL	0.1M	DTT	 	
o Reducing	agent	to	improve	reaction	efficiency	
? 1µL	Superscript		(Invitrogen)		
o Performs	reverse	transcription	using	dNTPs	to	produce	cDNA	
? 1µL	dNTPs	(Roche)	
o 10mM	of	each	deoxyribonucleotide	
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The	samples	were	incubated	at	42°C	for	one	hour	and	then	inactivated	via	incubation	
at	70°C	for	10	minutes.		
The	final	concentration	of	cDNA	after	the	reaction	is	47.4	ng/µl.	Samples	were	stored	
at	-20oC	until	required	for	Taqman®	assays.	
	
5.4.10 Determination	of	Housekeeping	Genes	via	Taqman®	
	
To	assess	what	housekeeping	genes	would	be	appropriate	in	Taqman®	assays,	a	
PerfectProbe	GeNorm	12	gene	kit	was	used	(Primerdesign;	Housekeeping	gene	panel:	
CYC1,	RPL,	B2M,	GAPDH,	YWH,	EIF,	ATP,	TOP1,	UBC,	ACTB,	SCHA).	The	kit	was	used	
according	to	manufacturer’s	instructions	and	RNA	isolated	and	converted	to	cDNA	
from	3	Primary,	3	MoP	and	3	MoM	samples	and	probes	were	loaded	onto	a	Micro	
Amp®	optical	96	well	plate	(Applied	Bioscience),	controls	were	also	carried	out.	The	
plate	was	loaded	onto	a	7500	Real	Time	PCR	system	(Applied	Biosciences)	and	the	run	
cycle	was	started	(	50	oC	for	2	min,	95	oC	for	10	min,	40	x	(	95	oC	for	15	s,	60	oC	for	1	
min))	and	fluorescence	from	the	reporter	dye,	TAMRATM	was	monitored.	The		primary	
analysis	and	labelling	was	carried	out	using	Taqman®	7500	software.		
	
For	running	a	Taqman	assay	a	standard	curve	was	run	for	each	set	of	primers.	RNA	
was	diluted	to	20	ng,	10	ng,	5	ng,	1.25	ng	and	0.625	ng	samples,	these	were	then	
loaded	in	a	96	well	plate.	The	working	stock	of	cDNA	was	diluted	to	5	ng/µl.	For	each	
PCR	reaction	12.5	µl	of	Precision	2	x	qPCR	Master	Mix	with	low	ROX	(Primer	design),	
1.25	µl	primers	(designed	by	Primer	Design,	quencher	dye	is	TAMRATM)	1.25	µl	H2O	
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and	10	µl	cDNA	sample	were	added	to	a	well	on	a	Micro	Amp®	fast	optical	96	well	
plate	(Applied	Bioscience).		
	
Once	all	the	wells	were	filled	the	plates	was	placed	into	a	7500	Real	Time	PCR	system	
(Applied	Biosciences)	and	the	run	cycle	was	started	(50	oC	for	2	min,	95	oC	for	10	min,	
40	x	(	95	oC	for	15	s,	60	oC	for	1	min))	and	the	fluorescence	from	the	report	dye,	
TAMRATM	was	monitored.		
	
To	analyse	the	data	obtained	standard	curves	were	constructed	using	the	cycle	
number	(Ct)	plotted	against	the	log	input	(Log	(µg	RNA	in	sample)).	The	x	and	y	
intercepts	of	the	standard	curve,	obtained	from	the	line	of	best	fit	(R2=	>	0.98)	are	also	
used	in	calculating	the	gene	expression	(in	arbitrary	units).	The	following	calculation	
was	used	to	identify	the	input:	
𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 = 10 ^  
(𝐶𝐶𝐶𝐶 − 𝑥𝑥)
𝑦𝑦
	
The	 input	of	 the	gene	of	 interest,	was	normalised	by	dividing	 the	gene	of	 interest	by	
the	 geometric	 mean	 of	 Top1	 and	 Cyc1	 since	 Normfinder	 software	
(http://moma.dk/normfinder-software)	 analysis	 revealed	 that	 these	 two	genes	were	
contamination	free	and	demonstrated	the	least	degree	of	change.	The	geometric	mean	
is	 defined	 as	 the	 nth	square	 root	 (n	 is	 equal	 to	 the	 number	 of	 samples)	 of	 the	 total	
values	of	each	sample	multiplied	by	each	other	i.e.	
	
𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 =  𝑠𝑠1. 𝑠𝑠2. 𝑠𝑠3…
?
	
n=number	of	samples		
s	=	gene	expression	of	housekeeping	gene	
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Top1	and	Cyc1	which	were	then	used	as	housekeeping	genes	in	future	Taqman®	low-
density	arrays	(TLDAs).		
	
5.4.11 Taqman®	Low	Density	Array	(TLDA)	
	
The	TLDA	(Life	Technologies,	Paisley,	UK)	was	designed	to	assess	genes	identified	
from	the	36	genes	from	the	microarray	experiment	which	demonstrated	the	highest	
degree	of	significance	on	ANOVA	(p<0.05)	across	all	three	phenotypes	and	which	also	
had	a	FC>2	irrespective	of	the	direction	of	change	in	expression.	Where	a	gene	was	not	
readily	available	on	the	commercial	platform	used	or	was	not	financially	viable	to	
design	the	probe	for,	the	next	gene	in	the	hierarchy	was	selected.		
	
TLDA	functions	as	an	array	of	reaction	vessels	for	the	PCR	step.	The	wells	of	the	TLDA	
contain	Taqman®	gene	expression	assays	that	detect	the	real-time	amplification	of	
user	specified	targets.	The	relative	levels	of	gene	expression	are	determined	from	the	
fluorescence	data	generated	during	PCR.	Custom	designed	TLDA	array	cards	allowed	a	
total	selection	of	48	genes	(inclusive	of	12	housekeeping	genes)	for	33	samples	(10	x	
Primary	THR	for	OA,	11	MoP	THR	revisions	for	aseptic	loosening,	and	12	MoM	THR	for	
ARMD).	TLDA	cards	are	preloaded	with	specified	custom	primer	probe	sets	and	all	
reagents	required	for	the	reaction.		
	
Patient	cDNA	is	loaded	into	the	array	via	ports	and	centrifuged	to	distribute	samples	
across	the	wells.	The	PCR	reaction	is	identical	to	the	process	for	manual	Taqman®	via	
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use	of	the	Biosystems	7900HT	Fast	Real-Time	PCR	system.	The	TLDA	is	optimised	so	
that	the	custom	primer-probe	sets	have	near	uniform	efficiency	across	cDNA	
concentrations.	No	independent	standard	curve	analysis	is	performed	since	the	system	
is	designed	not	to	need	this	step.		
	
cDNA	was	loaded	into	the	fill	reservoirs	and	the	plate	run	according	to	manufacturer’s	
instructions	using	the	Applied	Biosystems	7900HT	Real-Time	PCR	System	and	Applied	
Biosystems	Sequence	Detection	Systems	(SDS)	software	(Life	Technologies,	Paisley,	
UK).	Undetected	samples	were	discarded.	Relative	expression	levels	in	each	gene	of	
interest	were	analysed	by	normalising	to	endogenous	control	genes	TOP1	or	Cyc1	(∆Ct	
[endogenous	control	gene	Ct-gene	of	interest	Ct])	and	linearising	the	data	by	
expressing	it	as	2∆Ct.	Alternatively	data	was	expressed	as	a	fold	change	from	the	control	
(2∆∆Ct	[treatment	condition	2∆Ct	/	Control	2∆Ct).	Data	shown	was	normalised	to	TOP1,	as	
GeNorm	analysis	demonstrated	TOP1	to	be	the	most	stable	housekeeping	gene	
(normalising	to	Cyc1	yielded	similar	results).	
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5.5 Laboratory	Results	
5.5.1 Whole-Genome	Microarray	
	
Post	processing	via	variance	stabilization	and	quantile	normalisation	found	that	no	
genes	were	found	to	be	statistically	significantly	differentially	expressed	between	the	
MoP	and	MoM	phenotypes	via	Student’s	t-test	(p<0.05).	Since	the	p-value	is	not	
corrected	for	multiple	testing	a	false	discovery	rate	(FDR)	using	a	q-value	of	0.2	was	
used	as	a	threshold	to	control	the	number	of	false	positives.	The	q-value	represents	the	
smallest	value	at	which	a	gene	becomes	significant	using	a	false-discovery	rate	(FDR)	
method	using	the	Benjamini	and	Hochberg	multiple	testing	correction158.	The	q-value	
is	an	adjusted	p-value,	taking	in	to	account	the	false	discovery	rate	(FDR).		Applying	a	
FDR	becomes	necessary	when	thousands	of	variables	are	measured	(in	this	case	gene	
expression	levels	from	tens	of	thousands	of	transcripts)	from	a	small	sample	set.	A	p-
value	of	0.05	implies	that	we	are	willing	to	accept	that	5%	of	all	tests	will	be	false	
positives.		An	FDR-adjusted	p-value	(aka	a	q-value)	of	0.05	implies	acceptance	that	5%	
of	the	tests	found	to	be	statistically	significant	(e.g.	by	p-value)	will	be	false	positives.		
	
There	was	a	high	degree	of	noise	in	the	analysis	and	it	was	noted	that	for	multiple	
genes	there	was	a	large	order	of	inter-sample	variation	in	samples	of	the	same	
phenotype.		For	example	the	gene	CSN1S1	is	the	most	highly	expressed	gene	in	the	
MoM	phenotype	samples	but	has	a	high	q-value	(0.89)	hence	is	not	considered	to	be	
significant	despite	having	a	high	fold	change	(FC=4.5	MoP	vs.	MoM);	the	q	value	is	high	
since	expression	level	of	that	gene	is	highly	variable	amongst	individual	MoP	samples.		
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Examination	of	the	sample	relations	between	the	3	phenotypes	across	all	33,777	genes	
demonstrates	that	whilst	primary	OA	phenotypes	tend	to	cluster	separately	from	the	
other	two	phenotypes	there	is	a	high	degree	of	clustering	of	individuals	of	the	MoP	and	
MoM	phenotypes	(Figure	5.5-1).	
	
	
	
Figure	5.5-1	Sample	relations	based	on	33,777	genes	with	sd/mean	>0.1.	P	(primary	OA	
phenotype),	MOP	or	mp	(metal-on-polyethylene	phenotype)	and	MOM	or	mm	(metal-on-metal	
phenotype).	ALL	CAPS	+	number	(biological	replicates	in	the	first	microarray	experiment),	
lowercase	+	letters	a	to	d	(biological	replicates	in	the	second	microarray	experiment)	
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Since	this	approach,	whilst	being	reasonable	to	avoid	a	high	false	positive	rate,	did	not	
yield	any	genes	for	further	examination,	it	was	decided	to	apply	an	absolute	fold-
change	(FC)	cut-off	>1.5	with	a	q-value	of	0.2	across	all	3	phenotypes.	56	genes	were	
identified	which	fulfilled	these	criteria	across	the	3	phenotypes	(Figure	5.5-2)	
	
Figure	5.5-2	Heatmap	of	supervised	hierarchical	clustering	by	phenotype	of	56	genes	
differentially	expressed	between	3	phenotypes	(FC>1.5,	q=0.2);	primary	osteoarthritis	(p	or	P),	
MoP	THR	revision	for	aseptic	loosening	(MOP	or	mp)	and	MoM	THR	revision	for	ARMD	(MoM	
or	mm).	Columns	represent	individual	samples,	rows	represent	relative	expression	values	
where	green	represents	over-expression,	red	represents	under-expression	and	black	
represents	no	change.		
	
At	this	level	MoP	and	MoM	phenotypes	demonstrate	very	similar	patterns	of	relative	
gene	expression	in	contrast	to	Primary	OA	phenotype.	However,	56	genes	is	a	small	
sample	size	for	which	to	perform	pathway	analysis	and	so	mathematical	constraints	
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were	redefined	such	that	genes	differentially	expressed	were	selected	using	ANOVA,	
with	a	p	value,	based	on	permutations,	<0.05.	Genes	were	filtered	for	a	fold	change	≥2	
in	at	least	one	condition.		Hierarchical	clustering	was	done	using	Euclidian	distance.	
This	approach	yielded	130	transcripts	(Figure	5.5-3)	
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Figure	5.5-3Heatmap	of	supervised	hierarchical	clustering	by	phenotype	of	130	genes	
differentially	expressed	between	3	phenotypes,	p<0.05	and	FC>2.	Phenotypes	are	denoted	by	
primary	osteoarthritis	(p	or	P),	MoP	THR	revision	for	aseptic	loosening	(MOP	or	mp)	and	MoM	
THR	revision	for	ARMD	(MoM	or	mm).	Columns	represent	individual	samples;	rows	represent	
relative	expression	values	scaled	according	to	the	colour	key	at	the	top	of	the	diagram.		
	
For	network	generation,	the	130	transcripts	and	Log	ratio	values	were	uploaded	into	
IPA	application.	Each	identifier	was	mapped	to	its	corresponding	object	in	the	
Ingenuity®	Knowledge	Base.	All	molecules	were	overlaid	onto	a	global	molecular	
network	developed	from	information	contained	in	the	Ingenuity®	Knowledge	Base.	
Networks	of	network	eligible	molecules	were	then	algorithmically	generated	based	on	
their	connectivity.		
	
The	functional	analysis	identified	the	biological	functions	and/or	diseases	that	were	
most	significantly	associated	to	the	data	set.	The	130	transcripts	were	associated	with	
biological	functions	and/or	diseases	in	the	Ingenuity®	Knowledge	Base.	The	analysis	
of	the	networks	identified	the	biological	functions	and/or	diseases	that	were	most	
significant	to	the	molecules	in	the	network.	For	every	instance,	right-tailed	Fisher’s	
exact	test	was	used	to	calculate	a	p-value	determining	the	probability	that	each	
biological	function	and/or	disease	assigned	to	that	network	is	due	to	chance.	
	
Canonical	pathway	(CP)	analysis	identified	the	pathways	from	the	IPA	library	of	
canonical	pathways	that	were	most	significantly	associated	to	the	data	set.	The	
significance	of	the	association	between	the	data	set	and	the	canonical	pathway	was	
measured	in	2	ways159:	1)	A	ratio	of	the	number	of	molecules	from	the	data	set	that	
map	to	the	pathway	divided	by	the	total	number	of	molecules	that	map	to	the	
canonical	pathway	is	displayed.	2)	Right	Tailed	Fisher’s	exact	test	was	used	to	
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calculate	a	p-value	determining	the	probability	that	the	association	between	the	genes	
in	the	dataset	and	the	canonical	pathway	is	explained	by	chance	alone	(	,	Table	5.5-2,	
Table	5.5-3).		
	
Table	5.5-1	Associated	pathways	of	the	differentially	expressed	genes	(MoP	vs.	MoM	
phenotypes).	Fifteen	pathways	in	total	were	identified	as	associated	with	the	differentially	
expressed	genes	using	Ingenuity	Canonical	Pathway	analysis.	The	ratio	column	is	the	
proportion	of	the	differentially	expressed	genes	divided	by	the	total	number	of	genes	
associated	with	a	pathway.	
Ingenuity	Canonical	Pathway		 p	value	 Ratio	 Molecules	
	 	 	 	
Inhibition	of	Matrix	Metalloproteases	 0.0004***	 0.05	 TIMP3,MMP12	
Leukocyte	Extravasation	Signalling	 0.0100**	 0.01	 TIMP3,MMP12	
Oncostatin	M	Signalling	 0.0280*	 0.03	 TIMP3	
Primary	Immunodeficiency	Signalling	 0.0398*	 0.02	 IGLL1/IGLL5	
Glioma	Invasiveness	Signalling	 0.0436*	 0.02	 TIMP3	
GDNF	Family	Ligand-Receptor	
Interactions	
0.0562	 0.01	 GFRA2	
Bladder	Cancer	Signalling	 0.0660	 0.01	 MMP12	
HIF1	Signalling	 0.0776	 0.01	 MMP12	
Rac	Signalling	 0.0776	 0.01	 CYFIP2	
IL-6	Signalling	 0.0870	 0.01	 TNFAIP6	
Mitochondrial	Dysfunction	 0.1250	 0.01	 NDUFA4L2	
Granulocyte	Adhesion	and	Diapedesis	 0.1300	 0.01	 MMP12	
Agranulocyte	Adhesion	and	Diapedesis	 0.1380	 0.01	 MMP12	
Actin	Cytoskeleton	Signalling	 0.1570	 0.00	 CYFIP2	
Colorectal	Cancer	Metastasis	Signalling	 0.1690	 0.00	 MMP12	
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The	p-value	associated	with	a	pathway	analysis	is	a	measure	of	the	likelihood	that	the	
association	between	a	set	of	focus	genes	in	the	experiment	and	a	given	process	or	
pathway	is	due	to	random	chance.	The	smaller	the	p-value	the	less	likely	that	the	
association	is	random	and	the	more	significant	the	association.		
	
In	this	method,	the	p-value	for	a	given	process	annotation	is	calculated	by	considering	
(1)	the	number	of	focus	genes	that	participate	in	that	process	and	(2)	the	total	number	
of	genes	that	are	known	to	be	associated	with	that	process	in	the	selected	reference	
set.	The	more	focus	genes	involved,	the	more	likely	the	association	is	not	due	to	
random	chance,	and	thus	the	more	significant	the	p-value.	Similarly,	the	larger	the	
total	number	of	genes	known	to	be	associated	with	the	process,	the	greater	the	
likelihood	that	a	association	is	due	to	random	chance,	and	the	p-value	accordingly	
becomes	less	significant.	In	short,	the	p-value	identifies	statistically	significant	over-
representation	of	focus	genes	in	a	given	process.	Over-represented	functional	or	
pathway	processes	are	processes	which	have	more	focus	genes	than	expected	by	
chance	(right-tailed)	
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Table	5.5-2	Associated	pathways	of	the	differentially	expressed	genes	(MoM	vs.	Primary	OA	
phenotypes).	36	pathways	in	total	were	identified	as	associated	with	the	differentially	
expressed	genes	using	Ingenuity	Canonical	Pathway	analysis.	The	ratio	column	is	the	
proportion	of	the	differentially	expressed	genes	divided	by	the	total	number	of	genes	
associated	with	a	pathway.	
	
	
	
	
	
	
	
Ingenuity)Canonical)Pathways p)value Ratio Molecules
ErbB%Signaling 0.0007762 0.0465 FOS,FOXO1,BTC,HBEGF
Atherosclerosis%Signaling 0.0029512 0.0325 MMP3,CD36,PLA2G7,CLU
Neuregulin%Signaling 0.0087096 0.0341 BTC,HBEGF,ERRFI1
Oncostatin%M%Signaling 0.0114815 0.0588 TIMP3,MMP3
CDK5%Signaling 0.0120226 0.0303 FOSB,EGR1,ADCY3
Role%of%Tissue%Factor%in%Cancer 0.0158489 0.0273 EGR1,ITGAV,HBEGF
FXR/RXR%Activation 0.0234423 0.0236 FOXO1,CYP27A1,CLU
GNRH%Signaling 0.0239883 0.0233 FOS,EGR1,ADCY3
UDPUNUacetylUDUglucosamine%Biosynthesis%II 0.0281838 0.167 GFPT2
CXCR4%Signaling 0.0371535 0.0197 FOS,EGR1,ADCY3
EndothelinU1%Signaling 0.0501187 0.0174 FOS,ADCY3,PLA2G7
Granulocyte%Adhesion%and%Diapedesis 0.0537032 0.0169 MMP3,MMP12,CXCL6
Role%of%ILU17A%in%Psoriasis 0.060256 0.0769 CXCL6
Bile%Acid%Biosynthesis,%Neutral%Pathway 0.060256 0.0769 CYP27A1
Pyrimidine%Deoxyribonucleotides%De%Novo%Biosynthesis% 0.1004616 0.0455 AK1
ILU6%Signaling 0.1071519 0.0172 FOS,TNFAIP6
ILU17A%Signaling%in%Gastric%Cells 0.1135011 0.04 FOS
LXR/RXR%Activation 0.1148154 0.0165 CD36,CLU
Pyrimidine%Ribonucleotides%Interconversion 0.121899 0.037 AK1
TNFR2%Signaling 0.1303167 0.0345 FOS
Pyrimidine%Ribonucleotides%De%Novo%Biosynthesis 0.1303167 0.0345 AK1
ILU12%Signaling%and%Production%in%Macrophages 0.1370882 0.0148 FOS,CLU
Aryl%Hydrocarbon%Receptor%Signaling 0.1455459 0.0143 FOS,NQO1
Complement%System 0.1468926 0.0303 CFI
Inhibition%of%Angiogenesis%by%TSP1 0.151008 0.0294 CD36
Cell%Cycle%Regulation%by%BTG%Family%Proteins 0.1552387 0.0286 BTG2
ILU17A%Signaling%in%Fibroblasts 0.1552387 0.0286 FOS
Hepatic%Cholestasis 0.18281 0.0123 CYP27A1,ADCY3
iNOS%Signaling 0.1909853 0.0227 FOS
Role%of%NFAT%in%Regulation%of%the%Immune%Response 0.1981527 0.0117 RCAN1,FOS
RAR%Activation 0.2070141 0.0114 FOS,ADCY3
ILU10%Signaling 0.2792544 0.0147 FOS
LPS/ILU1%Mediated%Inhibition%of%RXR%Function 0.2831392 0.00913 HS3ST2,FABP5
LPSUstimulated%MAPK%Signaling 0.2964831 0.0137 FOS
TollUlike%Receptor%Signaling 0.2999163 0.0135 FOS
Acute%Phase%Response%Signaling 0.5584702 0.00592 FOS
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Table	5.5-3	Associated	pathways	of	the	differentially	expressed	genes	(MoP	vs.	Primary	OA	
phenotypes).	149	pathways	in	total	were	identified	as	associated	with	the	differentially	
expressed	genes	using	Ingenuity	Canonical	Pathway	analysis.	The	34	statistically	significant	
processes	(p<0.05)	are	displayed	above.	The	ratio	column	is	the	proportion	of	the	differentially	
expressed	genes	divided	by	the	total	number	of	genes	associated	with	a	pathway.		
	
	
	
	
	
	
	
	
	
	
	
Ingenuity)Canonical)Pathways p)value Ratio Molecules
Atherosclerosis+Signaling 0.00081283 0.0325 MMP3,CD36,PLA2G7,CLU
ErbB+Signaling 0.0030903 0.0349 FOS,BTC,HBEGF
Neuregulin+Signaling 0.00331131 0.0341 BTC,HBEGF,ERRFI1
LPS/ILO1+Mediated+Inhibition+of+RXR+Function 0.00645654 0.0183 ALDH1A3,HS3ST2,FABP5,LBP
LXR/RXR+Activation 0.00812831 0.0248 CD36,LBP,CLU
iNOS+Signaling 0.00977237 0.0455 FOS,LBP
UDPONOacetylODOglucosamine+Biosynthesis+II 0.01995262 0.167 GFPT2
ILO10+Signaling 0.02238721 0.0294 FOS,LBP
LPSOstimulated+MAPK+Signaling 0.02570396 0.0274 FOS,LBP
TollOlike+Receptor+Signaling 0.02630268 0.027 FOS,LBP
Role+of+ILO17A+in+Psoriasis 0.04365158 0.0769 CXCL6
Bile+Acid+Biosynthesis,+Neutral+Pathway 0.04365158 0.0769 CYP27A1
Histamine+Degradation 0.04365158 0.0769 ALDH1A3
CDK5+Signaling 0.04466836 0.0202 FOSB,EGR1
Fatty+Acid+Î±Ooxidation 0.05248075 0.0625 ALDH1A3
Oxidative+Ethanol+Degradation+III 0.05248075 0.0625 ALDH1A3
Role+of+Tissue+Factor+in+Cancer 0.05370318 0.0182 EGR1,HBEGF
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5.5.2 Verification	of	Microarray	using	TLDA	
	
Genes	for	TLDA	validation	of	the	microarray	were	selected	by	assessing	the	top	36	
genes	in	terms	of	fold	change	(FC)	>2	and	with	a	significant	difference	(p<0.05)	on	
ANOVA.	After	normalisation	to	Top1	the	TLDA	data	was	clustered	to	form	a	heatmap	
using	Cluster	3.0	(Eisen)	and	Treeview	software.		
	
Qualitatively	there	is	a	mirroring	of	the	pattern	of	expression	between	the	heatmaps	
obtained	from	the	microarray	and	the	TLDA.	Close	associated	between	the	expression	
patterns	are	seen	between	MoP	and	MoM	phenotypes	which	are	clearly	different	from	
the	expression	pattern	associated	with	the	primary	OA	phenotype	in	concordance	with	
the	microarray.	Whilst	overall	the	microarray	and	TLDA	demonstrate	an	agreement	in	
pattern	of	gene	expression,	a	2-way	ANOVA	comparing	absolute	fold	change	in	
expression	values	between	microarray	data	and	TLDA	data	demonstrated	7	genes	out	
of	36	which	had	a	significantly	different	level	of	expression;	CHIT1,	MMP12,	APCDD1L,	
CSN1S1,	TIMP3,	CRTAC1	and	OGN	(see	Tables	in	Appendix	G),	however	this	must	be	
interpreted	with	caution	since	the	microarray	data	is	a	qualitative	estimation	of	gene	
expression	whereas	the	TLDA	is	a	wholly	quantitative	method.	The	direction	of	change	
in	expression	for	individual	genes	was	consistent	between	array	and	TLDA.		
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Figure	5.5-4	Heatmap	displaying	differential	gene	expression	across	3	phenotypes	via	TLDA.	
Hierarchical	clustering	is	by	phenotype.	Red	represents	relative	over-expression,	green	
represents	relative	under-expression	and	black	indicates	no	change.	For	gene	functions	and	2-
way	ANOVA	data	please	see	Appendix.	
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5.6 Discussion	
This	is	the	first	study	to	comprehensively	investigate	gene	expression	changes	in	
periprosthetic	tissue	associated	with	revisions	due	to	aseptic	loosening	of	a	MoP	
implant	and	ARMD	from	MoM	THRs.	
	
Extraction	of	RNA	of	sufficient	quantity	and	quality	for	microarray	analysis	from	either	
fresh	or	frozen	ARMD	tissue	which	has	undergone	extensive	inflammatory	and	
necrotic	change	is	highly	technically	challenging	and	involved	significant	time	and	
resources	to	develop	a	reliable	method.	Extraction	of	high	quality	and	quantity	RNA	
from	fresh	or	frozen	tissue	associated	with	osteolytic	lesions	was	also	difficult;	this	
may	be	due	to	the	fact	that	some	patients	with	long-term	osteolysis	may	also	have	a	
degree	of	necrosis	present.	Other	groups	performing	gene	expression	profiling	of	
osteolytic	lesions	around	THRs160	have	found	similar	issues	even	with	immediate	flash	
freezing	to	prevent	RNA	degradation.			In	retrospect	examining	tissue	at	the	watershed	
between	tissue	affected	by	ARMD	and	healthy	tissue	may	have	provided	a	better	
insight	into	the	active	biological	processes	propagating	ARMD,	but	would	have	
significantly	affected	the	sampling	methodology	since	type	of	tissue	being	compared	
would	not	have	been	consistent.	Further	optimisation	of	tissue	quality	may	be	
achieved	by	interventions	such	as	the	avoidance	of	cutting	diathermy	when	obtaining	
samples	to	minimise	thermal	necrosis	of	tissue	and	immediate	snap	freezing	in	liquid	
nitrogen	to	prevent	RNA	degradation.		
	
Of	the	fifteen	pathways	that	were	associated	with	the	differentially	expressed	genes	
between	the	MoP	and	MoM	phenotypes,	no	more	than	two	significant	differentially	
expressed	genes	per	pathway	were	identified.	This	implies	that	overall	there	are	no	
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signature	pathways	in	which	genes	are	up	or	down-regulated	between	these	two	
conditions	and	as	such	any	differentiation	between	the	contributions	of	innate	
macrophage	and	adaptive	T-cell	immune	responses	cannot	be	made.	From	these	
findings	no	specific	inference	can	be	made	regarding	activation	of	pathways	known	or	
suspected	to	be	important	in	the	pathogenesis	of	ARMD	such	as	the	inflammasome	
danger	signalling	pathway,	HIF,	or	TLR4	mediated	pathways.	However,	microarray	
experiments	do	not	account	for	any	post-transcriptional	modification,	and	under-
representation	of	a	given	pathway	in	any	dataset	is	not	indicative	that	flux	through	
that	pathway	is	increased.	Factors	such	as	post-translational	modification	or	control-
coefficients	for	each	step	in	a	pathway	are	not	taken	into	account	and	these	may	have	a	
significant	impact	on	the	how	the	overall	biological	activity	of	a	pathway	is	
represented.			
	
In	the	comparison	of	MoM	and	MoP	phenotypes,	where	there	is	significant	expression	
in	a	given	pathway,	typically	this	involves	only	one	or	two	genes	(Table	5.5-1).	The	
most	frequently	involved	genes	common	to	the	highlighted	pathways	are	MMP12	and	
TIMP3.	The	relative	levels	and	patterns	of	expression	of	both	these	genes	in	the	
microarray	were	found	to	be	replicated	in	the	TLDA	validation.	The	matrix	
metalloproteinases	and	their	endogenous	regulators,	the	tissue	metalloproteinases	
(TIMPs)	are	responsible	for	the	physiological	remodelling	of	the	extracellular	matrix.	
TIMP3	is	a	secreted	protein	which	is	tightly	bound	to	the	extracellular	matrix	and	has	
been	shown	to	be	able	to	induce	apoptosis	through	ligand-independent	activation	of	
death	receptor	signalling	and	blockade	of	survival	pathways161.	TIMP3	is	under-
expressed	in	MoM	compared	to	MoP,	perhaps	reflecting	the	more	aggressive	nature	of	
destruction	in	ARMD	where	extensive	tissue	damage	may	have	already	occurred	by	
the	time	of	revision	surgery.	The	gene	encoding	MMP12	gives	rise	to	an	enzyme	which	
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is	known	to	degrade	elastin	and	is	moderately	over-expressed	in	osteolytic	
periprosthetic	tissue162.	MMP12	expression	is	relatively	even	across	MoP	and	MoM	
phenotypes	which	may	suggest	some	commonality	between	the	processes	of	
osteolysis	and	ARMD	in	terms	of	the	activation	of	periprosthetic	osteolytic	cascades	
giving	rise	to	bone	resorption	and	implant	failure.	It	is	not	possible	on	the	basis	of	
these	results	to	make	a	clear	assertion	if	the	expression	of	a	given	gene	or	set	of	genes	
within	any	given	pathway	makes	ARMD	or	periprosthetic	osteolysis	more	likely.		
	
Individual	genes	which	could	be	of	significance	have	been	highlighted	as	showing	
significant	differential	expression	between	MoM	and	MoP	phenotypes	and	may	
represent	avenues	for	further	research.	For	example	gene	expression	of	PRG4	
(proteoglycan	4	or	lubricin)	which	plays	a	role	in	joint	lubrication,	synovial	
homeostasis	and	tendon	gliding163	164is	consistently	overexpressed	in	MoM	
phenotypes	(Figure	5.6-1).	Further	investigation	may	reveal	if	over-expression	this	
gene	may	contribute	to	the	formation	of	the	fluid-filled	cystic	masses	associated	
commonly	seen	in	ARMD.	
	
Figure	5.6-1	Heatmap	demonstrating	relative	overexpression	of	PGR4	in	MoM	phenotypes	in	
comparison	to	primary	OA	and	MoP	phenotypes	
	
Whilst	the	pattern	of	relative	gene	expression	across	MoM	and	MoP	phenotypes	
appears	to	be	in	general	agreement,	there	is	some	suggestion	that	there	are	sets	of	
genes	and	pathways	which	differentiate	the	two	when	compared	to	the	control	
primary	OA	phenotype.	Using	canonical	pathway	analysis	to	compare	the	MoM	
phenotype	with	primary	OA	phenotype	(Table	5.5-2)	there	are	ten	significant	
pathways	with	at	least	3	focus	genes	per	pathway	found.	In	the	comparison	of	MoP	
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phenotype	with	primary	OA	phenotype	there	are	4	significant	pathways	with	at	least	
focus	genes	per	pathway	(Table	5.5-3).	The	high	differential	gene	expression	along	
with	the	higher	number	of	focus	molecules	identified	within	these	pathways	has	
identified	a	starting	point	for	further	in	silico	modelling	to	examine	any	potential	
interaction	which	might	provide	a	basis	for	a	more	focused	series	of	experiments	to	
examine	gene	expression	using	qRT-PCR	and	further	our	understanding	of	cellular	
mechanisms	in	ARMD	or	in	aseptic	loosening	and	periprosthetic	osteolysis.		
	
One	of	the	limitations	of	the	microarray	approach	is	that	it	is	only	apt	to	detect	large	
scale	changes	in	levels	of	gene	expression	and	so	even	taking	into	account	an	imperfect	
correspondence	between	RNA	and	protein	level	changes,	a	small	change	in	one	protein	
can	be	of	much	more	biological	significance	in	a	given	context	than	a	massive	change	in	
another.		
	
The	gene	expression	profile	of	osteoarthritic,	osteolytic,	and	ARMD	tissues	includes	
not	only	what	a	single	cell	type	is	expressing,	but	the	integral	expression	of	all	genes	of	
all	cells	and	cell	types	present	at	the	moment	of	harvesting.	This	is	in	contrast	to	in	
vitro	studies	which	benefit	from	using	single	cell	types	and	where	gene	expression	
profiling	can	be	undertaken	and	the	specific	cell	responses	can	be	linked	more	readily.	
In	clinical	studies	the	number	of	variables	(patient	factors,	implant	factors,	surgical	
and	technical	factors,	length	of	implantation)	offers	an	increased	layer	of	complexity.	
Using	the	experimental	techniques	and	analytical	methods	above	we	would	have	been	
in	a	good	position	to	confirm	any	complex	interactions	discovered	in	the	datasets	were	
actually	occurring	in	the	patient	at	the	moment	that	tissue	was	extracted.	The	fact	that	
we	have	been	unable	to	do	so	may	reflect	that	tissue	was	harvested	from	patients	who,	
irrespective	of	their	phenotype,	have	an	end-stage	condition	for	which	surgery	has	
been	mandated.	Gene	expression	profiling	from	tissues	at	an	earlier	stage	in	the	
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disease	process	may	have	yielded	more	insights,	but	would	have	had	to	have	been	
done	via	invasive	biopsy	with	little	diagnostic	or	therapeutic	benefit	to	the	patient.	
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6 General	Conclusions	
	
The	primary	objective	of	this	study	was	to	provide	evidence	to	aid	in	the	evaluation	of	
ARMD	and	its	cellular	mechanisms	in	a	local	cohort	of	patients	with	a	MoM	THR.	This	
has	been	accomplished.	The	study	has	contributed	to	the	understanding	of	the	natural	
history	of	ARMD	on	MAR	MRI	at	up	to	11	years	post	implantation	and	has	provided	
evidence	which	supports	the	validity	and	accuracy	of	using	blood	metal	ion	levels	as	a	
means	of	surveillance	of	MoM	THR	patients.	It	has	also	demonstrated	that	gene	
expression	profiles	in	periprosthetic	tissues	from	MoP	THR	revisions	for	
periprosthetic	osteolysis	and	MoM	THR	revisions	for	ARMD	are	similar.		
	
Returning	to	the	original	study	questions	in	Chapter	2	we	are	now	able	to	provide	
some	answers	and	have	an	overall	greater	understanding	of	the	biology	and	natural	
history	of	ARMD	in	the	context	of	MoM	THR.		
	
1. What	is	the	natural	history	of	ARMD	using	MARS	MRI?	
	
The	minimal	frequency	of	MR	imaging	required	to	adequately	screen	
populations	of	relatively	asymptomatic	patients	with	MOM	THR	was	not	
known	because	the	natural	history	of	the	disease	was	not	understood.	
	
For	those	patients	whose	first	MRI	was	classified	using	the	Anderson	criteria	
as	stage	A	or	“normal	postoperative	appearances”,	9.5%	developed	ARMD.	
This	occurred	at	7	to	11	years	after	the	initial	operation.	For	those	patients	
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with	ARMD	of	any	grade,	on	any	MR,	15%	deteriorated	on	a	subsequent	MR.	
Nineteen	percent	of	patients	staged	C1	were	reclassified	as	normal	on	a	
subsequent	MR	at	5	to	7	years.	This	either	reflects	a	reduced	specificity	for	MR	
in	detecting	mild	ARMD	or	true	resolution	of	the	disease	
	
This	study	did	not	include	a	substantial	number	of	patients	in	whom	their	
MOM	THR	failed	and	were	revised	early,	and	so	the	conclusion	is	that	for	this	
cohort,	ARMD	appears	to	develop	in	the	early	post-operative	phase.	Those	
patients	with	severe	disease	present	early	on.	Those	with	mild	disease	(C1)	are	
often	stable	for	many	years,	and	only	a	small	proportion	of	those	with	normal	
MRIs	will	develop	ARMD	but	when	they	do	it	is	usually	7	to	10	years	post	
implantation.	Our	conclusion	was	that	annual	assessment	of	asymptomatic	
patients	with	MOM	THR	with	MAR	MRI,	as	recommended	by	the	MHRA,	would	
seem	to	be	an	adequate	frequency	for	screening,	but	our	evidence	does	not	
necessarily	apply	to	all	types	of	prostheses.	Depending	on	prosthesis	type,	a	
patient	with	a	normal	post	operative	MRI	may	have	a	10%	chance	of	
developing	ARMD	at	7	to	11	years	after	surgery.	
	
Further	study	to	conclusively	establish	a	correlation	between	severity	of	
changes	on	MAR	MRI	staging,	blood	metal	ion	levels,	and	clinical	outcomes	is	
required	to	develop	a	robust	and	economical	surveillance	method	for	patients	
with	a	MoM	hip	arthroplasty.		
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2. What	is	the	relevance	of	blood	and	urine	metal	ion	levels	as	a	predictor	of	
disease	activity	and	does	diurnal	variation	exist	in	cobalt	and	chromium	
ion	levels	in	patients	with	a	MoM	THR?	
	
Measurement	of	metal	ion	levels	in	either	in	whole	blood,	serum,	or	plasma	
remains	a	useful	tool	as	part	of	the	long-term	monitoring	of	patients	with	a	
MoM	THR.		
	
Levels	of	plasma	Co	demonstrated	no	evidence	of	diurnal	variation	hence	it	
may	be	a	more	reliable	marker	than	plasma	Cr	for	ARMD.	This	raises	the	
question	as	to	whether	it	is	necessary	or	economical	to	measure	both	ions	in	
the	course	of	normal	practice.		
	
Where	a	diurnal	variation	in	levels	of	plasma	Cr	was	demonstrated,	although	
statistically	significant,	it	was	found	to	be	within	the	normal	acceptable	
tolerances	for	trace	metal	analysis	and	as	such	is	clinically	irrelevant.	Previous	
literature	does	indicate	an	exercise	related	cobalt	rise	with	large	diameter	
MoM	bearings,	but	in	our	study	we	have	demonstrated	that	in	patients	with	a	
normal	level	of	day-to-day	activity	there	appears	to	be	no	discernable	rise	in	
plasma	metal	ion	levels.	The	time	of	day	at	which	a	sample	of	blood	for	Co	or	Cr	
analysis	is	taken	is	clinically	irrelevant.	Further	studies	will	be	needed	to	
validate	these	findings	for	systems	in	where	more	particulate	debris	is	
generated	secondary	to	wear	such	as	is	seen	in	large	diameter	implants.		
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Urine	levels	of	Co	and	Cr	are	more	prone	to	fluctuation	across	the	course	of	the	
day	and	may	be	affected	by	renal	impairment	and	by	an	individual’s	level	of	
hydration,	making	them	an	unsuitable	method	for	monitoring.		
	
3. Is	there	a	difference	in	the	activation	of	biological	cascades	between	
patients	being	revised	for	periprosthetic	osteolysis	arising	from	a	MoP	
THR	versus	patients	with	a	MoM	THR	being	revised	for	ARMD?	
	
Gene	expression	in	joints	affected	by	ARMD,	periprosthetic	osteolysis,	and	
osteoarthritis	can	be	reliably	measured	by	microarray	experiment.	Our	
findings	of	the	microarray	were	validated	using	TLDA	which	suggests	that	the	
method	is	robust.	Significant	technical	challenges	in	terms	of	RNA	quality	
control	were	overcome	in	order	to	achieve	this.		
Overall	there	is	a	great	degree	of	similarity	between	osteolysis	and	ARMD	in	
terms	of	gene	expression.	No	definitive	biological	pathways	were	identified	
that	significantly	differentiated	the	two	pathologies	using	canonical	pathway	
analysis.	This	confirms	that	ARMD	does	share	common	pathways	in	the	
inflammatory	response	to	particulate	wear	debris	induced	by	secreted	
proinflammatory	and	osteoclastogenic	cytokines	and	the	periprosthetic	
osteolytic	cascades	governed	by	actions	of	MMPs.	Genes	of	biological	
importance	in	pathways	suspected	in	the	aetiology	of	ARMD	(HIF,	TLR4,	
Inflammasome	danger	signalling)	may	be	only	moderately	differentially	
expressed	and	so	not	readily	identified	using	the	mathematical	constraints	
applied	in	this	microarray	experiment.	Furthermore	factors	such	as	post-
translational	modification	or	control-coefficients	for	each	step	in	a	pathway	are	
not	taken	into	account	in	a	microarray	experiment	and	these	may	have	a	
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significant	impact	on	the	how	the	overall	biological	activity	of	a	pathway	is	
represented.	
	
	Further	research	in	this	area	may	well	be	better	served	by	further	reduction	of	
mathematical	constraints	when	examining	the	microarray	data	and	creation	of	
an	appropriately	selected	set	of	genes	of	interest	for	analysis	by	a	qRT-PCR	
method	which	requires	less	RNA	to	deliver	a	result.		
	
	
This	work	has	added	to	the	body	of	knowledge	concerning	ARMD,	its	natural	history	
on	a	cellular	and	radiological	level,	and	has	provided	a	contribution	to	the	evidence	
base	which	informs	us	as	the	optimum	strategy	for	monitoring	these	patients	before	
they	develop	catastrophic	complications.	MoM	devices	now	comprise	less	than	1%	of	
all	hip	arthroplasties	performed	in	the	UK	and	MoM	THR	has	now	largely	been	
confined	to	history	having	taught	us	important	lessons	on	implant	design,	
implantation,	regulation,	and	engineering.	Periprosthetic	osteolysis	and	aseptic	
loosening	remains	the	most	common	reason	for	implant	failure	and	need	for	revision	
arthroplasty.	These	studies	have	provided	a	potential	starting	point	for	further	
investigation	of	biological	cascades	involved	in	periprosthetic	osteolysis	using	
microarray	techniques.	
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£	 1,866	 per	 annum	 	Home/EU	 	 	 	 	
International	
TOTAL	=	£3,732	
Salary	
	
£	19,260	(20%	FTE	over	2	years)	
Consumables	
	
? General	 consumables,	
biochemical,	plasticware	
? Molecular	 Biology	 reagents,	
RNA/DNA	prep,	enzymes	
? Histology	reagents,	microscopy	
? Cell	 culture	 reagents,	 Taqman	
probes,	Master	mix		
TOTAL	=	£	10,241	
Technical	
Support	
£	 8,840.50	 per	 annum	 Laboratory	
technical	support	30%	FTE	of	Technician		
TOTAL	=	£17,681	
Conferences	
	
? £	195	–	British	Hip	Society	
meeting	
? £	210	–	British	Orthopaedic	
Research	Society	meeting	
	
TOTAL	=	£	405	
Feasibility	
Study	
	
	
n	=	12	PATIENTS	with	Ultima	TPS	THR	
? 4	 asymptomatic	 with	 normal	
MRI	
? 4	symptomatic	with	normal	MRI	
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Feasibility	
Study	
(cont’d)	
? 4	 symptomatic	 with	 abnormal	
MRI	awaiting	revision	
	
? £	 763.68	 (£15.91	 per	 patient	
per	day	x	4	days)	–	Clinical	Trials	
Research	Unit	overheads	
	
For	each	patient	initial	visit:	
	
? £	200		=	2	hourly	blood	cobalt	and	
chromium	analysis	per	patient	
(£50	per	sample	inclusive	of	
consumables)	
? £	150	=	morning,	afternoon,	and	
evening	cobalt	and	chromium	
urine	analysis	(£50	per	sample	
inclusive	of	consumables)	
? £	5.15		=	food	and	beverage	
allowance	
? £	15	=	travel	costs	
? £	40.56	=	fixed	nursing	costs	per	
patient	(cannulation,	drawing	
blood,	collection	of	urine	
specimens)	
	
INITIAL	 VISIT	 =	 £4,928.52	 (£	 410.71	
per	patient)	
	
SUBSEQUENT	 VISITS	 x	 3	 (costs	 per	
patient)	
	
? £	50	=	cobalt	and	chromium	blood	
analysis	inclusive	of	consumables	
(taken	at	either	8am,	12pm,	or	
5pm)	
? £	15	=	travel	costs	
	
TOTAL	=	£	2,340		
	
TOTAL	=	8,032.20	
Other		
	
? £	74.63	–	SPSS	statistics	software	
annual	student	licence		
? £	 190.80	 –	 Endnote	 X5	
bibliographic	software	
? £234.00	 –	 Introduction	 to	
Statistics	using	SPSS	
TOTAL	=	£	573.46	
TOTAL	 £	59,924.33	over	2	years.	
? £	40,664.66	(Total	Research	Costs	
over	2	years)	
? £	19,260	(Salary	at	20%	FTE	over	
2	years)	
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Section	2:	Goal	of	the	Study	
Please	 indicate	 research	 aims,	 objectives	 and	 deliverables	 (strictly	 maximum	
250	words)	
	
The	proposed	MD	project	will	review	the	literature	concerning	radiological	evaluation	
of	adverse	reactions	to	metal	hip	debris	(ARMD),	the	cellular	mechanisms	behind	this,	
and	will	investigate:	
1. Radiographic	evaluation	of	ARMD	using	MARS	sequence	MRI	scans	
2. Use	 of	 biomarkers	 including	 levels	 of	 cobalt	 and	 chromium	 species	 in	 blood	
and	urine	as	a	predictor	of	severity	of	disease.	
3. The	 use	 of	 Liquid	 Chromatography-Tandem	 Mass	 Spectrometry	 to	
demonstrate	 biomarkers	 in	 bone	 and	 tissue	 (in	 collaboration	 with	 Prof	 Bill	
Fraser,	UEA)	
4. Diurnal	variation	in	cobalt	and	chromium	ion	release.	
5. Use	of	clinical	outcome	measures	in	establishment	of	a	diagnostic	algorithm	to	
aid	decision	making	for	revision	hip	arthroplasty	
6. The	presence	or	absence	of	variation	in	immune	cells	and	cytokine	expression	
within	 the	 hip	 joint	 at	 revision	 surgery	 for	metallosis	 and	 compare	 this	with	
archived	tissue.	
7. The	 cellular	 and	 cytokine/chemokine/growth	 factor	 expression	 patterns	 in	
patients	 undergoing	 secondary	 surgery	with	 symptomatic	 and	 asymptomatic	
metal	on	metal	hip	bearings.		
	
	
Does	 your	 research	
involve	 testing	 on	
animals?		
	Yes																																							 	No	
If	Yes,	has	ethical	approval	been	obtained?	
What	 is	 your	 current	
position	 within	 your	
institution?	
Orthopaedic	Research	Fellow	
Please	 indicate	 your	
speciality	 and	 research	
interests?		
Trauma	 &	 Orthopaedic	 Surgery,	 Primary	 &	 Revision	 Hip	
Arthroplasty	
Are	 there	 any	 other	
funders	 involved	 in	 this	
project?		
	Yes																																							 	No	
If	Yes,	please	provide	details:	
Is	 there	 a	 conflict	 of	
interest	 that	 we	 should	
know	about?	
	Yes																																							 	No	
If	Yes,	please	specify:	
The	 principal	 investigator	 (or	 the	 respective	 institution)	 is	 obliged	 to	 agree	 to	 the	
terms	 and	 conditions	 of	 Orthopaedic	 Research	 UK	 standard	 academic	 contract	 and	
return	a	 signed	 copy	of	 the	 contract,	 no	 later	 than	3	months	after	 stage	4.	Contracts	
received	 after	 this	 period	 will	 not	 be	 approved	 for	 funding	 and	 subsequently	 the	
proposals	will	be	treated	as	void.	
	
	Agree																																							Date:	10/12/11	
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Section	3:	Background	to	Investigation	
Relevant	literature	and	work	already	conducted	by	the	applicant	related	to	the	
topic	of	research	interest	(strictly	maximum	1000	words)	
	
BACKGROUND:	
	
Our	 institution	 is	 actively	 following	 a	 cohort	 of	 545	patients	who	have	 had	 a	 28mm	
head	hybrid	metal	on	metal	(MoM)	total	hip	replacement	(Ultima	TPS,	Depuy)	in	which	
there	has	been	an	unexpectedly	high	failure	rate	91.		We	have	experienced	high	failure	
rates	in	a	cohort	of	96	patients	with	large	diameter	MoM	total	hip	replacements	(ASR,	
Depuy).	Both	implants	have	been	recalled	by	the	manufacturer	and	are	the	subjects	of	
Medicines	and	Healthcare	Regulatory	Authority	(MHRA)	Alerts.	We	are	a	major	centre	
for	 primary	 and	 revision	 hip	 surgery	 with	 significant	 experience	 of	 revisions	 for	
metallosis	in	a	variety	of	implants.	
Despite	 initial	 promise	 of	 decreased	wear	 rates	 and	 increasing	 suitability	 for	 use	 in	
younger	more	active	patients,	concerns	remain	about	potential	adverse	consequences	
of	 MoM	 bearing	 surfaces	 in	 terms	 of	 aseptic	 loosening	 and	 pain	 secondary	 to	 soft	
tissue	reaction	to	metal	debris.		
Elevated	 circulating	 levels	 of	 metal	 ions	 following	 MoM	 THR	 or	 resurfacing	
arthroplasty	are	not	uncommon	125	126	127	with	metal	ion	levels	reaching	a	steady	state	
approximately	one	year	following	implantation	128.	The	biological	pathways	leading	to	
adverse	periprosthetic	soft	tissue	reactions	associated	with	metal	debris	have	yet	to	be	
conclusively	 demonstrated,	 but	 may	 represent	 a	 delayed	 type	 IV	 (ALVAL)	
hypersensitivity	 reaction	 with	 subsequent	 effect	 on	 local	 cell	 populations	 in	
susceptible	individuals,	giving	rise	to	painful	soft	tissue	mass	or	pseudotumour	as	well	
as	osteolysis	and	loosening	68.		
It	 is	 suggested	 that	 soft	 tissue	 reactions	may	 be	 the	 result	 of	 increased	wear	 that	 is	
directly	correlated	with	elevation	of	cobalt	(Co)	and	chromium	(Cr)	in	vivo	where	the	
presence	 of	 extensive	 necrosis	 and	 macrophage	 infiltrate	 implies	 a	 metal	 debris	
cytotoxicity	165.			
The	Clark	 laboratory	at	UEA	has	extensive	experience	of	gene	expression	profiling	 in	
orthopaedic	tissues	166	167		including	a	recent	comparison	of	tissues	from	primary	THR	
and	 revision	 surgery	 (osteolysis	 vs.	 well-fixed).	 	 Tissue	 is	 stored	 in	 RNA	 Later	
immediately	 post-surgery,	 prior	 to	 downstream	RNA	 purification	 and	 analysis	 using	
qRT-PCR.	 	 Professor	 Bill	 Fraser	 has	 expertise	 in	 the	 measurement	 of	 circulating	
biomarkers	using	LC-MS/MS	including	markers	of	bone	metabolism.	
	
WORK	ALREADY	UNDERTAKEN:	
	
I	have	updated	a	database	of	650	Ultima	TPS	hips	implanted	in	545	patients	between	
February	1997	and	March	2005.	We	 revised	135	 (21%)	 in	82	males	 and	53	 females	
between	July	2001	and	November	2011	at	a	mean	of	6.2	years	from	primary	surgery.	
Mean	age	at	revision	was	58	years.	We	continue	to	revise	Ultima	TPS	hips	as	well	as	
other	MoM	bearings	based	upon	clinical	presentation	supplemented	by	evaluation	of	
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metal	 ion	 levels	 and	 radiological	 findings	 using	 Metal	 Artefact	 Reduction	 Sequence	
(MARS)	MRI	scan.	
MARS	MRI,	developed	at	our	institution	reduces	artefact	and	increase	the	conspicuity	
of	 soft	 tissue.	 A	 grading	 system	 has	 been	 developed	 which	 demonstrates	 great	
interobserver	reliability.	It	is	the	imaging	modality	of	choice	in	the	failing	MoM	THR.		
There	remains	no	clear	consensus	on	the	role	of	metal	ion	levels	in	MoM	disease.	
The	focus	of	work	to	date	has	been	to	investigate	associations	between	blood	metal	ion	
levels	and	abnormal	MARS	MRI.		
Metal	ion	levels	have	been	measured	in	191	patients	(35%)	with	serial	metal	ion	levels	
measured	in	a	number	of	patients.	Analysis	of	this	cohort	has	demonstrated	that	mean	
levels	of	cobalt	(Co)	were	significantly	higher	(p=0.003)*	 in	bilateral	THRs	(12.6ppb)	
than	unilateral	THRs	(9.21ppb).	Mean	 levels	of	chromium	(Cr)	were	not	significantly	
raised	 (p=0.09)	 in	 bilateral	 THRs	 (5.3ppb)	 than	 unilateral	 THRs	 (4.22ppb).	 In	
unilateral	THRs	there	were	higher	mean	values	 for	 females	 for	both	Co	and	Cr	metal	
ion	 levels.	 The	mean	 value	 of	 Cr	 for	 females	was	 4.95ppb	 versus	 3.81ppb	 for	males	
(p=0.008)*.	 The	 mean	 value	 for	 Co	 ions	 for	 females	 was	 9.69ppb,	 and	 for	 males	
8.66ppb	(p=0.254).	
There	 was	 no	 statistical	 difference	 between	 metal	 ion	 levels	 based	 on	 gender	 for	
bilateral	THRs.	
We	have	performed	MARS	MRI	scan	on	a	total	of	403	hips	(62%)	of	which	169	(42%)	
have	had	at	least	one	abnormal	scan.	
Blood	metal	ion	levels	are	higher	in	bilateral	Ultima	MoM	THRs	and	in	those	with	renal	
impairment.	 Levels	 of	metal	 ions	 are	 higher	 in	 females	with	 unilateral	 implants.	 No	
association	between	abnormal	MRI	and	metal	ion	levels	was	demonstrated.	
Timing	 and	 indications	 for	 revision	 remain	 challenging	 clinical	 problems	 since	 the	
natural	 history	 of	 metallosis	 remains	 unknown.	 Radiological	 appearances	 of	 MoM	
disease	 may	 not	 correlate	 with	 symptom	 severity	 thus	 revision	 surgery	 may	 be	
indicated	in	asymptomatic	patients	with	advanced	disease.	The	benefit	of	serial	MRI	in	
monitoring	disease	progression	is	uncertain.		
We	performed	a	retrospective	study	describing	the	medium	to	long-term	follow	up	of	
patients	with	MOM	THR	with	MARS	MRI.	Inclusion	criteria	were	symptomatic	patients	
with	MOM	THRs	who	had	not	undergone	 revision	 surgery	and	who	had	at	 least	 two	
serial	MARS	MRI	examinations.			
Patients	were	 identified	 from	a	database	and	all	MRI	examinations	were	reported	by	
an	 experienced	 observer	 and	 classified	 as:	 A	 (normal),	 B	 (Infection),	 C1	 (Mild	MOM	
disease),	C2	(Moderate	disease),	and	C3	(Severe	disease).		
A	total	of	223	MRIs	were	performed	on	103	THRs	between	2002	and	2007	(range	2-4	
MRI	per	THR).	The	median	time	from	surgery	to	first	MRI	was	5.2	years	(Interquartile	
range:	 3.9	 to	 6.7).	 The	 time	 between	 surgery	 and	 all	 MRIs	 ranged	 from	 0.8	 to	 13.4	
years.	Grades	for	all	MRIs	were:	A	59%	(131),	B	2%	(5),	C1	15%	(34),	C2	16%	(35)	and	
C3	8%	(18).		
64%	 (66)	 of	 first	MRIs	were	normal.	On	 a	 second	MRI	 of	 59	normal	 hips,	 93%	 (55)	
remained	normal	while	4	cases	(7%)	progressed	one	each	to	grade	B,	C1,	C2	and	C3.	10	
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of	these	normal	hips	were	scanned	a	third	time,	70%	remained	normal.	Three	normal	
hips	remained	normal	at	fourth	MRI.	
On	sequential	scans	of	103	hips,	only	14%	showed	disease	progression.		
In	 this	subset	of	our	cohort	most	patients	with	MOM	THR	who	do	not	undergo	early	
revision	 have	 normal	 MRI	 examinations.	 	 Progression	 from	 normal	 to	 abnormal,	 or	
from	mild	 to	more	 severe	MOM	 disease	 is	 uncommon	 and	 takes	 place	 over	 several	
years.			
	
Section	4:	Plan	of	Investigation	
Materials	&	methods,	research	timetable	(strictly	maximum	1000	words)	
	
	
WORK	PACKAGE	1	(WP1):	Literature	Review	&	Database	Analysis	
	
I	 have	performed	a	 literature	 review	 concerning	MoM	THR	development,	 postulated	
theories	on	cellular	mechanisms	in	adverse	reactions	to	metal	debris,	and	the	putative	
mechanisms	behind	MoM	THR	and	hip	resurfacing	failure.	
Ongoing	surveillance	of	our	cohort	of	650	Ultima	TPS	THRs	and	96	ASR	THRs	will	be	
undertaken	 throughout	 the	 course	 of	 the	 MD.	 Data	 in	 terms	 of	 metal	 ion	 levels,	
radiological	 MRI	 gradings,	 patient	 outcome	 measures	 (Oxford	 scores	 and	 EQ-5D	
scores),	 and	 revisions	 undertaken	 will	 be	 continually	 added	 and	 analysed	 for	
publication	and	discussion	at	scientific	meetings.	 Initial	work	has	been	submitted	for	
consideration	for	presentation	at	British	Hip	Society	meeting	in	March	2012.		
WP1	DELIVERABLES:	
? Knowledge	 of	 cellular	mechanisms	 in	 periprosthetic	 osteolysis	 and	metal	 on	
metal	disease	to	inform	laboratory	studies	
? Identification	of	patients	for	recruitment	into	further	studies	
	
WORK	PACKAGE	2	(WP2):	Laboratory	Studies	
The	study	will	seek	ethical	approval,	and	take	place	at	Norfolk	and	Norwich	University	
Hospital	 (NNUH),	 with	 the	 laboratory	 work	 being	 carried	 out	 at	 UEA	 School	 of	
Biological	Sciences.	Laboratory	studies	will	commence	August	2012	and	continue	for	a	
period	of	one	year.		
Informed	consent	will	 be	obtained	 from	patients	 attending	 specialist	MoM	 follow	up	
clinics.	 Patients	 in	 the	 Ultima	 TPS	 follow-up	 group	 will	 have	 a	 patient	 information	
sheet	 posted	 2	 to	 3	 weeks	 before	 their	 routine	 follow-up	 clinic.	 Those	 willing	 to	
participate	will	then	consented	and	the	sample	taken.	
Collection	of	samples	of	capsule,	femoral	and	acetabular	membrane,	muscle	and	bone	
from	primary	 joints,	 and	 revision	hip	arthroplasty	 in	28mm	head	 (Ultima)	and	 large	
head	 (ASR)	 MoM	 articulations	 for	 adverse	 reactions	 to	 metal	 debris	 will	 allow	 the	
investigator	to	compare	and	contrast	cytokine	and	cellular	components.	Tissue	will	be	
stored	in	RNA	Later	immediately	post-surgery,	prior	to	downstream	RNA	purification	
and	 analysis	 using	 qRT-PCR.	 We	 have	 already	 established	 permission	 and	
infrastructure	 for	 a	 tissue	 bank	 of	 samples	 collected	 from	 MoM	 revisions,	 revision	
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surgery	 of	 other	 bearing	 surfaces	 and	 primary	 THRs	 to	 act	 as	 comparators	 for	 our	
work.		
WP2	DELIVERABLE:	
? Knowledge	 of	 cellular	 and	 cytokine/chemokine/growth	 factor	 expression	
patterns	 in	 patients	 undergoing	 secondary	 surgery	 with	 symptomatic	 and	
asymptomatic	metal	on	metal	hip	bearings.		
	
	
WORK	PACKAGE	3	 (WP3):	Feasibility	 study	 into	Diurnal	Variation	 in	Metal	 Ion	
Levels	
There	 is	 no	 evidence	 in	 the	 literature	 examining	 the	 diurnal	 variation	 in	 metal	 ion	
levels	detectable	in	blood	and	urine.	There	is	no	consensus	of	opinion	as	to	whether	an	
isolated	elevated	metal	ion	level	is	indicative	or	predictive	of	a	pathological	state,	or	if	
circulating	 levels	of	metal	 ion	 levels	 fluctuate	with	 activity	 in	 a	 fashion	analogous	 to	
blood	glucose	levels.	I	wish	to	establish	a	feasibility	study	recruiting	participants	from	
our	 cohort	 of	 650	 Ultima	 TPS	 hips	 with	 symptomatic	 hips	 with	 a	 normal	 MRI,	
symptomatic	hip	with	abnormal	MRI	and	asymptomatic	hips	with	a	normal	MRI.	These	
patients	will	be	seen	 in	our	research	 trials	unit	and	have	blood	and	urine	specimens	
taken	at	 regular	 intervals	 from	8am	 to	5pm	 for	 cobalt	 and	chromium	 levels.	 I	would	
also	wish	to	examine	if	blood	levels	of	these	ions	significantly	alter	following	a	period	
of	time.		Ethical	approval	will	need	to	be	sought	and	recruitment	is	planned	to	start	in	
the	second	quarter	of	2012	with	completion	of	data	collection	by	the	end	of	2012.		
WP3	DELIVERABLE:	
? Knowledge	 of	 variance	 of	 blood	 ion	 level	 and	 how	 this	 correlates	 with	 MRI	
grading	in	order	to	inform	MHRA	guidance.	
	
WORK	PACKAGE	 4	 (WP4):	 Retrospective	 Analysis	 of	 Serial	MARS	MRI	 scans	 in	
MoM	Hips	
A	retrospective	study	of	MARS	MRI	examinations.		The	early	failure	and	revision	rates	
for	MOM	THR	are	well	described.	 	The	prognosis	 for	patients	who	do	not	need	early	
revision	 is	unknown.	 	The	 study	will	describe	 the	medium	 to	 long-term	 follow	up	of	
patients	with	MOM	THR	with	MRI.	
We	 shall	 analyse	 our	 cohort	 of	 650	 Ultima	 TPS	 hips	 with	 the	 inclusion	 criteria	 of	
symptomatic	patients	with	MOM	THRs	who	had	not	undergone	revision	surgery	and	
who	had	at	least	two	serial	MARS	MRI	examinations.		Patients	will	be	identified	from	a	
database	and	all	MR	examinations	are	to	be	reported	by	an	experienced	observer	and	
classified	 according	 to	 a	 grading	 system	 developed	 in	 Norwich	 as:	 A	 (normal),	 B	
(Infection),	C1	(Mild	MOM	disease),	C2	(Moderate	disease),	and	C3	(Severe	disease).		
WP4	DELIVERABLE:	
? Determining	 the	 value	 of	 MRI	 scan	 in	 monitoring	 patients	 with	 MoM	 hips	
which	may	inform	future	MHRA	guidance	
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WORK	PACKAGE	5	(WP5):	Prospective	study	correlating	intraoperative	findings	
at	MoM	hip	revision	surgery	with	pre-operative	MRI	grading	
A	 review	 of	 the	 literature	 has	 established	 that	 there	 is	 no	 validated	 system	 for	
macroscopic	 classification	 of	 metal	 on	 metal	 disease	 observed	 intraoperatively.	 We	
regularly	undertake	revisions	of	MoM	hips	in	our	cohort	of	650	Ultima	TPS	as	well	as	
revising	a	significant	number	of	other	MoM	implant	types.	We	would	seek	to	develop	a	
simple	 grading	 tool	 for	 assessment	 of	 extent	 of	 soft	 tissue	 destruction,	 bony	
destruction,	 implant	 loosening,	 and	 macroscopic	 evidence	 of	 wear	 and	 corrosion	 in	
order	to	establish	if	severity	of	disease	found	intraoperatively	correlates	to	predicted	
severity	of	disease	on	MARS	MRI	scan.		
	
WP5	DELIVERABLE:	
? Reliable	classification	system	for	grading	severity	of	MoM	disease	
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FIG	1.	Gantt	Chart:	Research	timetable	for	proposed	MD	“Role	of	Metal	Ions	in	Metal	
on	 Metal	 Hip	 Arthroplasty”	 from	 August	 2011	 to	 February	 2014	 (date	 format	
mm:dd:yy)	
	
	
Section	5:	Facilities	&	Resources	
Research/clinical/technical	 support,	 laboratory	 space,	 equipment	 and	
additional	funding	if	any	(strictly	maximum	250	words)	
	
Norwich	 Medical	 School	 provides	 a	 complete	 set	 of	 facilities	 and	 an	 educational	
programme	 for	 doctoral	 students	 including	 an	 800,00	 volume	 library	 of	 books	 and	
journals,	 a	 large	 range	 of	 electronic	 resources	 including	 major	 bibliographic	 and	
citation	databases	as	well	as	full	text	journal	archives.		
The	 Institute	 of	 Orthopaedics	 at	 the	 Norfolk	 &	 Norwich	 University	 Hospital	 is	 a	
dedicated	 research	 facility	 with	 ample	 office	 space,	 full	 time	 research	 practitioners,	
and	 administrative	 support.	 We	 have	 IT	 support	 for	 multiple	 workstations	 running	
patient	 electronic	 medical	 records,	 clinical	 information	 systems,	 high-resolution	
Picture	 Archiving	 and	 Communication	 software,	 as	 well	 as	 standard	 office	 and	
statistical	packages.	
The	NNUH	in	conjunction	with	UEA	has	a	Clinical	Research	and	Trials	Unit	staffed	by	
full	 time	 research	 nurses.	 	 A	 dedicated	 3T	 research	MRI	 scanner	 is	 available	 which	
offers	 increased	image	clarity	at	higher	speeds	especially	beneficial	 in	demonstrating	
musculoskeletal	pathology.		
We	have	a	fully	approved	Human	Tissue	Bank	(08/H0304/85	Cambridgeshire	1	REC)	
at	the	Norwich	Research	Park	in	which	to	store	tissue	for	this	and	future	work.		
The	Clark	 laboratory	 is	 housed	 in	 the	Biomedical	Research	Centre,	 a	 state-of-the-art	
facility	for	molecular	research.			All	expertise	and	equipment	is	available	to	support	the	
gene	 expression	 studies	 outlined	 above.	 There	 are	 excellent	mammalian	 cell	 culture	
facilities	and	a	wide	range	of	multi-user	equipment	including	ABI	7500	and	7700	Real-
Time	PCR	machines.	 There	 is	 a	Bioimaging	 facility	with	modern	 confocal,	 time-lapse	
and	fluorescent	microscopes,	a	fermentation	suite	for	bulk	culture	and	preparation	of	
recombinant	proteins,	and	a	newly	opened	Disease	Modelling	Unit.		
Section	6:	Research	Impact	
Possible	 beneficial	 outcome,	 relevance	 to	 orthopaedics	 &	 the	 musculoskeletal	
system	(strictly	maximum	250	words)	
	
A	cohort	of	545	patients	had	an	Ultima	MoM	THR	inserted	up	to	2004	when	it	became	
apparent	that	there	was	an	unacceptable	early	failure	rate.	Failure	may	be	due	to	high	
levels	 of	 corrosion	 from	 the	 implant	 stem.	 The	 reasons	 for	 this	 are	 unclear.	 Recent	
work	indicates	that	unlike	 in	 large	diameter	head	implants	 it	 is	not	the	MoM	bearing	
which	 is	 responsible.	 It	 could	 be	 galvanic	 corrosion,	 and	 work	 in	 Leeds	 has	 noted	
different	 levels	 of	 acidity	 from	 different	 bone	 cements.	 Greater	 knowledge	 has	
furthered	the	complexity.		
Norwich	 was	 the	 dominant	 site	 for	 this	 implant	 and	 the	 problems	 have	 not	 been	
reported	elsewhere.	Furthermore	 the	unusual	 feature	 is	 that	a	significant	proportion	
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of	 these	 patients	 have	 pain	 but	 normal	 X-rays.	 New	 MRI	 techniques	 developed	 in	
Norwich	allow	us	to	see	abnormalities	otherwise	not	visible.		
Analysis	of	cells,	 tissue,	bodily	 fluids,	and	 imaging	may	 identify	patients	at	risk,	 from	
those	 who	 are	 not.	 Although	 our	 population	 is	 unique,	 it	 transpires	 that	 all	 MoM	
implants	risk	the	problems	of	metallosis.	This	research	will	provide	valuable	 insights	
into	 the	 aetiology	of	metallosis	 in	 the	Ultima	 cohort	 and	 in	MoM	hip	 articulations	 in	
general	 and	 enable	 us	 to	 offer	 those	 at	 risk	 a	 surgical	 option	 for	 revision	 before	
significant	irreversible	soft	tissue	damage	is	established.		
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Section	9:	Layman’s	Summary	
Provide	lay	answers	to	the	following	questions	(strictly	maximum	500	words)	
	
1. What	is	the	basic	problem	that	you	are	trying	to	address?	
	
Metal-on-metal	(MOM)	bearings	in	total	hip	replacement	(THR)	aim	to	improve	clinical	
outcomes	and	survival	by	reducing	formation	of	large	polyethylene	wear	particles	and	
the	osteolysis	(bone	loss)	that	is	associated	with	them.	MoM	implants	include	alloys	of	
cobalt-	 chromium-molybdenum	 (CoCrMo)	 for	 their	 hardness.	 Wear	 particles	
generated	 by	 MOM	 hips	 in	 simulators	 are	 smaller	 than	 particles	 generated	 by	
metal-on-polyethylene	(MoP)	articulations,	but	MOM	hips	release	at	least	three	times	
more	 cobalt	 and	 chromium	 ions	 than	 MoP	 THRs.	 Wear	 particles	 and	 metallic	
by-products	are	 readily	distributed	 throughout	 the	body	by	 the	blood	and	 lymphatic	
vessels.	Much	attention	 is	 being	 given	 to	 the	 systemic	distribution	of	metal	 particles	
and	 ions	 and	 potential	 risks	 of	 cytotoxicity,	 hypersensitivity	 responses,	 immune	
dysfunction	and	genotoxicity.	
A	cohort	of	545	patients	had	an	Ultima	MoM	THR	inserted	up	to	2004	when	it	became	
apparent	that	there	was	an	unacceptable	early	failure	rate.	Failure	may	be	due	to	high	
levels	 of	 corrosion	 from	 the	 implant	 stem.	 The	 reasons	 for	 this	 are	 unclear.	 Recent	
work	indicates	that,	unusually,	it	is	not	the	metal-on-metal	bearing.	It	could	be	galvanic	
corrosion,	and	work	in	Leeds	has	noted	different	levels	of	acidity	from	different	bone	
cements.	Greater	knowledge	has	furthered	the	complexity.		
Norwich	 was	 the	 dominant	 site	 for	 this	 implant	 and	 the	 problems	 have	 not	 been	
reported	 elsewhere.	 Furthermore	 the	unusual	 feature	was	 that	 a	 third	had	pain,	 but	
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normal	 X-rays.	 New	 MRI	 techniques	 developed	 in	 Norwich	 allow	 us	 to	 see	
abnormalities	otherwise	not	visible.	
Analysis	of	cells,	 tissue,	bodily	 fluids,	and	 imaging	may	 identify	patients	at	risk,	 from	
those	 who	 are	 not.	 Although	 our	 population	 is	 unique,	 it	 transpires	 that	 all	 MoM	
implants	risk	the	problems	of	metallosis.		
2. What	is	the	estimated	incidence	of	this	particular	problem	in	the	general	
population?	
	
The	National	Institute	for	Health	and	Clinical	Excellence	states	a	10%	revision	rate	for	
THR	at	10	years.	Analysis	 of	 our	database	of	 650	Ultima	THRs	 reveals	 that	 between	
July	2001	and	November	2011	we	revised	135	hips	(21%).	
	
3. What	are	the	aims	and	objectives	of	this	research	study?	
	
Timing	of	revision	surgery	remains	a	problem	due	to	the	unknown	natural	history	of	
metallosis.	 We	 aim	 to	 characterise	 how	 these	 implants	 affect	 cells	 in	 surrounding	
tissues	and	which	patients	may	have	an	increased	susceptibility	to	metal	reactions.		
How	 we	 monitor	 disease	 using	 scans	 and	 metal	 ion	 levels	 along	 with	 symptom	
evaluation	may	help	predict	which	patients	will	go	on	 to	develop	severe	disease	and	
hence	benefit	from	earlier	revision.		
	
4. Is	this	research	going	to	solve	the	problem?	
	
Yes.	 We	 will	 be	 better	 able	 to	 inform	 patients	 of	 this	 disease	 and	 offer	 them	
appropriate	surgical	options	that	will	enhance	their	quality	of	life.		
	
5. What	are	the	long-term	benefits	to	patients	with	this	problem?	
	
In	patients	with	Ultima	TPS	hips	and	any	with	another	type	of	MoM	implant	we	may	
find	those	factors	that	make	them	at	risk	of	a	reaction	and	allow	for	closer	follow-up.	If	
they	have	had	a	reaction	we	may	be	able	to	tell	them	why.	
	
6. Provide	a	brief	background	about	yourself	and	your	interests.	
	
I	 am	 an	 orthopaedic	 trainee	 who	 has	 completed	 core	 surgical	 training.	 I	 am	
undertaking	 an	 MD	 to	 consolidate	 previous	 basic	 science	 research	 experience	 and	
apply	this	to	 future	clinical	practice.	 I	wish	to	develop	an	 interest	 in	hip	arthroplasty	
and	pelvic	trauma	surgery.	
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Appendix	B:	Bone	&	Joint	Publication	
on	Serial	MARS	MRI	Imaging	
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Appendix	C:	Diurnal	Variation	Study	
Protocol	
	
Lay	Summary	
We	 have	 a	 well-defined	 cohort	 of	 patients	 with	 an	 Ultima	 TPS	 metal	 on	 metal	
(MoM)	 total	 hip	 replacement	 (THR)	 with	 a	 catastrophic	 failure	 rate	 for	 which	 a	
series	of	ethically	approved	studies	have	been	undertaken.	
	
MoM	 THR	 is	 currently	 of	 national	 concern	 with	 the	 Medicines	 and	 Healthcare	
products	 Regulatory	 Agency	 (MHRA)	 guidelines	 recommending	 scans	 and	
measurements	 of	 metal	 levels	 in	 blood.	 However,	 it	 is	 unknown	 what	 variation	
there	exists	in	levels	of	metals	in	blood	on	a	daily	or	monthly	basis.	
	
This	study	aims	to	establish	if	there	is	any	variation	in	levels	of	metal	ions	in	blood	
or	urine	in	patients	with	MoM	THRs	that	are	performing	well,	those	that	are	failing,	
and	 those	 in	 which	 the	 picture	 is	 uncertain.	 We	 plan	 to	 provide	 data	 that	 will	
inform	the	MHRA	in	the	recommended	surveillance	protocol	of	patients	with	MoM	
hip	implants.	
	
We	 plan	 to	 establish	 if	 there	 is	 an	 additional	 value	 in	 the	 use	 of	 blood	
measurements	over	the	use	of	symptom-based	questionnaires.	
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Title	
	
Feasibility	Study:	Diurnal	Variation	in	Metal	Ions	in	MoM	THR	
Background	
	
The	 Department	 of	 Orthopaedics	 at	 the	 Norfolk	 &	 Norwich	 University	 Hospital	
(NNUH)	is	actively	following	a	cohort	of	545	patients	who	have	had	a	28mm	head	
hybrid	metal	on	metal	(MoM)	total	hip	replacement	(Ultima	TPS,	Depuy)	in	which	
there	has	been	an	unexpectedly	high	failure	rate	91.	The	implant	has	been	recalled	
by	 the	manufacturer	 and	 is	 the	 subject	 of	 a	Medicines	 and	 Healthcare	 products	
Regulatory	Authority	 (MHRA)	 alert.	 The	NNUH	 is	 a	major	 centre	 for	 primary	 and	
revision	hip	surgery	with	significant	experience	of	revisions	for	adverse	reactions	to	
metal	debris	(ARMD).	
	
Despite	initial	promise	of	decreased	wear	rates	and	increasing	suitability	for	use	in	
younger	 active	 patients,	 concerns	 remain	 about	 potential	 consequences	 of	MoM	
bearing	 surfaces	 in	 terms	 of	 aseptic	 loosening	 and	 pain	 secondary	 to	 soft	 tissue	
reaction	to	metal	debris.		
	
Elevated	 circulating	 levels	 of	 metal	 ions	 following	 MoM	 THR	 or	 resurfacing	
arthroplasty	are	not	uncommon	125	 126	 127	with	metal	 ion	 levels	 reaching	a	 steady	
state	 approximately	 1	 year	 following	 implantation	 128.	 The	 biological	 pathways	
leading	to	adverse	periprosthetic	soft	tissue	reactions	associated	with	metal	debris	
have	 yet	 to	 be	 demonstrated,	 but	 may	 represent	 a	 delayed	 type	 IV	 (ALVAL)	
hypersensitivity	 reaction	 with	 subsequent	 effect	 on	 local	 cell	 populations	 in	
susceptible	 individuals,	giving	rise	to	painful	soft	tissue	mass	or	pseudotumour	as	
well	as	osteolysis	and	loosening	68.		
	
Soft	tissue	reactions	may	be	the	result	of	increased	wear	that	is	directly	correlated	
with	 elevation	 of	 cobalt	 (Co)	 and	 chromium	 (Cr)	 in	 vivo	 where	 the	 presence	 of	
extensive	necrosis	and	macrophage	infiltrate	implies	a	metal	debris	cytotoxicity	165.		
Failure	may	be	due	to	high	levels	of	corrosion	from	the	implant	stem.	The	reasons	
for	this	are	unclear.		
	
Metal	ion	levels	have	been	used	as	a	surrogate	marker	for	wear	of	MoM	THRs.	The	
trigger	 level	 for	 Cobalt	 or	 Chromium	detectable	 in	 the	 blood	 of	 a	 patient	with	 a	
MoM	THR	that	suggests	a	poor	outcome	and	need	for	revision	surgery,	is	unknown.	
Currently	the	figure	of	7	parts	per	billion	(ppb)	suggested	by	the	MHRA	is	the	result	
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of	the	opinion	of	an	expert	panel	informed	by	a	single	study(8).	This	study	aims	to	
provide	 more	 accurate	 and	 useful	 data	 as	 well	 as	 fostering	 genuine	 patient	
involvement	in	the	research	phase.	
Aim	
	
The	purpose	of	the	feasibility	study	is	to	establish:	
	
1)	Scientific	Principles:	
	
? If	there	exists	variation	in	metal	ion	levels	detectable	in	blood	and	urine	
over	the	course	of	a	day	and	over	longer	periods.	
? Whether	data	supporting	the	existence	of	diurnal	variation	of	blood	and	
urine	metal	ion	levels	exists	in	this	population	and	if	so	how	variable	are	
the	data?	
? What	further	study	needs	to	be	undertaken	should	a	variation	exist.	
? Determination	of	an	appropriate	scale	for	future	study	dependent	on	the	
magnitude	of	variation	observed.	Does	the	measurement	of	blood	or	urine	
metal	ion	concentration	add	anything	extra	to	the	accuracy	of	decision	
making	over	the	use	of	Oxford	Hip	Score	and	EQ5D	clinical	outcome	
questionnaires?	
	
	
2)	Patient	Acceptability	
	
? Development	of	a	focus	group	consisting	of	patients	within	the	Norwich	
Metal	on	Metal	hip	cohort	to	encourage	wider	engagement	in	research	
activity	and	disseminate	findings.	
? Generate	appropriate	consents	and	patient	information	literature	for	this	
study.		
? Refinement	of	logistics	to	inform	ahead	of	a	larger	study.	
? Evaluation	of	acceptability	of	multiple	sampling	of	blood	and	urine.			
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Materials	and	Methods	
Patients	
For	this	feasibility	study	12	patients	will	be	recruited.		There	are	no	suitable	data	in	
the	literature	on	which	to	base	a	sample	size	calculation.	
Inclusion	criteria	
	
Patients	who	have	undergone	Ultima	TPS	THRs	in	Norwich.	
Exclusion	criteria	
	
? Patients	who	have	undergone	Ultima	TPS	THR	in	whom	the	prosthesis	has	
been	revised.	
? Patients	taking	medication	or	supplements	known	to	increase	cobalt	or	
chromium	excretion	
? Patients	who	are	unable	to	provide	informed	consent	at	time	of	
recruitment.	
	
Patient	Recruitment	
	
Suitable	patients	will	be	identified	by	the	clinical	team	from	a	secured	prospectively	
collated	database	of	Ultima	TPS	MoM	THR	patients	created	for	governance	
purposes.	Participants	will	be	stratified	into	the	following	categories.		
	
-	 Asymptomatic	with	normal	Metal	Artefact	Reduction	Magnetic	Resonance	
Imaging	(MAR	MRI)	scan;	n	=	3	
-	 Symptomatic	with	normal	MAR	MRI	scan;	n	=	3		
	
-	 Asymptomatic	with	abnormal	MAR	MRI	scan;	n	=	3	
-	 Symptomatic	with	abnormal	MAR	MRI	scan;	n	=	3	
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Patients	will	be	sent	an	information	sheet	at	least	2	weeks	in	advance	of	their	
scheduled	follow-up	with	their	orthopaedic	surgeon.	At	the	scheduled	follow-up	
appointment	a	member	of	the	research	team	will	be	available	to	answer	any	
questions	and	to	invite	patients	to	participate	in	the	study.		Patients	will	also	be	
asked	to	provide	informed	consent	for	storage	of	a	sample	of	blood	and	urine	in	
the	Human	Tissue	Bank.	No	details	will	be	passed	to	anyone	outside	of	the	clinical	
team	or	involved	in	the	patient's	usual	care	until	the	patient	has	agreed	to	enter	
the	study.	At	the	first	study	visit	a	member	of	the	research	team	will	take	informed	
consent.	
	
Cobalt	&	Chromium	Levels	
	
MoM	implants	are	associated	with	release	of	cobalt	and	chromium	particles	which	
are	soluble	in	blood	and	are	excreted	in	measurable	quantities	in	urine.	Analysis	is	
via	the	technique	of	Inductively	Coupled	Plasma	Mass	Spectrometry.	This	can	only	
be	undertaken	in	an	accredited	reference	laboratory	for	trace	metal	analysis.	
Samples	from	the	Norfolk	&	Norwich	Hospital	are	routinely	sent	to	a	laboratory	in	
Cardiff	which	fulfils	these	obligations.		
Informed	Consent	
Informed	consent	will	be	taken	by	the	principal	investigator	Mr	Darren	Ebreo.	
Patients	will	be	consented	for	blood	and	urine	to	be	taken	for	this	study	and	in	
addition	will	be	consented	for	donation	of	blood	and	urine	to	be	stored	in	the	
Human	Tissue	Bank	for	future	research.	Should	a	patient	decline	to	consent	for	
additional	samples	for	storage	in	the	Human	Tissue	Bank	it	does	not	preclude	their	
inclusion	in	this	study.		
Schedule	of	Participant	Visits	
	 	
Patients	will	be	invited	to	attend	our	dedicated	Clinical	Trials	Research	Unit	on	four	
occasions	 and	 be	 required	 to	 donate	 blood	 and	 urine	 specimens	 for	 analysis	 of	
Cobalt	 and	 Chromium	 levels	 at	 a	 specialist	 accredited	 reference	 laboratory	 for	
trace	metal	analysis	via	Inductively	Coupled	Plasma	Mass	Spectrometry.	Protocols	
for	 specimen	 collection,	 transport,	 and	 analysis	 are	 already	 established.	 Patients	
will	be	reimbursed	reasonable	transport	costs.	
	
1st	Visit:	
	
Patients	will	be	asked	to	complete	an	Oxford	Hip	Score	and	an	EQ-5D	form.	Both	of	
these	are	validated	outcome	measurement	tools	in	hip	arthroplasty.	A	medication	
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history	will	be	taken	on	the	first	visit	and	patients	will	be	asked	to	keep	trial	staff	
informed	of	any	changes	to	their	medication.	
	
Patients	 will	 be	 free	 to	 leave	 the	 Clinical	 Trials	 Research	 Unit	 between	
appointments	on	this	day.	Refreshment	will	be	provided.		
	
	
	
	 Blood		 Urine	
Early	 Morning	
(approx.	09:00)	
	
U&Es															(8.5ml	Gold	Vacutainer)	
Co	&	Cr											(6ml	Royal	Blue	Vacutainer)	
Tissue	Bank				(6ml	Royal	Blue	Vacutainer)	***	
Urinary	Co	&	Cr	
Lunchtime	
(approx.13:00)	
Co	&	Cr											(6ml	Royal	Blue	Vacutainer)	
	
Urinary	Co	&	Cr	
Early	 Evening	
(approx.	17:00)	
Co	&	Cr											(6ml	Royal	Blue	Vacutainer)	
	
Urinary	Co	&	Cr	
	
***	The	Tissue	Bank	Sample	 is	OPTIONAL.	Patients	will	be	asked	to	consent	 for	a	
separate	sample	for	storage	in	Human	Tissue	Bank	for	future	research.		
	
2nd	Visit	
	 Blood		 Urine	
Early	 Morning	
(approx.	09:00)	
14.5	mls	in	total	
U&Es															(8.5ml	Gold	Vacutainer)	
Co	&	Cr											(6ml	Royal	Blue	Vacutainer)	
	
Urinary	Co	&	Cr	
	
3rd	Visit	
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	 Blood		 Urine	
Lunchtime	
(approx.13:00)	
14.5	mls	in	total	
U&Es															(8.5ml	Gold	Vacutainer)	
Co	&	Cr											(6ml	Royal	Blue	Vacutainer)	
	
Urinary	Co	&	Cr	
4th	Visit	
	
	 Blood		 Urine	
Early	 Evening	
(approx.	17:00)	
14.5	mls	in	total	
U&Es															(8.5ml	Gold	Vacutainer)	
Co	&	Cr											(6ml	Royal	Blue	Vacutainer)	
	
Urinary	Co	&	Cr	
	
	
	
	
Primary	Endpoints	
	
The	study	will	conclude	at	the	last	visit	of	the	last	patient	and	once	results	of	all	
tests	have	been	completed	and	verified.		
Data	analysis	
	
Frequencies	and	associations	will	be	recorded.	Complex	statistical	analysis	is	not	
expected	from	the	data	generated.	These	data	will	be	used	to	perform	a	sample	
size	calculation	for	an	extended	study	using	a	larger	sample.			
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Timeline	
	
	
	
GANNT	chart	outlining	planned	progress	of	study	
	
Resources	
	
The	Clinical	Trials	and	Research	Unit	at	the	UEA	Campus	is	fully	staffed	and	
equipped	to	host	this	study.		
Funding	
	
This	study	is	supported	by	a	project	grant	from	Orthopaedics	Research	UK.	The	
research	proposal	constitutes	part	of	an	MD	project	which	has	been	funded	by	a	
grant	Orthopaedics	Research	UK	who	have	undertaken	an	independent	peer	
review	process	prior	to	the	award.	
	 	 	 	
Expertise	
Professor	Simon	Donell	and	Mr	John	Nolan	are	consultant	orthopaedic	surgeons	
with	expertise	in	the	field	of	metal	on	metal	hip	research.	Mr	Darren	Ebreo	is	an	
orthopaedic	research	trainee	with	responsibility	for	managing	research	projects,	
recruitment	and	obtaining	informed	consent.	All	have	published	in	peer-reviewed	
journals	and	presented	at	national	and	international	level	on	aspects	of	metal	on	
metal	hip	disease.	
	
Good	Clinical	Practice	in	Research	
The	researchers	will	adhere	to	the	principles	of	the	World	Medical	Association	
Declaration	of	Helsinki	2004	and	the	ICH	Good	Clinical	Practice	guidelines.		All	
researchers	listed	in	the	protocol	have	up	to	date	formal	Good	Clinical	Practice	
training.	
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Patient	Confidentiality	 	
Standard	operating	procedures	covering	Information	Governance	are	in	place	
within	the	Trust	and	both	clinical	and	research	teams	will	adhere	to	those	
standards.		
	
Biological	samples	will	be	dealt	with	in	accordance	with	existing	standards	in	
clinical	governance	and	standard	operating	procedures	are	in	place	for	the	
processing,	transport,	analysis,	and	disposal	of	biological	materials.	Materials	
stored	after	the	study	has	completed	will	be	entered	into	the	patient's	clinical	
record	and	will	be	stored	in	an	ethically	approved	human	tissue	bank.		No	access	to	
these	systems	is	permitted	by	non-authorised	accounts.	
	
	
Ethical	Considerations	
	
Blood	aspiration	is	greater	than	is	usual	but	total	volume	taken	is	significantly	less	
than	for	blood	transfusion	donation.	If	required	local	anaesthetic	gel	can	be	applied	
to	skin	prior	to	venepuncture.		
	
Reasonable	transport	costs	for	patients	to	attend	will	be	met.	Refreshments	will	be	
provided	for	participants	
Risk	
The	study	team	have	identified	level	of	risk	for	this	study	as	follows:	
	
	 	
Risk	to	 Severity	 Frequency	
Patients	
Mild	discomfort	 Moderate	
Severe	adverse	event	 Rare	
Study	 Low	
Trust	 Low	
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Results	
The	results	of	these	studies	will	be	disseminated	in	the	form	of	conference	
presentations	and	will	be	submitted	for	publication	to	peer	reviewed	journals.	
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Appendix	D:	Consent	Forms	
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Appendix	E:	Laboratory	Protocols	
	
Initial	sample	preparation	
Suitable	for:		 All	soft	tissue	including:	
? Capsule	
? Ligamentum	teres	
? Femoral	membrane	
? Acetabular	membrane	
? Muscle	
Intraoperative	samples	must	be	placed	in	a	sterile	universal	specimen	container	by	surgeon	or	
scrub	nurse	to	avoid	RNAse	contamination.		
Samples	must	be	kept	chilled	at	4oC	and	transported	to	laboratory.	
? The	Tissue	Lyser	is	incubated	overnight	at	4oC	
? Incubate	cell	lysis	ball	bearings	at	-80C	-	either	on	dry	ice	or	in	-80oC	freezer	for	10-20	
minutes.	
? Cut	tissue	into	approximately	2-3mm2	segments	and	place	into	eppendorfs.	Do	not	place	
more	than	0.5g	of	material	per	eppendorf	
? Add	500	uL	and	a	chilled	ballbearing	
? Place	eppendorf	in	the	cell	tissue	lyser	and	set	to	50Hz	for	20	minutes	
? Remove	approximately	500uL	of	the	resultant	supernatant	
? Add	400uL	chloroform	per	1ml	of	supernatant	recovered	
? Vortex	for	15	seconds	
? Spin	at	10,000	rpm	for	20	minutes	
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? Remove	the	aqueous	layer	
? Add	ethanol	1:1	
? Continue	with	RNEasy	kit	as	per	manufacturer’s	instructions	
RNA	Extraction		
? Incubate	at	4°C	for	5mins	
? For	500ml	trizol,	100µL	chloroform	was	added	(amount	of	trizol	may	vary	with	sample	
material)	
? Vortexed	15	seconds	
? Incubate	at	25°C	for	2	minutes	
? Spin	12,000g	for	10	minutes	at	4°C	
? Recover	aqueous	phase	into	RNAse	free	tubes	
? Add	250µL	isopropanol	(propan-2-ol)	
? Vortex	15	seconds	
? Spin	12,000g,	10	minutes,	4°C	
? Discard	supernatant	
? Air	dry	pellet	
? Suspend	pellet	in	20µL	DNA	free	water		
OPTIONAL	DNAse	Treatment	
? Add	1µL	DNAase	1	(Roche)	RNAse	free	
? Incubate	at	37°C	for	15	mins	
? Heat	at	70°C	for	10	mins	
? Freeze	at	-80°C	until	quantification	
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RNA	QUANTIFICATION	&	QUALITY	ASSESSMENT	
	
All	work	to	be	done	in	Taqman®	room	with	nuclease	free	eppendorf	tubes	and	pipette	tips.		
? Keep	RNA	on	ice	and	make	sure	thoroughly	defrosted	and	mixed	prior	to	use.		
? Login	to	nanodrop	computer	(password	nanodrop)	
? Clean	nanodrop	w/	water	prior	to	use	and	after	each	analysis	
? Make	sure	software	set	to	“RNA”	on	dropdown	
? “Blank”	the	software	w/	1.5µL	of	nuclease	free	water	
? Analyse	1.5µL	of	sample	on	nanodrop	
Things	to	note:	
[Nucleic	Acid]	(ng/µL)	–	generally	the	higher	the	better.	Nanodrop	is	less	accurate	at	>500	
260nm/280nm	–	suspect	contamination	with	values	less	than	1.8	
260nm/230nm	–	suspect	contamination	with	values	less	than	1.8	
RNA	=	260nm	
Proteins	=	280nm	
Organic	compounds	(e.g.	phenols	etc)	=	230nm	
To	prepare	for	RT	reaction:	
Need	to	derive	volume	of	sample	solution	to	contain	1µg	RNA		
i.e.	1/[RNA](ng/µL)	from	nanodrop	reading	obtained	above	
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N.B.	if	this	number	is	less	than	2	then	will	need	to	dilute	by	adding	5µL	of	RNase	free	water	to	
5µL	of	sample	solution	in	a	new	nuclease	free	tube	and	then	running	it	through	the	nanodrop	
again.	
Then	need	to	derive	column	“µL	up	to	9	µL”		
i.e.	“9	–	(1/[RNA](ng/µL))	
Working	table	should	looks	something	like	this:	
Sample		 ng/µL	 	 µL	for	1µg	 	 µL	up	to	9µL	
	
REVERSE	TRANSCRIPTION	(RT	REACTION)	
Randomly	prime	the	RNA	
? Add	calculated	volume	of	water		
? Add	2µL	of	random	primers	(always	to	be	kept	on	ice)	
? Add	calculated	volume	of	RNA	(1µg)	
? Total	volume	per	tube	=	11µL	
? Incubate	at	70°C	for	10mins	
N.B.	Don’t	forget	to	make	up	a	“control”	sample	which	is	essentially	a	duplicate	of	one	of	your	
samples.	
RT	Reaction	(Generation	of	cDNA)	
? Make	up	a	“Master	Mix”	(n.b.	Reagents	need	to	be	defrosted	and	spun	before	use)	
? 4µL	5	x	buffer	(first	strand	buffer)	
? 2µL	DTT	(0.1M)	
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? 1µL	dNTPs	
? 1µL	superscript	II	(replace	w/H2O	for	the	“control”)	NB	always	keep	this	one	on	ice.		
? 1µL	RNAsin	or	Water	
? A	separate	“control”	version	of	the	above	mix	needs	to	be	made	for	the	control	specimen	
? Add	9µL	of	the	relevant	Master	Mix	to	each	sample,	which	should	give	you	a	total	
volume	of	20µL	
? Incubate	at	42°C	for	1	hour,	then	70°C	for	10	mins.		
? Store	at	-20°C	(long	term	–	anything	over	a	year),	or	4°C	(short	term	for	up	to	a	year)	
	
RNA	Isolation	from	Tissue	Bound	in	OCT	
	
Tissue	specimens	stored	for	histology	purposes	are	typically	snap	frozen	and	bound	to	cork	
disks	in	Optimal	Cutting	Temperature	Compound	(OCT).	RNAse	later	and	other	RNAse	
prevention	treatments	are	not	usually	used	as	these	specimens	are	typically	sectioned	and	
Hematoxylin	and	eosin	(H&E)	stained.	The	stock	of	various	tissue	samples	are	catalogued	and	a	
variety	of	specimens	meet	the	requirements	for	the	current	research	into	Metal-on-Metal	
(MOM)	hip	replacements	that	have	to	be	revised	due	to	pain	and	or	loosening.		
	 Below	is	detailed	the	methods	and	optimization	steps	necessary	for	RNA	extraction	
from	tissue	specimens	bound	in	OCT	and	stored	at	-80oC.		
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Methods	and	Materials	for	RNA	Extraction	from	Frozen	Specimens	
	
Binding	tissue	to	cork	
Transverse	sections	of	tissue,	approximately	1	cm	in	length,	were	cut	using	sterile	and	RNAse	
free	scalpels	and	scissors,	then	stored	on	ice.	Cool	n-hexane	(95	%)	over	dry	ice	for	20	minutes,	
then	place	a	cork	disk	(cant	remember	the	size)	into	the	n-hexane	and	freeze	for	2	minutes.	
Remove	and	place	a	drop	of	OCT	onto	the	cork	then	the	tissue.	Place	the	sample	in	the	n-hexane	
for	a	further	4	minutes	until	frozen.	Remove	and	cover	the	sample	in	OCT	and	freeze	again.	
Store	in	steralins	at	-80	oC.		
		
Cryostat	and	Microtome	
To	section	samples	a	…	cryostat	containing	a	microtome	was	used	and	the	temperatures	set	
between	-27	oC	and	-30	oC.	The	cork	bound	samples	are	attached	to	a	chuck	using	OCT	and	then	
the	chuck	is	placed	into	the	specimen	holder.	The	angle	of	the	microtome	was	set	to	3	o	and	a	
feather	S35	“fine”	blade	was	inserted	into	the	blade	holder.	Sections	of	20	µm	thick	were	used	
to	cut	into	the	tissue,	the	sample	was	then	polished	by	taking	8µm	sections.	For	histology	
sections	the	microtome	is	set	to	cut	at	8	µm	thick	and	sections	were	taken,	then	flattened	and	
attached	to	glass	slides.	For	RNA	extraction	the	microtome	was	set	to	20	µm	sections	were	
taken	and	the	curls	were	removed	and	placed	into	sterile	and	cooled	eppendorfs.		
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H&E	Staining	
Sections	bound	to	glass	slides	were	stained	by	following	a	standard	H&E	staining	protocol,	see	
table	1.	Coverslips	were	attached	using	DPX	mounting	media	and	then	observed	with	a	
microscope	with	a	x10	and	x40	objective	lense	and	x10	optical	lense.		
Table	1	–	H&E	staining	protocol		
Solution	 Time	
(minutes)	
Ethanol	100	%		 5	
Ethanol	90%	 5	
Ethanol	70	%	 5	
Ethanol	50	%		 5	
Ethanol	30	%	 5	
dH2O	 0.25	
Hematoxylin	solution	
(Harris	Modified;	Sigma)	
6	
Bluing	–	running	H2O	 3-6	
Acid	Alcohol	(70	%	ethanol,	
1	%	Hydrochloric	Acid)	
0.1	
H2O	–	running		 Rinse	
dH2O	 Rinse	
1	%	Eosin	 0.1	-	0.2	
H2O	–	running		 Rinse	
dH2O	 Rinse	
Ethanol	100	%		 5	
Ethanol	90%	 5	
Ethanol	70	%	 5	
Ethanol	50	%		 5	
Ethanol	30	%	 5	
Xylene	 5	
Xylene	 5	
DPX	(BioScience)	 	
	
RNA	extraction	
The	20	µm	sections,	curls,	taken	from	the	tissue	specimens	were	stored	on	ice	and	500	µm	
TRIzol®	Reagent	(Invitrogen)	was	added	and	stored	on	ice.	A	Tissue	LyserLT	(Qiagen)	system	
and	5mm	stainless	steal	beads	was	used	to	lyse	the	tissue	samples.	The	lyser	was	set	at	50	Hz	
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and	run	for	10	minutes.	The	TRIzol®	was	removed	and	200	µm	of	chloroform	was	added	to	
every	500	µm	TRIzol®,	the	samples	were	the	vortexed	for	15	s.	The	samples	were	then	spun	at	
28,000	RCF	4	oC	for	20	minutes.	The	aqueous	phase	was	removed	and	mixed	1:1	with	100	%	
ethanol.	This	was	then	added	to	a	Qiagen	RNeasy	Mini	Kit	column	and	then	continued	according	
to	the	manufactures	guide.	
RNA	quality	
RNA	isolated	was	run	on	an	Experion	(BIORAD)	using	StdSense	Chips.	The	methods	were	
carried	out	according	to	the	manufacturers	guidelines.	
Results	
Optimising	RNA	extraction	from	tissue	sections.	
Sample	1278104	was	used	as	a	test	tissue	sample	to	optimize	the	RNA	extraction	from	fixed	
tissue.	Using	the	cryostat/microtome	20	µm	curls	were	taken	from	the	tissue	sample,	to	
optimize	how	many	curls	would	be	needed	2,	4	and	8	curls	were	taken	and	the	RNA	extracted.	
Table	2	show	the	RNA	concentration	obtained	from	the	curls.	From	taking	8	curls	100	ng/µl	
was	obtained,	to	gain	50	%	more	RNA,	12	curls	of	tissue	will	be	used	in	further	experiments.	An	
increase	in	curls	was	decided	as	in	MOM	tissues	some	tissue	may	be	necrotic	and	therefore	the	
RNA	yield	will	be	reduced.	
Table	2	RNA	extracted	from	curls	taken	from	sample	1278104	
	 ng/μl	 260:280	 260:230	
2	curls	 40	 2.12	 1.11	
4	curls	 65	 2.05	 1.4	
8	curls	 100	 2.07	 0.56	
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RNA	extraction	from	MOM	samples		
Samples	stored	at	the	Cottman	Centre	(Norwich,	Norfolk)	contained	various	MOM	samples	from	
2007	to	2012.	One	sample	from	each	year	was	used	(the	year	is	identified	in	the	first	two	digits	
of	the	sample	ID	[Table	3]).	A	total	of	12	curls	were	taken	from	the	samples	and	the	RNA	
extraction	was	carried	out	as	before.	Table	3	shows	that	even	in	samples	over	6	years	old	RNA	
was	extracted	from,	however	it	is	not	known	whether	the	RNA	isolated	is	of	a	great	quality.	To	
investigate	further	the	RNA	was	run	on	an	Experion,	see	Fig	1	and	Table	4.	
	
Table	3	RNA	isolated	from	MOM	tissue	samples	
Sample	ID	 Nucleic	Acid	Conc.	
ng/µl	
260:280	 260:230	
07TB0043	 131.5	 2.09	 1.27	
08TB0059	 186.6	 2.08	 1.42	
09TB0029	 17.8	 2.15	 0.95	
10TB0003	 30.3	 2.11	 1.51	
11TB0004	 65.2	 2.09	 0.74	
12TH0006	 52.8	 2.12	 2.37	
	
	
Out	of	the	6	samples	of	RNA	,	it	was	found	that	the	RNA	was	of	a	good	quality	(RQI	≥7)	and	so	
this	RNA	could	be	used	for	Taqman®	or	other	array	techniques.	The	samples	09TB0029	and	
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10TB0003	showed	no	bands	in	the	gel	and	so	it	could	be	that	the	RNA	has	been	degraded,	or	
that	the	RNA	was	not	loaded	correctly,	either	too	little	or	too	much.	Therefore	further	tests	will	
be	carried	out	on	these	two	samples.		
	
	
Table	4	RNA	quality	and	quantity	for	MOM	hip	tissue	samples.		
Lane	 Sample	 RNA	ng/µl	 Ratio	(28S/18S)	 RQI	
L	 Ladder		 160	 	 	
1	 07TB0043	 136.25	 1.19	 7.6	
2	 08TB0059	 143.19	 1.41	 7.9	
3	 09TB0029	 8.41	 1.04	 N/A	
4	 10TB0003	 1.95	 1.74	 N/A	
5	 11TB0004	 73.67	 1.24	 8.8	
6	 12TH0006	 47.34	 1.57	 8.1	
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Fig	1	RNA	quality,	see	table	4	for	sample	ID	
	
Discussion	
These	results	demonstrate	that	it	is	possible	to	isolate	a	good	high	quality	yield	of	RNA	from	
tissue	samples	bound	in	OCT.	Low	yields	of	RNA	and	low	RQI	numbers	could	be	due	to	a	variety	
of	factors.	The	tissue	from	MOM	patients	can	have	large	areas	of	necrosis,	which	yields	little	to	
no	RNA.	Other	factors	also	include	the	tissue	type,	capsule	tissue	tends	to	yield	more	RNA	than	
labrum,	which	is	fibrocartilaginous	and	is	harder	to	physically	break	down.	The	method	
developed	above	maybe	able	to	over	come	RNA	isolation	from	tougher	tissues.	Lysing	fresh	
tissue	can	be	problematic	with	regards	to	getting	enough	RNA	out	of	more	fibrous	and	cartilage	
tissues	and	so	binding	samples	in	OCT	may	over	come	this.		
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RNA	Quality	Control		
Experion	(Bio-Rad)	Protocol	
	
1) Bring	following	kit	to	room	temp	(15-20	mins)	
? RNA	stain	(blue)	–	light	sensitive	
? Loading	buffer	(yellow)	
? RNA	gel	(green)	
Vortex	all	tubes	and	spin	to	bottom	
2) Clean	electrodes	before	and	after	use	
? Zap	cleaning	chip,	2	mins	(Experion	electrode	cleaner)	
? Water	cleaning	chip,	2	mins	(Experion	DEPC	treated	water)	
? Water	cleaning	chip,	1	min	
? Air	dry	
3) Prepare	gel	stain	(18ul	per	chip)	
? Add	600	ul	RNA	gel	to	filter	column	and	spin	@	1500	gx,	10	mins	(use	within	4/52	or	re-
filter)	
? Add	65ul	filtered	gel	to	clean	tube,	add	1ul	RNA	stain	(always	at	a	65:1	ratio)	
? Briefly	vortex	
	
4) Prepare	RNA	Ladder	&	samples	(1ul	per	chip	plus	1ul	excess)	
? Denature	at	70degC,	2	mins	(only	denature	enough	for	1	chip	at	a	time)	
? Place	RNA	ladder	immediately	on	ice	5mins,	spin	down	before	use	
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? Transfer	1.2uL	of	RNA	sample	to	new	0.5	tube	and	denature	as	above	
? Keep	on	ice	until	needed	
	
5) Prime	the	Chip	
? Add	9ul	gel-stain	to	highlighted	GS	well	directly	to	the	bottom	of	the	well.	Do	not	expel	
air,	do	not	pipette	down	the	side.		
? Place	chip	in	priming	station	
? Set	to	B1	
? Start	and	wait	for	beep	
? Check	for	air	bubbles	
	
6) Load	samples	(use	a	new	tip	each	time)	
? Add	9	ul	gel	stain	to	other	GS	well	
? Add	9ul	gel	only	to	“G”	
? Add	5ul	loading	buffer	to	all	sample	wells	and	well	“L”	
? Add	1ul	denatured	RNA	ladder	to	“L”	
? Add	1	ul	to	wells	1-12	
? Vortex	chip	on	specialised	vortex	platform	for	1	min	
7) Launch	software	
? Select	“new	run”	
? Select	“Eukaryote	Total	RNA	StdSens”	
? Select	“start”	
? Select	number	of	samples,	then	“ok”	
? Clean	electrodes	as	before	
? Export	data	via	“print	to	PDF”	option	
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TIPS	 	
Check	that	all	wells	appear	to	have	same	diameter	circles	prior	to	running	Experion		
Will	usually	tell	indicate	within	20%	of	analysis	if	there	is	a	problem	with	one	of	the	wells	
If	there	is	a	problem,	visually	inspect	and	if	sample	is	adherent	to	the	side	of	the	well,	push	it	
down	with	a		clean	pipette	tip	taking	care	not	to	aspirate	
If	still	an	issue	try	uptaking	well	contents	into	a	clean	pipette	and	re-dispensing	to	expel	air	
bubbles.		
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Appendix	F:	Minimum	Information	About	
a	Microarray	(MIAME)	Requirements	
	
Minimum information about a microarray experiment (MIAME) 
Background information:  A brief description of the experiment 
(e.g., the abstract from the related publication, links to the 
publication, any supplemental websites or database accession 
numbers:  
 
Metal-on-metal	(MoM)	total	hip	replacements	were	thought	to	be	more	suitable	for	young	patients	
with	 increased	 mobility	 on	 longevity	 	 compared	 to	 the	 metal-on-	 polyethylene	 (MoP)	 implants.	
However,	there	has	been	a	high	rate	of	failure,	adverse	reactions	to	the	MoM	bearing	surfaces	have	
resulted	in	implant	failure,	pain	and	the	development	of	inflammatory	masses.	Adverse	reactions	to	
metal	debris	 (ARMD)	 is	an	emerging	cause	of	major	morbidity	 in	hip	arthroplasty	that	significantly	
impacts	 upon	 quality	 of	 life,	 provides	 a	 major	 technical	 challenge,	 and	 contributes	 a	 significant	
workload	in	revision	hip	surgery.	
	
The	aim	of	our	research	is	to	characterise	gene	expression	in	tissue	attained	from	MoM,	MoP	and	
Primary	 total	 hip	 replacements.	 With	 this	 information	 we	 can	 examine	 how	 reactions	 to	
polyethylene	 and	 metal	 debris	 might	 trigger	 the	 activation	 of	 biological	 cascades	 involved	 with	
osteolysis,	 loosening,	 and	 ARMD.	 If	 a	 characteristic	 gene	 expression	 signature	 is	 found,	 it	 is	
envisaged	that	this	may	lead	to	future	work	to	reveal	a	reliable	set	of	biomarkers	of	disease	activity	
in	these	conditions.	
	
 
Experiments purpose and justifications: The goal of the experiment – 
one line maximum (e.g., the title from the related publication):  
 
Comparison	of	patterns	of	gene	expression	in	patients	with	primary	osteoarthritis,	aseptic	loosening	
following	metal-on-polyethylene	THR,	and	ARMD	secondary	to	metal-on-metal	THR.		
 
Experimental factors and keywords:  For example, time course, cell 
type comparison, the parameters or conditions tested, such as time, 
dose, or genetic variation:  
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Samples	 of	 hip	 capsule,	 pericapsular	 tissue	 and	 bursa	 from	 patients	 undergoing	 primary	 hip	
arthroplasty	for	osteoarthritis,		MoP	revision	for	aseptic	loosening	and	MoM	revision	for	ARMD.	
	
Within	 the	MoM	group	patients	will	have	had	either	and	Ultima	MoM	28mm	Hybrid	THR	primary	
arthroplasty	or	a	large	diameter	ASR	THR	MoM	arthroplasty.		
	
 
Experimental design - relationships between samples, treatments, 
(e.g., a diagram or table showing experimental factors under study 
and biological replicates in each group/treatment):  
 
Specimen	ID	 Tissue	Type	 Disease	process	
P	A	 Human	Hip	Capsule	 Primary	THR	for		Osteoarthritis	
P	B	 Human	Hip	Capsule	 Primary	THR	for	Osteoarthritis	
P	C	 Human	Hip	Capsule	 Primary	THR	for	Osteoarthritis	
P	D	 Human	Hip	Capsule	 Primary	THR	Osteoarthritis	
MOP	A		 Human	Hip	Capsule	 MoP	Revision	for	Aseptic	
Loosening	
MOP	B	 Human	Hip	Capsule	 MoP	Revision	for	Aseptic	
Loosening	
MOP	C	 Human	Hip	Capsule	 MoP	Revision	for	Aseptic	
Loosening	
MOP	D	 Human	Hip	Capsule	 MoP	Revision	for	Aseptic	
Loosening	
MOM	A		 Human	Hip	Capsule	 MoM	Revision	for	ARMD	[Ultima	
MoM	THR]	
MOM	B		 Human	Hip	Capsule	 MoM	Revision	for	ARMD	[Ultima	
MoM	THR]	
MOM	C	 Human	Hip	Capsule	 MoM	Revision	for	ARMD	[Ultima	
MoM	THR]	
MOM	D	 Human	Hip	Capsule	 MoM	Revision	for	ARMD	[ASR	
MoM	THR]	
 
Type of chips required to use: Illumina	Human	HT-12	v4	Expression	Bead	Chip	
 
The origin of each biological sample:  (e.g., name of the organism, 
the provider of the sample) and its characteristics (e.g., gender, 
age, and developmental stage, strain, disease state): 	
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Specimen	ID	 Tissue	Type	 Gender	 Disease	process	
P	A	 Human	Hip	Capsule	 Female	 Primary	THR	for		
Osteoarthritis	
P	B	 Human	Hip	Capsule	 Female	 Primary	THR	for	
Osteoarthritis	
P	C	 Human	Hip	Capsule	 Female	 Primary	THR	for	
Osteoarthritis	
P	D	 Human	Hip	Capsule	 Female	 Primary	THR	
Osteoarthritis	
MOP	A		 Human	Hip	Capsule	 Male	 MoP	Revision	for	
Aseptic	Loosening	
MOP	B	 Human	Hip	Capsule	 Female	 MoP	Revision	for	
Aseptic	Loosening	
MOP	C	 Human	Hip	Capsule	 Male	 MoP	Revision	for	
Aseptic	Loosening	
MOP	D	 Human	Hip	Capsule	 Female	 MoP	Revision	for	
Aseptic	Loosening	
MOM	A		 Human	Hip	Capsule	 Male	 MoM	Revision	for	
ARMD	[Ultima	MoM	
THR]	
MOM	B		 Human	Hip	Capsule	 Female	 MoM	Revision	for	
ARMD	[Ultima	MoM	
THR]	
MOM	C	 Human	Hip	Capsule	 Male	 MoM	Revision	for	
ARMD	[Ultima	MoM	
THR]	
MOM	D	 Human	Hip	Capsule	 Male		 MoM	Revision	for	
ARMD	[ASR	MoM	
THR]	
 
 
Cell line/tissue type/Source/ history/passage:  
 
Human,	Hip	tissue,	Capsule	and	peri	capsular	tissue		
 
Genetic modifications/characteristics: N/A 
 
 
Ref. to clinical data/information: 
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Developmental stage: N/A 
 
Manipulation of biological samples and protocols used (e.g., growth 
conditions, treatments, separation techniques):  
 
Hip	Tissue	was	lysed	at	4	oC.	
 
In vivo/vitro treatments:  
 
P	(A,	B,	C,	D)	=	4	x	Primary	THR	for	clinical	&	radiological	OA	
	
MoP	(A,	B,	C,	D)	=	4	x	Revision	arthroplasty	for	aseptic	loosening	of	a	Metal	on	Polyethylene	THR	
	
MoM	(A,	B,	C,	D)	=	4	x	Revision	arthroplasty	for	ARMD	in	a	patient	with	a	Metal	on	Metal	THR	
 
Organism part: Human	Hip	Tissue	[capsule	and	pericapsular	tissue]	
 
Tissue/cell harvesting methods/ Separation technique:  
	
Intraoperative	 specimens	were	 harvested	 and	 immediately	 placed	 in	 RNAlater	 (Life	 Technologies)	
and	stored	at	-80	oC	
Tissue	was	lysed	using	a	Qiagen	Tissue	Lyser,	at	50	Hz		
	
Strain or line/ Genetic Variation: N/A 
 
Growth condition: N/A 
 
Technical protocols for preparing the hybridization extract (e.g., 
the RNA or DNA extraction and purification protocol), and labeling:  
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0.5g	of	Tissue	was	lysed	in	500	µl	TRIzol.	RNA	was	extracted	by	chloroform	(500	µl	per	1	ml	TRIzol)	
and	precipitated	 in	 100	%	ethanol.	 RNA	was	 then	 cleaned/purified	 using	Qiagen	RNeasy	 Kit	 (RNA	
isolation).	To	increase	concentration	RNA	precipitation	method:	[1/10th	vol,	3M	sodium	acetate,	2.5	
x	vol.	100	%	ethanol],	-80	oC	12	hr,	spin	[500	µl	75	%	ethanol]	spin,	rehydrate. 
 
RNA source and extraction methods: 	
 
RNA Amplification used if any: N/A 
 
Group Name and contact details: 
 
Prof	Ian	Clark,	Dr	Darren	Ebreo	and	Dr	Heather	Felgate	
University	of	East	Anglia,	Norwich,	NR4	7TJ	
	
Email:		 H.Felgate@uea.ac.uk	
	 I.Clark@uea.ac.uk	
	 darren.ebreo@gmail.com	
	
We	 the	 above	 confirm	 that	 results	 obtained	 using	 the	 microarray	 facility	 will	 be	 fully	 and	
appropriately	 acknowledged	 within	 the	 paper.	 We	 will	 forward	 any	 publication	 citation	 upon	
receipt.		
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Appendix	G:	TLDA	Gene	Tables	
	
	
	
These	tables	give	details	of	the	top	36	genes	identified	as	being	differentially	expressed	across	3	
phenotypes	with	an	absolute	fold	change	FC>2	and	p<0.05	used	to	verify	the	findings	of	the	
microarray	experiment.	A	2	way	ANOVA	was	performed	using	the	FC	values	from	the	
microarray	data	versus	those	derived	from	TLDA.	Information	derived	from	gene	ontology	
database	at	www.pubmed.com
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 Gene$ Function$ p$value$
CD36$
Thrombospondin$receptor;cellular$adhesion$molecule$
$
The protein encoded by this gene is the fourth major glycoprotein of the platelet surface and serves as a receptor for 
thrombospondin in platelets and various cell lines. Since thrombospondins are widely distributed proteins involved in a 
variety of adhesive processes, this protein may have important functions as a cell adhesion molecule. It binds to 
collagen, thrombospondin, anionic phospholipids and oxidized LDL. It directly mediates cytoadherence of Plasmodium 
falciparum parasitized erythrocytes and it binds long chain fatty acids and may function in the transport and/or as a 
regulator of fatty acid transport. Mutations in this gene cause platelet glycoprotein deficiency. 
$
ns#
CHIT1$
Chitotriosidase.  
 
Secreted by activated human macrophages and is markedly elevated in plasma of Gaucher disease patients. The 
expression of chitotriosidase occurs only at a late stage of differentiation of monocytes to activated macrophages in 
culture 
#
P<0.05*#
CYP27A1$
Cytochrome P450, family 27, subfamily A, polypeptide 1 
 
Encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are 
monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids 
and other lipids. 
 
#
ns#
HS3ST2$
Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 
 
The enzyme encoded by this gene is a member of the heparan sulfate biosynthetic enzyme family. It is a type II 
integral membrane protein and possesses heparan sulfate glucosaminyl 3-O-sulfotransferase activity. This gene is 
expressed predominantly in brain and may play a role in the nervous system 
#
ns#
CD52$
CAMPATH-1 Antigen/Cluster of Differentiation 52 
 
CD52 is present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes were 
derived. It also is found on monocytes[1] and dendritic cells  
#
ns#
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 Gene$ Function p$value!
PLA2G7$
Phospholipase A2.  
The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to 
biologically inactive products. Defects in this gene are a cause of platelet-activating factor acetylhydrolase deficiency 
 
ns!
ALDH1A3$
Aldehyde dehydrogenase 1 family, member A3. Gene encodes an aldehyde dehydrogenase enzyme that uses 
retinal as a substrate. Mutations in this gene have been associated with microphthalmia, isolated 8, and expression 
changes have also been detected in tumor cells. 
!
ns!
MMP12$
Matrix Metallopeptidase 12.  
 
Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal 
physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease 
processes, such as arthritis and metastasis. Most MMP's are secreted as inactive proproteins which are activated 
when cleaved by extracellular proteinases. It is thought that the protein encoded by this gene is cleaved at both ends to 
yield the active enzyme, but this processing has not been fully described. The enzyme degrades soluble and insoluble 
elastin. It may play a role in aneurysm formation and studies in mice suggest a role in the development of emphysema. 
 
!
P<0.01**!
GZMB$
Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1).  
 
Cytolytic T lymphocytes (CTL) and natural killer (NK) cells share the remarkable ability to recognize, bind, and lyse 
specific target cells. They are thought to protect their host by lysing cells bearing on their surface 'nonself' antigens, 
usually peptides or proteins resulting from infection by intracellular pathogens. The protein encoded by this gene is 
crucial for the rapid induction of target cell apoptosis by CTL in cell-mediated immune response.  
 
!
ns!
ENPP1$
Ectonucleotide pyrophosphatase/phosphodiesterase 1.  
 
The encoded protein is a type II transmembrane glycoprotein comprising two identical disulfide-bonded subunits. This 
protein has broad specificity and cleaves a variety of substrates, including phosphodiester bonds of nucleotides and 
nucleotide sugars and pyrophosphate bonds of nucleotides and nucleotide sugars. This protein may function to 
hydrolyze nucleoside 5' triphosphates to their corresponding monophosphates and may also hydrolyze diadenosine 
polyphosphates. Mutations in this gene have been associated with 'idiopathic' infantile arterial calcification, ossification 
of the posterior longitudinal ligament of the spine (OPLL), and insulin resistance. 
ns!
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 Gene$ Function p$value!
FOSB$
FBJ murine osteosarcoma viral oncogene homolog B 
 
The Fos gene family consists of 4 members: FOS, FOSB, FOSL1, and FOSL2. These genes encode leucine zipper 
proteins that can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1. As 
such, the FOS proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. 
Alternatively spliced transcript variants encoding different isoforms have been found for this gene. 
!
ns!
FOS$
FBJ murine osteosarcoma viral oncogene homolog.  
 
Genes encode leucine zipper proteins that can dimerize with proteins of the JUN family, thereby forming the 
transcription factor complex AP-1. As such, the FOS proteins have been implicated as regulators of cell proliferation, 
differentiation, and transformation. Alternatively spliced transcript variants encoding different isoforms have been found 
for this gene. 
!
ns!
COL22A1$
Collagen, type XXII, alpha 1.  
 
The COL22A1 gene on human chromosome 8q24.2 encodes a collagen that structurally belongs to the FACIT protein 
family (fibril-associated collagens with interrupted triple helices). Collagen XXII exhibits a striking restricted localization 
at tissue junctions such as the myotendinous junction in skeletal and heart muscle, the articular cartilage-synovial fluid 
junction, or the border between the anagen hair follicle and the dermis in the skin. It is deposited in the basement 
membrane zone of the myotendinous junction and the hair follicle and associated with the extrafibrillar matrix in 
cartilage. In situ hybridization of myotendinous junctions revealed that muscle cells produce collagen XXII, and 
functional tests demonstrated that collagen XXII acts as a cell adhesion ligand for skin epithelial cells and fibroblasts. 
This novel gene product, collagen XXII, is the first specific extracellular matrix protein present only at tissue junctions. 
 
!
ns!
EGR1$
Early growth response 1. 
  
Protein encoded by this gene belongs to the EGR family of C2H2-type zinc-finger proteins. It is a nuclear protein and 
functions as a transcriptional regulator. The products of target genes it activates are required for differentitation and 
mitogenesis. Studies suggest this is a cancer suppressor gene. 
 
!
ns!
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 Gene$ Function p$value!
NR4A2$
Nuclear receptor subfamily 4, group A, member 2 
 
Gene encodes a member of the steroid-thyroid hormone-retinoid receptor superfamily. The encoded protein may act as 
a transcription factor. Mutations in this gene have been associated with disorders related to dopaminergic dysfunction, 
including Parkinson disease, schizophernia, and manic depression. Misregulation of this gene may be associated with 
rheumatoid arthritis. 
!
ns!
APCDD1L$ Adenomatosis polyposis coli down-regulated 1-like ! p<0.05*!
AMTN$
Amelotin 
 
The mineralized portions of teeth, the dentin and enamel, are formed by mesenchyme-derived odontoblasts and 
epithelium-derived ameloblasts, respectively. Amelotin is specifically expressed in maturation-stage ameloblasts  
 
!
ns!
CHI3L2$
Chitinase 3-like 2 
The protein encoded by this gene is similar to bacterial chitinases but lacks chitinase activity. The encoded protein is 
secreted and is involved in cartilage biogenesis. 
!
ns!
CSN1S1$
Casein alpha s1 
!
Milk!protein!gene!
P<0.001***!
MMP3$
Matrix$Metalloproteinase$3.$$
$
Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal 
physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease 
processes, such as arthritis and metastasis. Most MMP's are secreted as inactive proproteins which are activated 
when cleaved by extracellular proteinases. This gene encodes an enzyme which degrades fibronectin, laminin, 
collagens III, IV, IX, and X, and cartilage proteoglycans. The enzyme is thought to be involved in wound repair, 
progression of atherosclerosis, and tumor initiation. The gene is part of a cluster of MMP genes which localize to 
chromosome 11q22.3 
$
ns!
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 Gene$ Function$ p$value!
GJB2$
Gap junction protein, beta 2, 26kDa 
 
This gene encodes a member of the gap junction protein family. The gap junctions were first characterized by electron 
microscopy as regionally specialized structures on plasma membranes of contacting adherent cells. These structures 
were shown to consist of cell-to-cell channels that facilitate the transfer of ions and small molecules between cells. 
!
ns!
TNFALP6$
Tumor necrosis factor, alpha-induced protein 6 
 
The protein encoded by this gene is a secretory protein that contains a hyaluronan-binding domain, and thus is a 
member of the hyaluronan-binding protein family. The hyaluronan-binding domain is known to be involved in 
extracellular matrix stability and cell migration. This protein has been shown to form a stable complex with inter-alpha-
inhibitor (I alpha I), and thus enhance the serine protease inhibitory activity of I alpha I, which is important in the 
protease network associated with inflammation. This gene can be induced by proinflammatory cytokines such as tumor 
necrosis factor alpha and interleukin-1. Enhanced levels of this protein are found in the synovial fluid of patients with 
osteoarthritis and rheumatoid arthritis 
!
ns!
CFI$
Complement factor I 
 
This gene encodes a serine proteinase that is essential for regulating the complement cascade. The encoded 
preproprotein is cleaved to produce both heavy and light chains, which are linked by disulfide bonds to form a 
heterodimeric glycoprotein. This heterodimer can cleave and inactivate the complement components C4b and C3b, 
and it prevents the assembly of the C3 and C5 convertase enzymes. Defects in this gene cause complement factor I 
deficiency, an autosomal recessive disease associated with a susceptibility to pyogenic infections. Mutations in this 
gene have been associated with a predisposition to atypical hemolytic uraemic syndrome, a disease characterized by 
acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. Primary glomerulonephritis with 
immmune deposits is another condition associated with mutation of this gene 
!
ns!
PCOLCE$
Procollagen C-endopeptidase enhancer 
 
Fibrillar collagen types I-III are synthesized as precursor molecules known as procollagens. These precursors contain 
amino- and carboxyl-terminal peptide extensions known as N- and C-propeptides, respectively, which are cleaved, 
upon secretion of procollagen from the cell, to yield the mature triple helical, highly structured fibrils. This gene encodes 
a glycoprotein which binds and drives the enzymatic cleavage of type I procollagen and heightens C-proteinase 
activity. 
ns!
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Gene$ Function! p$value!
ITGAV$
Integrin, alpha V 
 
This gene encodes a protein that is a member of the integrin superfamily. Integrins are heterodimeric integral 
membrane proteins composed of an alpha chain and a beta chain. This protein undergoes post-translational cleavage 
to yield disulfide-linked heavy and light chains that combine with multiple integrin beta chains to form different integrins. 
This protein has been shown to heterodimerize with beta 1, beta 3, beta 5, beta 6, and beta 8; the heterodimer of alpha 
v and beta 3 is the Vitronectin receptor. This protein interacts with several extracellular matrix proteins to mediate cell 
adhesion and may play a role in cell migration. It is proposed that this protein may regulate angiogenesis and cancer 
progression. Alternative splicing results in multiple transcript variants that encode different protein isoforms. Note that 
the integrin alpha 5 and integrin alpha V chains are produced by distinct genes 
 
ns!
TIMP3$
TIMP metallopeptidase inhibitor 3 
 
This gene belongs to the TIMP gene family. The proteins encoded by this gene family are inhibitors of the matrix 
metalloproteinases, a group of peptidases involved in degradation of the extracellular matrix (ECM). Expression of this 
gene is induced in response to mitogenic stimulation and this netrin domain-containing protein is localized to the ECM. 
Mutations in this gene have been associated with the autosomal dominant disorder Sorsby's fundus dystrophy 
!
P<0.05*!
CLIC5$
Chloride intracellular channel 5 
 
This gene encodes a member of the chloride intracellular channel (CLIC) family of chloride ion channels. The encoded 
protein associates with actin-based cytoskeletal structures and may play a role in multiple processes including hair cell 
stereocilia formation, myoblast proliferation and glomerular podocyte and endothelial cell maintenance. Alternatively 
spliced transcript variants encoding multiple isoforms have been observed for this gene. 
!
ns!
ADAMTSL2$
ADAMTS-like 2 
 
This gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) and 
ADAMTS-like protein family. Members of the family share several distinct protein modules, including a propeptide 
region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual 
members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. The 
protein encoded by this gene lacks the protease domain, and is therefore of a member of the the ADAMTS-like protein 
subfamily. It is a secreted glycoprotein that binds the cell surface and extracellular matrix; it also interacts with latent 
transforming growth factor beta binding protein 1. Mutations in this gene have been associated with geleophysic 
 
ns!
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 Gene$ Function! p$value!
SEMA3A$
Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A 
 
This secreted protein can function as either a chemorepulsive agent, inhibiting axonal outgrowth, or as a 
chemoattractive agent, stimulating the growth of apical dendrites. In both cases, the protein is vital for normal neuronal 
pattern development. Increased expression of this protein is associated with schizophrenia and is seen in a variety of 
human tumor cell lines. Also, aberrant release of this protein is associated with the progression of Alzheimer's disease 
 
ns!
BTC$
Betacellulin 
 
The protein encoded by this gene is a member of the EGF family of growth factors. It is synthesized primarily as a 
transmembrane precursor, which is then processed to mature molecule by proteolytic events. This protein is a ligand 
for the EGF receptor 
!
ns!
CRLF1$
Cytokine receptor-like factor 1 
 
This gene encodes a member of the cytokine type I receptor family. The protein forms a secreted complex with 
cardiotrophin-like cytokine factor 1 and acts on cells expressing ciliary neurotrophic factor receptors. The complex can 
promote survival of neuronal cells. Mutations in this gene result in Crisponi syndrome and cold-induced sweating 
syndrome 
!
ns!
CRTAC1$
Cartilage acidic protein 1 
 
gene encodes a glycosylated extracellular matrix protein that is found in the interterritorial matrix of articular deep zone 
cartilage. This protein is used as a marker to distinguish chondrocytes from osteoblasts and mesenchymal stem cells in 
culture. The presence of FG-GAP motifs and an RGD integrin-binding motif suggests that this protein may be involved 
in cell-cell or cell-matrix interactions. Copy number alterations in this gene have been observed in neurofibromatosis 
type 1-associated glomus tumors. Alternative splicing results in multiple transcript variants 
!
P<0.05*!
ERRFI1$
ERBB receptor feedback inhibitor 1 
 
ERRFI1 is a cytoplasmic protein whose expression is upregulated with cell growth. It shares significant homology with 
the protein product of rat gene-33, which is induced during cell stress and mediates cell signaling 
!
ns!
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 Gene$ Function p$value!
NDUFA4L2$
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 
 
an enzyme of the respiratory chains of myriad organisms from bacteria to humans. It catalyzes the transfer 
ofelectrons from NADH to coenzyme Q10 (CoQ10) and, in eukaryotes, it is located in the 
inner mitochondrial membrane. It is one of the "entry enzymes" of cellular respiration or oxidative phosphorylation in the 
mitochondria 
!
!
ns!
AK1$
Adenylate kinase 1 
 
Adenylate kinase is an enzyme involved in regulating the adenine nucleotide composition within a cell by catalyzing the 
reversible transfer of phosphate group among adinine nucleotides. Three isozymes of adenylate kinase have been 
identified in vertebrates, adenylate isozyme 1 (AK1), 2 (AK2) and 3 (AK3). AK1 is found in the cytosol of skeletal 
muscle, brain and erythrocytes, whereas AK2 and AK3 are found in the mitochondria of other tissues including liver 
and heart. AK1 was identified because of its association with a rare genetic disorder causing nonspherocytic hemolytic 
anemia where a mutation in the AK1 gene was found to reduce the catalytic activity of the enzyme 
!
!
ns!
GFPT2$
Glutamine-fructose-6-phosphate transaminase 2 
is an enzyme that catalyzes the chemical reaction 
L-glutamine + D-fructose 6-phosphate  L-glutamate + D-glucosamine 6-phosphate 
Thus, the two substrates of this enzyme are L-glutamine and D-fructose 6-phosphate, whereas its two products are L-
glutamate and D-glucosamine 6-phosphate. 
This enzyme belongs to the family of transferases, specifically the transaminases, which transfer nitrogenous groups. 
!
ns!
GPR64$
G protein-coupled receptor 64  
 
GPR64 is significantly overexpressed in the Wnt signaling-dependent subgroup of medulloblastomas as well as in 
ewing sarcomas and carcinomas derived from prostate, kidney or lung 
!
ns!
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 Gene$ Function p$value!
NTN4$
Netrin 4 
 
Netrins are a class of proteins involved in axon guidance. 
ns!
ZNF385B$
Zinc finger protein 385B 
 
Detected in germinal center of lymph node (at protein level). Expressed in spleen, lymph node and 
tonsil 
ns!
SCARA3$
Scavenger receptor class A, member 3 
 
This gene encodes a macrophage scavenger receptor-like protein. This protein has been shown to deplete reactive 
oxygen species, and thus play an important role in protecting cells from oxidative stress. The expression of this gene is 
induced by oxidative stress 
!
ns!
HBEGF$
Heparin-binding EGF-like growth factor 
 
HB-EGF-like growth factor is synthesized as a membrane-anchored mitogenic andchemotactic glycoprotein. An 
epidermal growth factor produced by monocytes and macrophages, due to an affinity for heparin is termed HB-EGF. It 
has been shown to play a role in wound healing, cardiac hypertrophy, and heart development and function 
!
ns!
OGN$
Osteoglycin 
 
This gene encodes a protein which induces ectopic bone formation in conjunction with transforming growth factor beta. 
This protein is a small proteoglycan which contains tandem leucine-rich repeats (LRR). 
!
P<0.05*!
SBSPON$
Somatomedin B and thrombospondin, type 1 domain containing 
 
O-glycosylation of TSR domain-containing proteins 
Receptor-mediated endocytosis 
!
ns!
PITX1$
Paired-like homeodomain 1  
 
Transcriptional regulator involved in basal and hormone-regulated activity of prolactin 
ns!
